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Abstract 
Proteins are the biological macromolecules central to most cellular functions. The native 
structure of protein determines its function and any perturbations such as mutation, changes 
in pH, macromolecular crowding, oxidative stress, may promote protein misfolding and/or 
aggregation. Protein misfolding or aggregation can contribute to diseases either through 
loss of proteins’ critical function or by gain of toxic function. Among the various proteins 
associated with neurodegeneration, trans-active response (TAR) DNA binding protein 43 
(TDP-43) has sparked interest in researchers due to its diverse role in several 
neurodegenerative diseases like Amyotrophic Lateral Sclerosis (ALS), Frontotemporal 
Lobar degeneration (FTLD), Alzheimer’s, Parkinson’s and Huntington’s disease. Most of 
the reported work on TDP-43 protein have been carried out on truncated version of the 
protein from prokaryotic source due to difficulty in expressing and purifying the full- length 
protein. Another protein, amyloid β peptides role in Alzheimer’s disease has been studied 
in great detail. However, the role posttranslational modifications play in Aβ related toxicity 
has not been fully explored. In this dissertation, I address these two major gaps as follows: 
1) I have successfully purified full- length TDP-43 protein using a eukaryotic source and 
carried out some physicochemical characterization. Now this full- length protein which is 
from eukaryotic source can be used to better understand proteins role in health and disease. 
2) I explored the physicochemical properties of acetylated Amyloid β peptides includ ing 
its effects on modulating toxicity in SH-SY5Y cell lines (neuroblastoma) and primary 
neuronal cultures.  This work underscores the importance of posttranslational modifica t ion 
such as acetylation of Aβ peptides on toxicity as well as aggregate morphology which will 
lead to better drug designs in future. 
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Chapter 1 Background 
1.1 Proteins 
Proteins, this word is familiar to us, since our childhood we learnt that proteins are the 
building block of our body. Made up of 20 different amino acids, proteins play role in 
performing a wide variety of biological function. In order to be functionally active, protein 
needs to fold into its native, three-dimensional structure.  In addition, about 20-30% of 
proteins in eukaryotic cells lack their three-dimensional structure and remains folded once 
they interact with their binding partners. The newly synthesized proteins have a greater 
chance of being misfolded leading to aggregation and forms a toxic species under the 
cellular conditions1. Cells have several quality control measures like molecular chaperones, 
which guide the correct de novo folding or refolding of the protein, and help to prevent 
aggregation of non-native proteins. Ubiquitin-proteasome system (UPS) and Phagosome-
lysosome system helps to degrade the misfolded proteins (Figure 1)2,3. Despite having 
cellular control measures, there is evidence showing the presence of misfolded and 
aggregated proteins appearing at late stage of life in several neurological and systemic 
diseases. The most likely cause of this is decline in the proteostasis capacity of a cell with 
the aging of an individual. Studies have suggested the several genetic and environmenta l 
factors can contribute to protein misfolding and aggregation. Change in conformation of 
normal protein leads to protein destabilization, which eventually leads to disease condition. 
Mutation, changes in metal ions, pH, macromolecular crowding, oxidative stress or high 
concentration of misfolded protein might drive the process of protein misfolding and 
aggregation3.  In order to strengthen the understanding of protein folding, misfold ing, 
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aggregation and toxicity, I will discuss the different forces involved in protein folding, 
posttranslational modifications, factors leading to misfolding and aggregation. In addition, 
I will highlight how morphology/nature of aggregates of disease proteins along with key 
proteins contribute to cytotoxicity leading to neurodegenerative diseases. This will help 
underscore the importance of my two main body of work included as chapters in this 
dissertation.  
 
Figure 1: Representation of the Protein misfolding and fibrillization. Genetic and 
environmental factors might play the role in the process of aggregation thus resulting into 
the deposition of aggregated proteins in the nucleus, cytoplasm and extracellular space. 
Several cellular quality control systems like molecular chaperones, the ubiquit in 
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proteasome system and the phagosome-lysosome system facilitate in the reduction of 
accumulation of misfolded proteins. Reprinted with permission from Forman, S. et.al. 
20042. 
1.2. Physical forces involved in protein folding  
Protein folding is a complex process that has been studied for more than a century. As 
every protein requires very unique set of parameters for its correct folding, protein folding 
problem has intrigued researchers for a very long time. Researchers are interested in 
understanding how native structure of proteins acquires its well folded 3D structure. A 
protein starts as a sequence, like a chain of amino acids that rapidly folds, residues come 
close (2 to 7 Å; short/medium-range distance) to each other held by non-covalent forces, 
forming the native structure of a protein.  Now, a substantial amount of information about 
a protein can be obtained from Protein Databank (PDB), which has collection of more than 
100,000 protein structures. Interestingly, proteins are only marginally stable at room 
temperature and its stability can be affected by the weak non-covalent interactions. This 
makes understanding of these different types of molecular interactions involved in protein 
stability very important. The major non-covalent forces in a protein are: Hydrogen bonds, 
Van der Waals interaction, Electrostatic interactions, and hydrophobic interactions that 
contribute to protein folding and stability. In the following paragraphs, I will discuss briefly 
about each of these forces. 
1.2.1 Hydrogen bonds 
During protein folding, due to contact with water 70% of the peptide groups and 65% of 
polar side chains are buried in the interior of the protein4. Hydrogen bonds are formed by 
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the interaction of the hydrogen atoms that are covalently bonded to the electronegative 
atoms (usually N, O, S). Hydrogen bonding provides the rigidity to the protein structure. 
Both polar side-chains as well as carbonyl oxygen and N-amide proton from peptide bond 
can take part in H-bonding. H-bond also provides the structural integrity to the α-helix and 
β-sheet conformations of proteins. The strength of the hydrogen bond is usually in the range 
of 2-10 kcal/mol which depends on the orientation as well as electronegativity of the 
bonding atoms. The concept of H-bonding as the dominant force in protein folding was 
first suggested by Mirsky and Pauling (1936). They introduced the possibility of formation 
of H-bond between carbonyl C=0 and amide NH groups of the peptide backbone5. 
1.2.2 Electrostatic interactions 
The earliest known protein denaturants were acids and bases, hence researchers assumed 
that electrostatic interactions are the forces responsible for protein folding. Any process 
that is driven electrostatically is dependent on pH/ ionic strength. The total charge on the 
protein is determined by the protein whereas salt determines the extent of interaction. 
Linderstrom-Lang was the first person to propose the quantitative model of electrostatic 
interactions for native proteins in 19245. Electrostatic interactions can affect protein 
stability in different ways. One such way is due to the non-specific repulsion interaction 
which arises when the protein is extreme charged. The native protein can be destabilized 
by increasing the charge of the solution either by increasing acidity or basicity of the 
solution. This results in the increase in the charge density in the folded protein compared 
to the unfolded one leading into its destabilization due to greater charge repulsion. For this 
reason, when the protein is at its isoelectric point, there is no effect of electrostatic 
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interaction on protein stability. Another way that affect the protein stability includes 
specific charge interactions. Ion pairing or the salt bridge is observed when the side chains 
of two oppositely charged amino acids are in close proximity to each other. As the charge 
in the protein increases, the destabilization of folded protein takes place but the ion pairing 
can stabilize the protein. Earlier in 1930’s the dominant force in protein folding was 
considered to be ion pairing. Studies shows that ion pairing affects the protein stability but 
is not considered as the dominant force as much of the charges are centered on the surface 
6,7. 
1.2.3 Hydrophobic interactions 
Hydrophobic interactions occurs in a protein as a result of nonpolar side chain of amino 
acids as well as other nonpolar solutes prefer to cluster in nonpolar environment rather than 
a polar solvent.  The formation of bond reduces the interaction of nonpolar residues with 
water thus making the interaction highly favorable. During folding of the protein, the 
hydrophobic side chains of amino acids are buried down in the interior of the protein core 
and polar amino acids are not found in the interior of the protein8. The case for importance 
of hydrophobic interaction in protein folding was first made strong by Kauzmann.  
1.2.4 Van der Waals Interactions 
Van der Waals interactions are the weak interactions with the stabilization energies of 0.4 
to 4.0 kJ/mol. Interactions with the fixed and induced dipoles results into Van der Waals 
attractions. These kinds of interactions occur largely in proteins and contribute 
significantly to stability of protein.  
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1.2.5 Intrinsic propensities 
Intrinsic propensities do not relate to single type of force but is related to preference of 
certain confirmation by di-or tri-peptides, their size or sequence, which can arise from the 
local interactions. The stability of the long polypeptides chains in aqueous solutions is due 
to intrinsic propensities. For instance, As the length of the polypeptide chain increases the 
stability of the helix is also increased. Although while considering the free energy from 
individual residue is small but summing up the free energy over many residues results into 
strong force that favors helix formation. The intrinsic propensities is also responsible for 
protein confirmation when it folds.  
1.3 Energy landscape of protein folding  
Getting back into the history of protein folding, the researchers assumed that the folding of 
the protein takes place in distinct pathways through particular intermediate states. Figure 2 
shows the classical pathways for protein folding. The graphical representation of protein 
folding in the funnel shape is the generic representation that is applicable not only to 
proteins but also to RNA and compact polymers. It represents that protein folds through 
several intermediate pathways. Studies by protein denaturation experiments suggested 
protein exist as a two-state model, i.e. at equilibrium they either can exist as fully native or 
fully unfolded structure4. Later, Ptitsyn and coworkers found that several destabilizing 
conditions such as low pH can lead to protein with expanded form, with loose tertiary 
structure but still having the secondary structure in considerable amount which was called 
as molten globule 4, 5-7, 9.  
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The large polypeptide chain has complex folding pathways and different models have been 
developed to describe the pathways. Among those model one describes that the folding 
process is hierarchical in which the local secondary structures are formed first where the 
amino acids sequence fold into α and β sheets. Next, the super secondary structures are 
formed which occurs due to the long-range interactions, like two α-helices come together 
and form stable structure. This process takes place until the folding process of a protein is 
completed. In another model, the folding is mediated by the hydrophobic interactions 
among non-polar residues where the polypeptide is collapsed spontaneously into compact 
state. At this stage, there is a high content of secondary structures, however much of the 
side-chain of amino acids are not fixed. The resultant from the hydrophobic collapse are 
often termed as molten globule state. While considering how protein folds, most of the 
proteins folds by incorporating the features of both models. Proteins may take a different 
route for folding that results into same end point with several folding intermediates.  
The process of protein folding can be viewed as a free-energy funnel. The unfolded states 
contain high degree of conformational entropy as well as free energy. The narrowing of 
funnel takes place as the folding process proceeds where the decrease of entropy takes 
place. The semistable intermediates are represented by the small depressions that are found 
along the side of the funnel and they slow down the process of folding. At the end of the 
funnel, a native confirmation is present where other folding intermediates are reduced10.  
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Figure 2: Folding pathways of a protein A. Classic approach of a protein folding pathway 
B. Funnel-shaped landscape of a protein folding9. Reprinted with permission from 
Englander and Mayne. Proc Natl Acad Sci U S A. 2014 Nov 11; 111(45): 15873–
15880201597.   
1.4 Disulfide bonds 
Disulfide bond is present in most proteins and it ensures the correct folding of proteins 
under native conditions. Disulfide bonds occupy 15% of the human proteome and are 
present mainly in secreted protein where it makes up to 65%. Next to peptide bond, the 
common covalent link between the amino acids in the protein is the disulfide bond. 
Disulfide bonds are known to decrease the entropy of the unfolded state thereby stabilizes 
the protein thermodynamically. The presence of disulfide bonds are found in 55% of the 
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pathologic amyloid forming proteins underscoring the importance of disulfide bonds in 
aggregation kinetics, nature of aggregates, as well as its role in cellular toxicity. For proper 
folding of protein into its native structure, many proteins require the correct formation of 
disulfide bonds. Protein misfolding results when there is abnormal reduction/formation of 
disulfide bonds. Disulfide bonds are involved in proteins involved in neurodegenerat ion. 
Until date, the role of disulfide bonds have been studied and found to be important in three 
proteins involved in neurodegeneration: prion, SOD1 and Tau. The folding/misfold ing 
pathway can thus be traced by determining the thiol-disulfide status in the protein. For 
example, the folding/misfolding is regulated by thiol-disulfide status in case of SOD1 (Cu, 
Zn-superoxide dismutase) . The stabilization of matured SOD1 is achieved by the 
formation of intramolecular disulfide bonds whereas the reduction of these disulfide bonds 
leads to the misfolding and aggregation of SOD1 due to a decrease in conformationa l 
stability of a protein. Therefore, the disulfide bonds play important role in familial form of 
amyotrophic lateral sclerosis (fALS) .  
1.5 Posttranslational modification (PTM) of proteins 
Synthesis of the proteins occurs during a process of ‘translation.’ The chemical changes 
that protein may have after the process of translation or concomitant with translation is 
commonly known as posttranslational modifications. Posttranslational modifications is 
present in both prokaryotes and eukaryotes. However, the modifications are present more 
in eukaryotic cells where the enzyme constitutes 5% of the genome that carry out 
posttranslational modification of protein. Post-translation modification can be enzymatic 
and non-enzymatic depending on its attachment of the chemical group to amino-acid side 
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chain11.The most common modifications includes the formation of disulfide bonds, 
cleavage of the precursor proteins or the addition or removal of low molecular weight 
groups covalently, which results into modifications like acetylation, biotinylat io n, 
amidation, deamidation, farnesylation, formylation, cysteinylation, geranylgeranylat ion, 
glutathionylation, glycation, glycosylation, hydroxylation, methylation, mono-ADP-
ribosylation, myristoylation, oxidation, palmitoylation, phosphorylation, poly(ADP-
ribosyl)ation, stearoylation, or sulfation11-16. 
Table 1: Posttranslational modifications and their target amino acids with enzyme 
involved.  
Amino acid residue(s) Protein/Enzyme involved Post-translation modification 
Tyrosine, Serine, 
Threonine 
Kinases, phosphatases Phosphorylation 
Lysine Ubiquitin-activating 
enzymes, Ubiquitin ligases 
Ubiquitination 
Lysine Acetyltransferases, 
deacetylases 
Acetylation 
Lysine, Arginine Methyltransferases, 
demethylases 
Methylation 
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Lysine  Glycation 
Lysine Ubiquitin-activating 
enzymes, Ubiquitin ligases 
Sumoylation 
Asparagine Glycosyltransferases, 
deglycosylases 
Glycosylation N-linked 
Serine/ Threonine Glycosyltransferases, 
deglycosylases 
Glycosylation O-linked 
Glycine N-Myristoyltransferases Myristoylation 
Tyrosine Sulfatases, sulfatases Sulfation 
Cysteine Prenylation/Palmitoylation 
Farnesyltransferases / DHHC 
protein acyltranaferases, 
acyl- protein thioesterases 
Prenylation/Palmitoylation 
 
Lysine, Proline, 
Arginine, Threonine  
 Carbonylation 
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Cysteine, Methionine  S-nitrosylation 
Post-translational modification alter protein’s structure and also affects its cellular and 
physiological functions. This leads to change in protein’s size, charge, or conformation, 
altering its hydrophobicity, binding affinity and enzyme activity. Some of the common 
posttranslational modifications found in eukaryotes along with their target amino acids and 
enzymes involved are highlighted in Table 1. Posttranslational modifications of the 
proteins can be detected by various methods. The analytical methods like column 
chromatography, thin-layer chromatography, radiolabeling of proteins and polyacrylamide 
gel electrophoresis is used for the detection of PTM. Apart from that protein sequencing 
and Western blot is also widely used. Currently, mass spectrometry and antibody based 
detection is most commonly used.  Antibody- based detection is based on the availability 
of the polyclonal or monoclonal antibodies that can specifically recognize the modified 
amino residue present in the peptide or the protein. This is accompanied by the detection 
either by using the Chemiluminescence (Western blotting) or the Absorbance/Fluorescence 
(ELISA) methods.  On the other hand, detection of PTM by mass spectrometry is based on 
the change in mass. Based on the type of the modification involved there occurs the specific 
change in the mass of the peptide/ amino acid which is confirmed by the Mass 
spectrometry. Tandem mass spectrometry is also used to identify the modification involved 
at the specific site11-13. 
 Among the various PTM, phosphorylation is the most common modification which 
involves the reversible addition of the phosphoryl group to the three amino acids: serine, 
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threonine or tyrosine from the adenosine triphosphate (ATP). This modification leads to 
change in conformation resulting into altered cellular function and signaling. The changes 
involve activation or deactivation of an enzyme by affecting its catalytic activity and/or 
increase a tendency of a protein to misfold and aggregate. Secondly, phosphorylation also 
helps to bind other proteins by facilitating its recruitment. Likewise, considering 
acetylation, about 80-90% of the eukaryotic proteins are acetylated. However, it is not clear 
what the biological role of those acetylated proteins are. Acetylation leads to blockage of 
positively charged lysine side chains by the neutral acetyl groups thereby altering the 
protein’s charge distribution.  Though, acetylation was first reported in histones, it is also 
observed in cytoplasmic proteins. Lysine acetylation regulates gene transcription in histone 
proteins. Histone acetylation is related to transcriptional activation whereas transcriptiona l 
suppression is the result of deacetylation. Talking about ubiquitination, it involves addition 
of 8 kDa polypeptide to the target proteins through the C-terminal glycine present in 
ubiquitin. Ubiquitination also targets lysine residues like acetylation and methylat ion. 
Ubiquitination acts as a signaling scaffold during biological responses. The proteins that 
are targeted by ubiquitination are usually the ones that needs to relocated or degraded.  
Posttranslational modification plays important role in protein folding and aggregation. 
Among these modifications like phosphorylation, acetylation, ubiquitination are observed 
in many diseases including neurological disorders. For example: In Parkinson’s disease, 
which affects around 6.3 million worldwide, α-synuclein protein is involved in this disease 
and posttranslational modifications like phosphorylation , ubiquitination  or nitration are 
known to be involved in the aggregation of α-synuclein protein and is known to possess 
several impacts in its cellular neurotoxicity. Due to the role of PTMS, in a signaling 
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pathways, in many diseases they are used as a potential therapeutic target or as a biomarker. 
Studying PTMs also helps to understand the disease pathology.  
1.6 Protein aggregation 
The key macromolecules of the living systems include proteins, lipids, carbohydrates and 
nucleic acids. Among which protein plays a vital role in performing wide variety of 
functions. About 100,000 types of proteins are involved in controlling the reactions 
involved in life of the living organisms. How one protein is distinguished from another is 
based on the constituents of amino acids 17. 
Failure of a polypeptide chain to maintain or reach its three-dimensional structure leads to 
aggregation. Though protein aggregation is widely studied topic but there are some key 
questions which some unanswered questions which includes: Mechanism underlying the 
protein aggregation, nature and structure of the aggregates, reason behind same protein 
leading to ordered and disordered aggregates, toxic species, specificity of intermolecular 
interactions, effect of environmental factors on aggregation rate and methods to prevent 
those aggregation18. In most of the cases, aggregation is usually irreversible which is due 
to the equilibrium shifted towards favor of aggregate rather than soluble form. Some of the 
aggregates like in vivo amyloid deposits are reversible 19,20. However, under the native like 
conditions the process is irreversible once the insoluble aggregates are formed.  
Protein misfolding diseases includes a broad range of diseases which occurs due to failure 
of a specific protein /peptide to maintain its native conformational state.  Many of these 
misfolding diseases are associated with the formation of organized fibrillary structures rich 
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in β-sheet structures from its soluble form 21, 22. Although the work by Christian Anfinsen 
showed that the proper folding of protein is directed by the amino acid sequence of it, now 
it is acknowledged that the variations in the folding trajectory of a protein to its native form 
including alternative states associated to pathogenesis is also governed by the same 
sequence. Apart from these different environmental as well as metabolic stresses, 
molecular crowding, aging, synthesis errors that are related to the cellular environment also 
act in addition to sequence-based challenge. 
1.6.1 Types of protein aggregates 
Basically, there are two broad classification of protein aggregates. Protein aggregates are 
classified as in vitro and in vivo aggregates, fibrillar and amorphous aggregates. Apart from 
these, aggregates are also classified as physical and chemical, reversible and irreversib le, 
soluble and insoluble. The amyloid fibrils are the ordered aggregates that are observed both 
in vivo and in vitro whereas the disordered aggregates are the inclusion bodies that are 
amorphous and are formed in vivo. The aggregates that are formed in vitro during refolding 
of the proteins at high concentration are usually disordered aggregates. The physical 
aggregates refers to the non-covalent and chemical aggregates refers to the covalent 
aggregates. Similarly, the soluble oligomers include dimer to decamer22. 
Amyloid fibrils: 
The term amyloid refers to extracellular proteinaceous deposits which are abnormal fibrous 
and are found in tissues and organs. Initially, the word was coined by Schleiden and in 
mid-19th century Virchow described the term in the deposits of iodine stained observed in 
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the autopsy of liver. Amyloid fibrils are formed from soluble proteins which turn into 
insoluble structure rich in β-sheet structure and are resistant to degradation. Later on, the 
properties of the amyloid like specifically binding to the Congo red was discovered 
suggesting the structure of amyloid to be fibrillar. The use of transmission electron 
microscopy and X-ray fiber diffraction pattern further confirmed the morphology and 
cross-β structure of amyloid. Ranging from size of 7-12 nm in diameter, amyloid fibrils are 
dissociated at high concentration of denaturant. Compared to other fibrous protein, the role 
of amyloids in providing structural, motility or support is not known but is related to 
number of the diseases which are known as amyloidosis. Some of these diseases includes 
Alzheimer’s, type II diabetes, the spongiform encephalopathies23. Understanding the 
formation and physicochemical properties of amyloid is the highly studied area.  
 
Figure 3: TEM images of Aβ1–42 aggregates in LMW (top) or HMW (bottom) incubation 
at the indicated times24. (Scale bars, 100 nm.). Reprinted with permission from Nakayama, 
W.T. et.al. (2016)24. 
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Amorphous aggregates 
Amorphous aggregates are the disordered structures and are common to most proteins. 
Formation of amorphous aggregates are observed during the process of protein expression 
purification and even when amyloidogenic proteins fails to form amyloid fibrils. Evidence 
suggests that amorphous aggregates are also observed in disease conditions 25, 26.  
Protein aggregation and understanding the mechanism underlying it is important to 
researchers in academia as well as industry. Amyloidogenic aggregates are hallmark of 
several diseases such as type II diabetes, systemic amyloidosis, Alzheimer’s, and 
Parkinson’s diseases. However, role of amorphous aggregation in the disease process is 
not understood very well and were thought not to be associated with any diseases. 
Nevertheless, recent research shows that it is found in several diseases. For instance: Cause 
of cataracts is due to aggregation of crystalline protein which are amorphous in nature 27. 
In Parkinson’s disease, in addition to an amyloidogenic structures, formation of amorphous 
aggregates by α-synuclein have been reported28. Also, in TDP-43 protein associated 
aggregates, both amorphous and amyloid fibrils have been reported by different groups. 
Formation of amorphous aggregates is of greatest importance especially in the production 
as well as storage of industrial enzymes and therapeutic proteins29. Although importance 
of amorphous aggregates in the disease process has been established, it is not clear which 
form of aggregate is more toxic. Protein aggregates size can be characterized by different 
methods like Light Scattering method (LS), Dynamic Light Scattering (DLS), and Size 
Exclusion Chromatography (SEC).   
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Figure 4: SEM images of lysozyme insoluble aggregates. The insoluble aggregates of 
lysozyme in presence of 10mM DTT incubated for 4h (left) and 7d (right) respectively. 
Scale bar = 1µm for both images. Reprinted with permission from Yang et.al. (2015)30 
Copyright © 2015 American Chemical Society. 
The nature or morphology of the protein aggregates is governed by several factors. It is not 
characterized by the sequence of amino acids alone as the same protein can form 
amorphous or fibrillar structure depending on the environmental conditions it is exposed 
to. Among these factors like pH, temperature, external environment, salt concentration etc., 
pH is known to play a key role in determining the nature of aggregates. This is because pH 
affects the net charge on the proteins. It has been reported that the proteins preferably form 
fibrillar structure when they have high net charge and when the pH favors low net charge 
the result is amorphous like aggregates. This finding has been supported by a study done 
on seven different proteins where effect of pH resulted different morphology of a protein .  
Protein aggregation and toxicity is widely studied topic. Also, there has always been a 
question regarding the nature of aggregates and its associated toxicity, i.e. which aggregate 
form of the protein is most toxic. Until recently, the mature amyloid fibrils that are mostly 
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detected in the pathological diseases were considered to be most toxic to the cells. A 
number of experimental data now suggests that pre-fibrillar aggregates, which are close in 
properties to amorphous aggregates, protofibrils or protein micelles are most-toxic to cells. 
This has been reported in number of studies carried out with Aβ peptides, α-synucle in 
indicating that the toxic species are the early aggregates. This suggests importance of 
understanding the toxic nature of aggregates as all aggregates generated and rich in β- sheet 
are not necessarily toxic in nature.  
1.7 Protein aggregation in neurodegenerative diseases 
Accumulation of protein aggregates in the neurons is a common feature observed in several 
neurological disorders. Neurodegenerative disorders are a clinical condition that involves 
the loss of neurons gradually leading to the cognitive, behavioral and physical defects31. In 
order to identify the neurological pathologies, the identification of protein involved in 
neurodegenerative disease is essential31. There are several neurodegenerative diseases like 
Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), 
Amyotrophic lateral sclerosis (ALS), Lewy Body dementia, and Prion like disease 
identified, and each disease has a unique protein and gene involved in it.  Involvement of 
different proteins leading to distinct clinical symptoms and diseases have complicated the 
research focusing on identifying some major common properties shared by these disease 
proteins.  
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease that causes axonal 
degeneration leading to motor neuron dysfunction and cell death. ALS is a sporadic disease 
but about 10% of the cases are found to be a familial33. Copper /Zinc Superoxide dismutase 
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1 (SOD1) is the major enzyme involved in ALS and mutations in SOD1 has resulted in 
major progress in the identification of pathogenesis in the field of ALS. The pathogenesis 
of SOD1 mutant is associated with the gain of toxic function and not with the loss of normal 
function.  
Among the various proteins identified in neurodegenerative diseases, Trans-active 
response (TAR) DNA binding protein 43 (TDP-43) is increasingly implicated in several 
neurodegenerative diseases like Alzheimer’s disease, ALS, FTLD-U, Huntington and 
Lewy body diseases. This explains TDP-43 as a high value target protein. Knowing the 
involvement of a common protein in multiple neurodegenerative diseases has a greater 
application in identifying the mechanism involved in all these disease conditions. In case 
of neurodegenerative disorders, the common features seem to be the presence of insolub le 
intracellular aggregates, that are often phosphorylated and ubiquitinated34-36. Association 
of TDP-43 is found to be in neurodegenerative diseases as the aggregates of this protein 
are present in patients with ALS and FTLD. In cases of TDP-43, the pathology has 
distinguishing features like mislocalization of TDP-43 to the cytoplasm, the loss of nuclear 
localization, as well as truncation. Therefore, TDP-43 proteinopathies involves all the 
characteristic features that are linked to neurodegenerative diseases having the TDP-43 
pathology 34.  
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1.8. Proteins used in study 
1.8.1 TDP-43 
Trans-active response (TAR) DNA binding protein is a 43kDa protein, first identified in 
1995 as transcriptional inactivators of HIV virus35-37. This protein could bind with the TAR 
DNA element of HIV virus, hence named TAR DNA binding protein. TDP-43 is a 414 
amino-acid protein belonging to the family of heterogeneous nuclear ribonucleoprote ins 
and share many features of this family35,38. TDP-43 is highly conserved among 
invertebrates and mammals, with its expression present in nearly all tissues39. Structurally, 
distinguished by two RNA recognition motifs (RRM) i.e. RRM1 and RRM2 along with N-
terminal and C-terminal regions, this protein is best known as RNA and DNA binding 
protein 34-35, 40-43. TDP-43, being a protein of nuclear origin is known to play various roles 
in metabolism of RNA including mRNA stability, splicing, transport, miRNA processing, 
transcriptional repression. Under the pathological conditions these functions are altered or 
there is an abnormal function leading to neurotoxicity. Moreover, the actual cause of 
neurotoxicity is still not clear. Some studies support toxicity due to gain of function and 
others support the toxicity due to loss of functions First identified in 2006, in a 
ubiquitinated aggregates of a FTLD and ALS associated patients, TDP-43 protein caught 
attention of many researchers and since then about 18,200 papers have been published on 
TDP-43 till date. Accumulation of TDP-43 aggregates is present in approximately 98% 
ALS and 50% FTD. Apart from that 50% of Alzheimer’s disease is associated with TDP-
43 pathology.  
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1.8.2 Amyloid–Beta  
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and distinct Aβ 
aggregates are observed as the disease progresses. Getting back into 1907, Alois Alzheimer 
first reported the findings of an autopsy of 55-year women as presence of neurofibrillary 
tangles and neuritic plaques who died of progressive behavioral and cognitive disorder. In 
1984, Glenner and Wong purified and found that these substances was a peptide of 4.2-
kDa, with amino acids of 40 or 42 in length, which was thought to be cleaved from some 
large precursor. In 1987, Kang et.al. cloned the amyloid precursor protein which confirmed 
the prediction made by Glenner and Wong and the peptide isolated was known as Amylo id 
β peptide in short Aβ peptide44. 
Amyloid beta is produced as a proteolytic product of the precursor protein known as APP 
which results from the cleavage by proteases, β-and γ-secretases. The proteolytic 
processing of APP results into two products of varying lengths especially at the carboxy 
terminal of the peptide. The two different forms of Aβ are of 40 and 42 amino acids in 
length known as Aβ40 and Aβ42 respectively. In normal individual, Aβ40 is the major 
form of Aβ produced. In a pool of Aβ only 5-15% of total Aβ is occupied by Aβ4245. 
Though Aβ40 is present in higher concentration in cerebrospinal fluid compared to Aβ42, 
the amyloid plaques from Aβ42 comprises the major component in AD brains. Further, 
Ratio of Aβ42 /Aβ40 plays a critical role in AD, where the increased ratio is associated 
with the early onset of familial AD and lowered ratio leads to decreased deposition of Aβ 
in transgenic mice. Also, the higher ratio correlates with the increased neurotoxicity. Aβ42 
is more aggregation prone compared to Aβ40, hence results into early deposition than 
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Aβ40. This leads to explanation that although both isoforms are present, Aβ42 and Aβ40 
preferentially aggregates with their own species.  
1.9 Motivation: 
Protein misfolding and aggregation is at the core of many neurodegenerative diseases. The 
common pathophysiological feature shared for several neurodegenerative diseases is 
accumulation of distinctly misfolded and aggregated proteins in brains, in cytosol, 
intranuclear, or extracellular spaces. Different neurodegenerative diseases like 
Amyotrophic Lateral Sclerosis, Frontotemporal dementia, Alzheimer’s disease, 
Parkinson’s diseases, Huntington diseases, Lewy body diseases etc. have characterized 
distinct aggregates in distinct part of the neuron. The unique characteristic is that each of 
these diseases has specific protein involved in its pathogenesis, e.g. SOD1 in ALS, 
Amyloid β in Alzheimer’s, and α-synuclein in Parkinson’s disease. While the general 
mechanism of toxicity in these diseases in understood, still the molecular level of 
understanding for these diseases is a subject of intense debate. This is complicated further 
by lack of information on distinct physicochemical properties of proteins including its 
aggregated structures at a molecular level, making difficult to understand its role in the 
disease processes.  
The main focus of this research is expression and purification of full- length TDP-43 
protein using eukaryotic expression system and understand its aggregation property using 
reducing and non-reducing environment and test its toxicity which is covered in Chapter 
3. A number of studies have been carried out in TDP-43 protein using the prokaryotic 
expression system. However, having method for purification in eukaryotic system is 
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lacking. Therefore, in this research we have explained the standardized methods for 
purification and addressed some of the aggregation and toxicity properties of full length 
aggregates. This will help to shed some light in the understanding the role of the protein in 
the disease process.  
Posttranslational modification is the common modifications that takes place in protein. 
Among the various modifications, acetylation of protein is one of the major modifica t ion 
that taking place in eukaryotes. Aβ is the protein which is involved in Alzheimer’s disease. 
Study on the effect of the lysine acetylation on this protein is not reported in detail, though 
information of acetylation on lysine 28 is available. Therefore, in chapter 4, the effect of 
acetylation on lysine16 on Aβ (1-42) aggregation is discussed. For this purpose, the single 
acetylated lysine residues at position 16, 28 or double acetylated KKAc was used and its 
comparison with WT was performed. Understanding the effect of lysine acetylation on Aβ 
(1-42) aggregation will help to develop the proper therapeutic targets for treatment of 
Alzheimer’s disease.  
As discussed in above sections, several factors like pH, temperature, reducing environment 
also causes protein destabilization that leads to protein aggregation. Therefore, 
understanding the role of protein either by changing the charge on the protein, or by 
reducing the disulfide bonds in it helps in providing some clue on its pathogenesis. As 
evident, same protein can generate different types of aggregates under the conditions it is 
exposed, it is equally important to understand under what conditions the different 
aggregates are formed and what is the level of toxicity of those aggregates at cellular level. 
Given that, not all aggregates generated are toxic, if we could investigate the toxicity of 
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aggregates based on its morphology or biophysical properties would provide a big insight 
in understanding the molecular mechanism in disease process as well as help in selecting 
the targets for drug discoveries. This topics will also be discussed in chapter 3 and 4.  
Explanation of techniques used in conducting experiments described in chapters 3, 4 will 
be discussed in Chapter 2. Various techniques ranging from cell biology, biophysical and 
biochemical and imaging will be covered. This provides details on each technique along 
with its applications which helps to guide as we go through experimental details in Chapter 
3 and 4.  
Future applications of the projects are discussed in Chapter 5. In future, since we have 
already standardized the method of purification of full- length protein, more TDP-43 full-
length protein can be generated to study in great detail of its biophysical and biochemica l 
properties. Though, we have some preliminary data on disulfide status of protein by 
treating with mal-PEG, more extensive study can be conducted using different 
concentration of reducing agent and mal-PEG. This will help us to understand the disulfide 
status of the protein which is still ambiguous to all researchers. In addition, the role of pH 
on protein stability, structure and toxicity can be studied by altering the pH of the protein 
and observing its aggregation property, morphology and toxicity. Not only that the 
protein’s biophysical properties like hydrophobicity, flexibility etc. can be studied in great 
detail using biophysical techniques. Gathering all these, information’s together will 
provide some useful answers on structure of this protein and its associated toxicity.  
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Chapter 2: Methods 
In this chapter, I will discuss about the different techniques used in accomplishing the work 
explained in Chapter 3 and 4. This chapter serves as providing detailed information’s on 
each techniques with its applications and limitations. The work in one of the chapter is 
about the expression and purification of TDP-43 protein. And I also carried out biophys ica l 
and biochemical characterization of protein. To better understand the methods involved I 
have represented each project in flow-diagram along with its description.  
             
Figure 1: Schematic representation of techniques used in Expression and purification of 
TDP-43 protein.  
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Figure 2. Schematic representation of techniques used in chapter 4. 
2.1 Affinity chromatography  
Expression and purification of protein is routinely employed in biochemical studies. 
Among the different purification techniques, affinity chromatography is one of the 
powerful technique which involves the use of affinity tags that fuses with protein of 
interest. Immobilized metal-affinity chromatography (IMAC) is used for purification of 
recombinant proteins which contains short affinity tag like polyhistidine residues. 
Purification using polyhistidine tags has been used successfully in different expression 
systems like E.coli, mammalian, baculovirus infected insect cells, Saccharomyces 
cerevisiae. These tags are generally employed on either N- or C- terminal of the protein. 
IMAC chromatography results into high yield of protein purification with up to 95% of 
purity. IMAC employs the interaction of  the stationary phase which is the immobil ized 
matrix consisting of transition metal ion (Co2+, Ni2+, Cu2+, Zn2+) with the side chain of 
amino acid. Histidine has the high affinity with the metal ions like nickel ion present in the 
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column matrix and results into strong interaction due to the formation of the coordination 
bonds between imidazole ring on the histidine with the transition metal ion.  As a result of 
which, peptides that contain the histidine residues are retained in the column which can be 
eluted from the column by increasing the concentration of imidazole in the buffer system1 ,  
2. 
In Chapter 3, we used Ni-NTA affinity chromatography to purify our proteins. The column 
was was first packed with HisPur™ Ni-NTA resin. This resin has the capacity of binding 
upto 60mg of 6XHis tag protein per ml of resin and is applicable under both native and 
denaturing conditions. After packing the column, the column was equilibrated with 
equilibration buffer containing 10mM imidazole. Then, the protein lysate/urea soluble 
/detergent soluble fraction was loaded on the column and unbound fraction was collected. 
The column was further washed with wash buffer containing increasing concentration of 
imidazole to remove unbound fractions. Finally, the protein was eluted from column using 
the elution buffer with high concentration of imidazole.  
2.2 Polyacrylamide gel electrophoresis (PAGE) 
Electrophoresis is a technique that involves the separation of proteins based on the 
migration of a charged particles in an electrical field. Electrophoresis of proteins are 
generally carried out in Polyacrylamide gel which is a cross linked polymer that acts as a 
molecular sieve and slows the migration of proteins approximately in proportion to their 
charge to mass ratio. SDS PAGE (Sodium Dodecyl Sulfate Polyacrylamide Gel 
Electrophoresis) and Native PAGE are the most commonly used gel electrophoresis. SDS 
PAGE employs SDS (sodium dodecyl sulfate), an anionic detergent that denatures 
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secondary and non–disulfide–linked tertiary structures of a protein. One SDS molecule 
binds to every two amino acid residues thus the SDS confers a large net negative charge 
on the protein molecule that allows the migration of all proteins in the same direction. The 
proteins migrate through the pores in the gel towards the positive electrode at the bottom. 
By the end of electrophoresis, the smaller proteins will be closer to the bottom of the gel 
and the larger proteins will be closer to the origin. After electrophoresis proteins in the gel 
can be visualized by the use of Coomassie blue dye which binds to the proteins but not to 
the gel. Selection of proper gel concentration is critical for separation of proteins. Lower 
percentage gels are better for resolving high molecular weight proteins, while higher 
percentages are needed to resolve smaller proteins. SDS PAGE has a wide application like 
separating different proteins based on their molecular weight, monitoring the progress of 
protein purification, identifying molecular weight of unknown proteins based on the 
electrophoretic mobility with reference to standard marker, separating the different 
subunits of a protein. 
Native or Non-denaturing PAGE is a type of gel electrophoresis which is carried out in the 
absence of SDS so that the proteins are not denatured and are in well-folded structure. In 
this method, proteins are separated based on the protein's charge and their hydrodynamic 
volume. The mobility of proteins is based on the intrinsic charge on the protein at the pH 
of the running buffer. The proteins in the Native PAGE retain their folded conformation so 
the migration is also affected by the conformation of proteins i.e: higher mobility is seen 
for more compact conformations and lower for larger structures like oligomers. Native 
page is used to identify changes in protein migration due to oligomers, unfolded or molten 
globule or other modified conformation, changes in charge due to chemical modifica t ion 
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like degradation and aggregation. Another advantage of native gels is that it is possible to 
recover proteins in their native state after the separation. Therefore, Native PAGE is one 
of the most powerful technique for studying the composition and structure of native 
proteins, since both the conformation and biological activity of proteins remain intact 
during this technique.  
The electrophoresis gels are formulated in buffers such that it provides conduction of an 
electrical current through the matrix. In order to obtain optimal resolution of proteins 
stacking gel is casted over the top of the resolving gel. Also, the pH of Tris in stacking gel 
is 6.8 whereas the pH of Tris in Resolving gel is 8.8 which allows the proteins in a loaded 
sample to be concentrated into a tight band during the first few minutes of electrophores is 
before entering the resolving gel. This process occurs as Glycine ions has isoelectric point 
near pH 6 so at that pH glycine has net charge zero so it migrates slower in the gel and 
chloride ions has negative charge so can migrate faster in gel and proteins remain in 
between the Glycine and chloride ions forming a layer in the stacking gel. Selection of 
proper gel concentration is critical for separation of proteins. The gel consists of 
acrylamide, bisacrylamide initiator, TEMED, denaturant (SDS) and a buffer with an 
adjusted pH. Acrylamide has a property of auto polymerization and bisacrylamide forms a 
cross link with acrylamide and thus results into the gel. The concentration used will depend 
on the size of the proteins to be separated adequately. Ammonium persulfate is a source 
for free radical that initiate the process of polymerization. TEMED accelerate the rate of 
formation of free radicals from persulfate which in turn accelerate the polymerization. APS 
and TEMED should be prepared fresh as APS and TEMED are highly hygroscopic and 
start to decompose rapidly in presence of water leading to rapid loss of their reactivity. The 
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rate of polymerization and the properties of the resulting gel depend on the concentrations 
of free radicals. Increasing the amount of free radicals results in a decrease in the average 
polymer chain length, an increase in gel turbidity and a decrease in gel elastic ity. 
Decreasing the amount shows the reverse effect. Glycerol increases the density of the 
sample, and bromophenol blue which is a tracking dye that has the mobility higher than 
other analytes and helps to track the progress of electrophoresis3. 
In Chapter 2, we used SDS-PAGE for testing our proteins as well as for running western 
blot. The reduced samples were prepared by adding the 5% β-mercaptoethanol in sample 
whereas non-reduced samples were prepared by incubating the samples with 
Iodoacetamide for 2 hours in dark and the reaction was terminated by adding the sample 
buffer without reducing agents. Samples were boiled for 5 minutes and samples were 
loaded on 12% /15% SDS gels. The gel were run for 3 hours using Tris-Glycine-SDS 
running buffer (25mM Tris, 192mM glycine, 0.1% SDS, pH 8.3). The gels after separation 
were stained with Coomassie blue and after the destaining process the images were 
captured on Epson Scanner.  
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Figure 3: Schematic illustration of SDS-PAGE.  Protein samples are loaded on the wells 
and the samples run from cathode to anode under the application of an electric field. 
Reprinted with permission of the publisher.  
2.3 Western blot 
Western blot is the most commonly used technique in the cell and molecular biology. It is 
used to detect the protein in the blot separated by the gel. In this technique, first the 
protein/mixture of proteins is separated on the basis of molecular weight using the Sodium 
dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (PAGE). Using a proper 
membrane which can be PVDF (polyvinylidene difluoride), Nylon, or nitrocellulose, the 
gel is transferred into the membrane using the transfer buffer under the specific voltage. 
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PVDF membrane is more stable compared to other membranes and also allows relabeling 
and easy storage. PVDF membrane provides high protein binding capacity due to its 
hydrophobic nature. Nitrocellulose membrane is not good for use of transfer of low 
molecular weight proteins due to its large pore-size. However, it has the advantages of low 
background. The membrane becomes brittle and difficult to handle when it’s dry. Nylon 
membrane has lots of advantages but due to its high background binding and irrevers ib le 
staining of some dyes, it’s less common than the other two. The protein band is detected 
using the antibodies. The membrane after the transfer is blocked with blocking solution 
which is basically 5% skimmed milk or 5% Bovine Serum Albumin. The blocking step is 
carried out to remove any nonspecific binding. Blocking is followed by the incubation with 
primary antibody that is specific to the protein of interest. The unbound proteins are washed 
off and then incubated with the secondary antibody which is HRP conjugated is used to 
detect the protein band using the chemiluminesence method. The band observed can be 
quantified that is related with the amount of protein present. Detection method for the 
western blot can be direct or indirect. In the direct method, only one antibody is required. 
The primary antibody is conjugated to an enzyme or fluorophore which detects the antigen 
that is present in the blot. The most commonly employed detection method is the indirect 
detection method. In this method, the primary antibody is unlabeled, and this is added to 
blot to bind with the antigen and the detection is facilitated by the secondary antibody that 
is conjugated to the enzyme or fluorophore which may be biotin, fluorescent probes, HRP 
or Alkaline phosphatase (ALP). The advantage of using indirect method is same secondary 
antibody can be used for multiple primary antibodies4. 
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In chapter 2, we used Western blot to confirm the expression of our protein. After the run 
of the gels, the gel was transferred into PVDF membrane using the transfer buffer for an 
hour. The membrane was blocked with 5% skimmed milk for an hour and then incubated 
with primary antibody (1:4000) for overnight at 40C. Next day, the membrane was 
incubated with secondary antibody (1:10000) for 2 hours and finally the image was 
acquired using the GelDoc.  
2.4 Scanning Electron Microscopy 
Electron microscope uses the electrons instead of visible light used by light microscopes. 
The electron beams are travelled through the instrument which is facilitated by the high 
vacuum. Due to the smaller wavelength of the beam the electron microscope is superior to 
light microscopes in distinguishing smaller details. For example, the wavelength for 
electrons accelerate by 100kV is only 0.004 nm when compared to wavelength of green 
light which is 550 nm. There are basically two types of electron microscopes: Scanning 
electron microscopes (SEM) and Transmission electron Microscopes (TEM). Comparing 
two instruments in terms of resolution, SEM can resolve 1-5nm whereas resolution of TEM 
is 0.1nm. In TEM, image formation takes place by the electrons beam that is transmitted 
through the sample, whereas in case of SEM, the beam is scanned across the sample and 
signals are detected by the detectors which uses the electrons that are reflected from surface 
of the sample to generate the image. The field of view is wider in SEM in comparison to 
TEM. SEM is advantageous over TEM in detection of unstable biomolecules due to its 
utilization of low voltage in the range of 1-10kV. TEM on the other hand uses high voltage 
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in the range of 100-200kV which makes its use limited to stable biomolecules which is not 
affected by high voltage.  
When the incident electron beam strikes the sample, different types of electron emission 
are generated depending upon the type of interaction and depth of penetration. These 
signals can be backscattered electrons, secondary electrons, X-rays, transmitted electrons, 
scattered electrons, Auger electrons etc. Some of the signals produced are depicted in figure 
4. 
 
Figure 4: Representation of the different signals that are produced when interaction of an 
incident electron beam takes place with sample. SEM and TEM are used to detect most of 
these signals 5. Figure adapted from  
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Scanning Electron Microscopy (SEM) is the most widely used technique for imaging the 
morphology and composition of various materials. Although the use of SEM was described 
in 1942, its commercial use became available only in 1965 when Oatley and co-workers 
from Cambridge University reported their work. SEM has many applications apart from 
characterizing the topographical, morphological, and compositional information. It is used 
to detect, analyze or identify the crystalline structures, variations in compositions of 
chemicals surface fractures analysis, surface contamination examination. In SEM, the 
images are generated either by the backscattered electron (BSE) or the Secondary electrons 
(SE). Backscattered electrons are produced when the interaction between beam and the 
sample is elastic. The specimen’s atomic number greatly determines the production of 
backscattered electrons. As a result of which, the specimen with higher atomic number 
appears brighter compared to the one with lower atomic number making it’s uses in 
understanding composition of specimen. Secondary electrons are produced when the 
interaction between beam and the sample is inelastic. SE is the commonly used signal for 
imaging and is mainly related to the topography and used to detect the morphology of 
samples 6,7.  
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Figure 5:  FESEM images of 40µM lysozyme incubated at 370C for 24 hours. (A) Sample 
with 1mM TCEP (B) Sample with 1mM TCEP and 1M Glycine. Scale bar =10 µm, 5 µm 
and 1 µm from left to right respectively. 
The working principle of SEM is depicted in Figure 6. The electron gun forms a stream of 
electron under high vacuum. These electrons are then accelerated with upto dozens of Kev 
energy and focused by the electromagnetic lens into a monochromatic beam. This thin 
beam inject the sample and the interaction of beam with the sample is detected and 
transformed into an image.  
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Figure 6: Schematic representation of principle of SEM.  Figure adapted from Goldstein, 
J., et.al. Scanning Electron Microscopy and X-ray Microanalysis. Third Edition.  
One of the important aspect that needs to be taken care of while taking images of 
biomolecules, examples proteins using SEM is burning or degradation of the sample due 
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to the high energy electron bombardment. Also, when the nonconducting specimens are 
subjected to imaging, charge-up of specimen occurs and the secondary electrons are not 
emitted. As a result of which, image shift, deformation and abnormal contrast occurs. In 
order to prevent this, the specimens are first added into sputter and allowed to dry and then 
coated with conducting materials like gold or platinum. The average range for the coating 
varies from 1 to 20nm which depends on the samples’ stability.   
In the following chapters 3 and 4, the morphology of the aggregates were confirmed using 
a cold field emission high resolution scanning electron microscope (Hitachi S-4700 
FESEM). Samples were first diluted in MilliQ water and washed to remove the salts and 
buffer using Millipore Amicon® Ultra centrifugal filters (3 kDa cut off). For this, samples 
were centrifuged at the speed of 7,000 × g at 4oC and repeated thrice. After the washing 
step, samples were aliquoted on stubs and left to dry at room temperature. Before imaging, 
samples were coated with platinum at the thickness of 10 nm using a sputter coater. Images 
were acquired using the acceleration voltage of 10 kV and emission current of 5μA8. 
2.5 Cell based assays: 
Cell proliferation or viability is the most commonly employed technique to test the health 
of the cells. Cell metabolism and health can be affected by various physical and chemical 
agents. These agents can lead to cellular toxicity either by preventing protein synthesis, 
leading to cellular destruction, binding to receptors in irreversible manner, or inhibit ing 
enzymatic reactions. This makes need of effective, cheap and reliable method to test cell 
viability as well as toxicity9.  Different methods are available for testing cell viability or 
cytotoxicity like colorimetric, dye exclusion methods, fluorometric and luminometr ic 
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assays. In the following sections two most commonly used assays for cell viability and cell 
toxicity as well as measurement of free radical will be discussed. 
2.5.1 MTS assay  
MTS assay is a colorimetric method that is used for determining the number of viable cells. 
This assay is commonly employed for testing cell proliferation, cytotoxicity and chemo 
sensitivity assays. The principle lies on formation of colored formazan from the conversion 
of a tetrazolium salt (5-(3-carboxymethoxyphenyl)-2-(4,5-dimethyl-thiazoly)-3-(4-
sulfophenyl) tetrazolium, inner salt by the activity of living cells. The quantity of formazan 
product as measured by the amount of 490nm absorbance is directly proportional to the 
number of living cells in culture. MTS assay has many advantages ranging from 
convenient, rapid, sensitive, economical and precise method for measuring in vitro cell 
proliferation assay. The disadvantages of this assay is the absorbance value measured at 
490nm is affected by the length of incubation, cell type, cell density and the ratio of reagent 
to cells in culture. Studies suggested that within the short time incubation i.e. upto 5 hours 
the linear relationship was observed for incubation time and absorbance 9,10. 
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Figure 7: Mechanism of MTS assay. Structures were drawn using ChemDraw Pro 17.1 
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Figure 8: Representation of general scheme for MTS assay. 
In the current thesis, MTS assay was employed to detect the cell viability in chapter 4. The 
effect of aggregates amyloid beta protein was tested using SH-SY5Y human neuroblastoma 
cells (from ATCC). In brief, SH-SY5Y cells was cultured in DMEM/F-12 medium 
containing 10% FBS and 100 U/ml penicillin-streptomycin. The cells were seeded at the 
density of 2 x 104 cells/well on 96-well plates and incubated overnight at 37oC in 5% CO2 
humidified environment. All cellular experiments were conducted within first 10 passage 
of cells. Following day, the cells were washed twice with 1X PBS. Then, 100 µl of fresh 
media containing samples at desired concentrations were prepared and added to cells in 
replicates of six. The cells containing samples were incubated at 37oC in 5% CO2 
humidified environment for 48h. Similarly, controls were prepared without adding any 
samples and containing only cells. After the incubation, MTS reagent ( CellTiter 96® 
AQueous One Solution Cell Proliferation (MTS) Assay kit (Promega)) was added to each 
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well and incubated for 4 h at 37oC.  Finally, the absorbance was measured at 490 nm using 
a plate reader (BioTek Instruments, Inc.). Blanks were prepared for background subtraction 
and contained only media with test samples but without any cells.  
 2.5.2 Lactate dehydrogenase (LDH) assay 
LDH is commonly employed technique for detecting the cytotoxicity in the cells. A 
cytosolic enzyme (LDH) is present in different types of cells and is released when there is 
damage to plasma membrane. The amount of released LDH can be quantified by using a 
coupled enzymatic reaction.  In the first step, the conversion of lactate to pyruvate is 
catalyzed by the LDH through the reduction of NAD+ to NADH.  Secondly, the 
tetrazolium salt (INT) is reduced by diaphorase using NAD+ leading to the formation of a 
red formazan product. The amount of LDH released in the media is directly proportional 
to the level of formazan formation which is measured by taking absorbance at 490nm. LDH 
assays has several features ranging from its reliability, quick and easy evaluation of cell 
death. On the other hand, when talking about the limitations, some of the compounds like 
serum (e.g. fetal calf serum) have inherent LDH activity leading to high background 
reading. So, serum free or low serum media is usually preferred for this assay 9,11,12. 
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Figure 9: LDH assay principle.  
LDH assay was employed to test the toxicity of aggregates to cells in chapter 4. The effect 
of aggregates from amyloid beta peptides were tested using SH-SY5Y human 
neuroblastoma cells (from ATCC) and  primary neuronal culture. In brief, SH-SY5Y cells 
was cultured in DMEM/F-12 medium containing 10% FBS and 100 U/ml penicillin-
streptomycin. The cells were seeded at the density of 2 x 104 cells/well on 96-well plates 
and incubated overnight at 37oC in 5% CO2 humidified environment. All cellular 
experiments were conducted within first 10 passage of cells. Following day, the cells were 
washed twice with 1X PBS. Then, 100 µl of fresh media containing samples at desired 
concentrations were prepared and added to cells in replicates of six. The cells containing 
samples were incubated at 37oC in 5% CO2 humidified environment for 48h. Simila r ly, 
controls were prepared without adding any samples and containing only cells. After the 
end of incubation, 10 μl of lysis solution (CytoTox 96® Non-Radioactive Cytotoxic ity 
Assay (LDH) Assay kit, Promega) was added to maximum LDH release control wells and 
incubated for 45 minutes at 37 °C in 5% CO2. Then, 50µl of supernatant from all the wells 
were transferred into a new plate and to each of those wells 50µl of LDH reagent was 
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added. The plate was further incubated in dark for 30 minutes. After incubation, 50µl of 
stop solution was added to each well. Absorption at 490 nm were collected using a plate 
reader (BioTek Instruments, Inc.). Blanks were prepared for background subtraction and 
contained only media with test samples but without any cells. 
2.5.3 ROS measurement 
Reactive oxygen species (ROS) are formed by the reduction of oxygen molecules which 
contains unpaired electron (one or more) and are highly reactive in nature. The most 
commonly occurred ROS includes superoxide radical (O2−), hydroperoxyl radical 
(HO2−), hydroxyl radical (HO−), peroxyl radical (ROO−), alkoxyl radical (RO−), 
hydrogen peroxide (H2O2), singlet oxygen (1O2), nitric oxide (NO) and hypochlorous acid 
(HOCl). ROS plays an important role in health and diseases like they are known for their 
protective and functional role in immune system. On the other hand, they are thought to 
play role in cancer, neurodegenerative diseases, atherosclerosis, and diabetes. Cells have 
antioxidant defense mechanism to overcome the production of free radicals in the cells. 
However, oxidative stress occurs when the balance of free radicals exceeds its defense 
mechanism. Reactive Oxygen Species (ROS) can be easily measured using 2′, 7′–
dichlorofluorescin diacetate (DCFDA), where the nonfluorescent DCFDA is converted to 
the fluorescent compound in presence of ROS. The scheme for this reaction is shown in 
Figure 10.  This assay is very sensitive to changes in redox state of the cell and is easy to 
perform and is an inexpensive method which can be used to detect the changes in ROS 
over the time 13,14,15. 
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Figure 10: Reaction showing the conversion of DCFDA to fluorescent compound by 
ROS.  Structures were drawn using ChemDraw Pro 17.1 
In chapter 4, we used 2',7'-dichlorofluorescin diacetate (DCFH-DA) fluorescence assay to 
measure the ROS in the cell.  Like MTS and LDH assay, SH-SY5Y human neuroblastoma 
cells (from ATCC) were cultured and were plated at 2 × 104 cells/well on 96-well plates 
and allowed to grow overnight. The next day, cells were washed with 1X PBS buffer (pH 
7.4) twice. Then, cells were incubated with 20 µM DCFH-DA for 45 minutes at 37 °C in 
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dark. After incubation, the cells were washed twice with 1X PBS (pH 7.4) and then 100µl 
of fresh media containing peptide samples were added to DCFH-DA (Sigma) treated cells 
in six replicates and incubated for 24 h at 37 °C in 5% CO2 humidified environment. Cells 
without any treatment and blanks were also incubated under identical condition. For 
positive control, cells after DCFH-DA treatment were incubated with 50 µM of t-butyl-
hydroperoxide (tBHP) for 4 h at 37 °C. Finally, the fluorescence intensity was measured 
using fluorescence plater reader (Fluoroskan Ascent, Thermo Scientific) at excitation 
wavelength of 485 nm and emission wavelength of 538 nm.  
2.6 UV-Vis spectroscopy  
UV- Vis spectroscopy deals with the measurement of absorbance in the UV and visible 
range ranging from 200-800nm. While fluorescence spectroscopy measures the transitions 
from excited to ground state, absorption spectroscopy measures the transition from ground 
to excited state.   The principle of UV-absorbance is based on the Lambert Beer’s Law.  
According to the Beer-Lambert Law, the absorbance of a solution is directly proportional 
to the concentration of the substance present in that solution and is expressed as,  
A = c l 
Where, A = absorbance; l = optical path length expressed in cm; = molar extinct ion 
coefficient, expressed in M-1cm-1; c= molar concentration. The three aromatic amino 
acids namely Phenylalanine, Tyrosine and Tryptophan are responsible for the absorption 
of light in UV range. Protein shows the absorption maxima around the wavelength of 
280nm due to the presence of these three aromatic amino acids. Among them phenylalanine 
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contributes the least due to its lower absorptivity and is usually not accounted for protein 
UV absorbance. UV-Vis spectroscopy is also used to measure the concentration of a 
sample. It is widely used for the quantitative analysis and also for measurements of 
conformational changes of proteins and nucleic acids, ligand-binding reactions. Since, the 
absorbance not only depend on the structure but also only the local environment, this 
method is also used to quantify the protein aggregation. This is basically accomplished by 
measuring the turbidity of the solution. The increase in turbidity leads to increase in 
absorbance which signifies the increase in protein aggregates. 
2.7 Fluorescence spectroscopy  
Fluorescence is a slow process which usually occurs in the order of 10-9 to 10-7 seconds. 
When an molecule receives an energy of certain wavelength it is excited from ground state 
to its excited state. Since, the excited electron is not stable in its excited state, it returns 
back to the ground state emitting a light of certain energy which is measured as a 
fluorescence. Fluorophores are the fluorescent compounds and are aromatic in nature. 
Jablonski diagram best describes the phenomenon of absorption, fluorescence and 
phosphorescence which is shown in Figure 11. As shown in the figure below, the radiative 
transitions are represented by the solid arrows and the non-radiative transitions are 
represented by the dashed arrows. The notation S0, S1 and S2 represents the different 
energy levels namely ground, first and second respectively. Internal conversion and 
Intersystem crossing are an example of the non-radiative transitions. Intersystem crossing 
occurs between the states of different spin multiplicity. Coupling of vibrational state of 
higher electronic state to lower electronic states results into internal conversion. For 
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Emission of photons leads to release of energy and is observed when electron return to 
different vibrational level of S0 from S1. This emission is measured as fluorescence. 
Phosphorescence is generally observed when the electron from triplet state return back to 
ground state. Compared to S1, triplet state is lower energy level hence phosphorescence 
has longer emission wavelengths than fluorescence. 
Intrinsic and extrinsic fluorescence are the most commonly used fluorescence methods to 
detect the changes in protein structure. Fluorescence spectroscopy is widely employed 
technique in studying the protein folding due to its sensitive detection of emission spectra, 
which is greatly affected by the change in local environment as well as the structure of the 
fluorophore.  
 
Figure 11. Jablonski diagram representing the absorption, fluorescence and 
phosphorescence. The different electronic states are represented by S0 (ground), S1 (first), 
S2 (second), and T1 (triplet) state. Fluorescence and Phosphorescence represents the 
radiative transitions and internal conversion, intersystem crossing and vibrationa l 
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relaxation represents the non-radiative transitions. Figure Adapted from Alvaraz.V. et.al. 
201221. 
Intrinsic fluorescence of a protein is the mainly contributed by two aromatic amino acids 
tyrosine and tryptophan. Due to the highest absorption coefficient of tryptophan compared 
to other two aromatic amino acids Phenylalanine and Tyrosine (Figure 2.9), intrins ic 
fluorescence is measure of tryptophan residue. The fluorescence contributed by the 
tryptophan is highly sensitive to local environment as a result of which, it can be blue 
shifted which is towards shorter wavelength when the protein is under the native condition 
and red shifted fluorescence is observed when the protein is unfolded. This characterist ic 
can be used to monitor the conformation change of a protein and measure the protein 
unfolding phenomenon. During folding of the protein, the hydrophobic residues are buried 
down in the protein core and is not exposed to the solvent. . The intrinsic fluorescence can 
be used to study the protein denaturation in presence of denaturants like Guanidine HCl 
(GdnHCl) at different pH. Figure 13, Shows the chemical denaturation of cytochrome C 
protein at pH 4, 7 and 10. The protein cytochrome C in presence of denaturant guanid ine 
HCl (GdnHCl), shows the increase in the fluorescence intensity with the increase in the 
concentration of the guanidine HCl. This is due to exposure of the hydrophobic residue 
especially Tryptophan to the aqueous environment during the process of protein unfold ing. 
The peak fluorescence intensity thus observed can be used to plot the denaturation curve 
which is in the sigmoidal shape (Figure 13). The native fit line, transition fit line and 
denatured fit line obtained from the curve helps to calculate the different thermodynamic 
parameters like ΔG, ΔH, ΔS, Cm.  
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Figure 12: Structure of three aromatic amino acids Phenylalanine (Phe), Tyrosine (Tyr) 
and Tryptophan (Trp). Structures were drawn using ChemDraw Pro 17.1 
      
Figure 13. Chemical denaturation curves of Cytochrome C at pH 4.0, 7.0, and 10.0 as a 
function of guanidine HCl concentration. Fluorescence emission of proteins were collected 
at 300-600 nm, with excitation at 280 nm. The peak intensities at 355 nm were normalized 
as fraction of denatured. Concentration of protein was 0.3 mg/ml at all pH.  
Extrinsic fluorophores are the compounds that are covalently linked to ligands or proteins 
and associated with the transfer of fluorescence energy. Electrostatic and hydrophobic 
interactions are the major non-covalent interactions that are involved during the interaction 
of extrinsic fluorophores with proteins. These dyes are very sensitive to the local 
environment. Extrinsic fluorophores help in characterization of protein such as it can be 
used to study the changes in conformation, structure, size, kinetics of a protein, surface 
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hydrophobicity, probe active sites of enzyme, detect intermediates of molten globule, 
monitor folding and unfolding of protein, and its species that are produced during the 
process of aggregation 22. 
Table 2.1. Common extrinsic fluorescent dyes and their applications / 
Dyes Applications 
Thioflavin T (ThT)  Detect the morphology of aggregates 
ANS  Protein folding, Aggregation Kinetics, Surface 
hydrophobicity 
Bis-ANS Protein conformation , Surface hydrophobicity, Protein 
folding and unfolding kinetics 
Congo Red Amyloid fibril analysis 
Nile Red Detect changes in protein conformation, surface 
hydrophobicity unfolding/folding 
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Figure 14: Some common extrinsic fluorescent dyes used in protein aggregation studies. 
Structures were drawn using ChemDraw Pro 17.1 
ANS (1-anilinonaphthalene-8-sulfonate) and Bis-ANS (dimeric analogon 4, 4′-bis-1 
anilinonaphthalene-8-Sulfonate), are the fluorescent dyes that are used for the protein 
characterization. The dye ANS is the most commonly used dye to measure the surface 
hydrophobicity. ANS fluorescence is highly sensitive to the local environment and shows 
increase in fluorescence in non-polar environment whereas in polar environment it is 
weakly fluorescent. Also, the fluorescence depends on the polarity, viscosity and 
temperature of dye’s environment. The increase in quantum yield with the blue shift of 
emission maxima results from the decrease in dielectric constant of the solvent. The 
mechanism for binding of ANS to protein is through the hydrophobic and electrostatic 
interactions. However, the sulfonate group of ANS pairs with the positive amino acids on 
the proteins like lysine, arginine and histidine through ion-pairing making it the 
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predominant interactions. Apart from this the weak forces like van der Waals interactio ns 
is also necessary to make the ions pairs stable. On the other hand, the major interaction 
between Bis-ANS and protein is the hydrophobic interaction. The binding affinity may 
vary due to the different sizes of the dye and the number of binding sites present on the 
protein. Both dyes have similar intrinsic fluorescence properties but when compared to the 
UV absorption and fluorescence emission, Bis-ANS displays UV-absorption maximum as 
well as emission shifted towards longer wavelength. Though the interaction in Bis-ANS is 
driven by the hydrophobic interaction it does not bind strongly with the organized 
structures. For its strong binding, it requires the molten globule like structures and has 
weak reactivity towards amyloid fibrils. Therefore, ANS and Bis-ANS provides different 
information in protein aggregation. Bis-ANS provides information on flexibility of the 
structure of aggregates i.e. whether it forms loose or tight structures. Tht (Thioflavin T) is 
a fluorescent dye that is most commonly used to characterize the amyloid fibrils. The 
fluorescent intensity of Tht dye is less depended on the polarity and affected by the 
viscosity and rigidity of the environment. The interaction of the Tht to amyloid fibril is 
driven by the hydrophobic interactions with the side chains of amino acids. Now it is 
evident that Tht not only binds to the fibrils but also to the non-fibrils structure resulting 
into the increase in fluorescence.  
In chapter 4, Horiba Jobin Yuon spectrofluorometer (Fluoromax-4) was used for 
fluorescence measurement. All dyes stocks were prepared in 100% ethanol and were 
diluted in respective buffers to prepare working stocks for incubation with samples. UV-
Vis spectrophotometer was used to measure the concentration of each dyes.  The extinct ion 
coefficient used was ANS ε350 nm = 5,000 M-1cm-1, bis-ANS ε385nm=16,790 M-1cm-
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1. Both dyes were used at the final concentration of 10µM and incubated with 10µM of 
protein samples on ice for 15 minutes before acquiring emission spectra. The emission 
spectra were collected from 400-700nm range with excitation at 360nm for bis-ANS and 
380nm for ANS dye. Samples were run in triplicates with incubation in dark with dyes. 
2.8 Immunofluorescence  
Immunofluorescence is the most commonly used technique to detect the localization and 
endogenous expression level of protein of interest by using the specific antibodies that is 
conjugated with the fluorescent dye. Immunofluorescence is a form of 
immunohistochemistry which uses fluorophores to detect the target. This technique can be 
used on cultured cells and individual cells, tissue sections. Several factor accounts into its 
application ranging from type of cells, nature of antigen, specificity and sensitivity of 
antibodies, permeabilization and fixation method, imaging of the cell. The fluorescence 
detection method involves the use of direct or indirect method 23. The direct method uses 
of single antibody that is linked to the fluorophore. The antibody recognizes the target 
antigen/ molecule and binds specifically to it which can be detected using the fluorescence 
microscope. This method has advantage over the indirect method because of the direct 
conjugation with the fluorophore which minimizes the number of staining step as well as 
problem of background signal, antibody cross-reactivity or non-reactivity. However, direct 
method is less sensitive compared to the indirect method. The indirect method on the other 
hand uses two antibodies primary and secondary. The primary antibody binds to the target 
molecule and secondary antibody contains the fluorophore which recognizes the primary 
antibody and binds to it. This method requires more steps than direct method.  
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In Chapter 3, we applied immunofluorescence technique to detect the cellular localiza t ion 
of our TDP-43 protein using N and C-terminal antibodies. Also, in chapter 4, to detect the 
effect of Abeta peptides on primary neuronal culture we employed immunofluorescence 
method in addition to cellular toxicity. The specific details on procedure is described under 
respective chapters. 
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3.1 Introduction: 
Amyotrophic lateral Sclerosis (ALS) is an adult-onset neurodegenerative disease 
characterized by the premature loss of upper and lower motor neurons leading to death of 
motor neuron in the brain, brainstem and spinal cord. Patients with ALS have life 
expectancy of only 3-5 years after the onset of disease1. About 10% of the ALS cases are 
familial and rest remains to be sporadic2-4. Frontotemporal Lobar degeneration (FTLD) is 
the second common form of cortical dementia observed in patients below the age of 655,6. 
FTLD leads to loss of neurons in the frontal and temporal cortex and is characterized by 
the alteration in personality, social behavior, and language dysfunction. The hallmark of 
ALS and FTLD includes ubiquitin positive abnormal protein aggregates in the brain of 
affected patients7,8. The presence of ubiquitinated aggregates of transactive response DNA 
binding protein 43 kDa (TDP-43) in FTLD and ALS patients in 2006 raised a lot of interest 
in understanding the role of this protein in the pathogenesis of ALS and FTLD diseases 
9,10,11. The pathogenic mechanism involved in ALS has not been solved yet but in case of 
FTLD and ALS patients, TDP-43 is known to be accumulated in the cytoplasmic inclus ion 
of affected areas of the spinal cord and brain12. The common pathological features with 
ALS and FTLD include the presence of cytoplasmic inclusions with ubiquitin and TDP-43 
positive, α-synuclein and tau negative. The primary cause for the ALS being identified as 
the dominant mutation in TDP-43 resulted in further research being directed toward 
understanding the role of TDP-43 in neurodegeneration13,14. In addition to ALS and FTLD, 
TDP-43 is also involved in several other diseases like Alzheimer’s, Parkinson’s, Lewy 
Body and Huntington15-18. 
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A 414- amino acid residue protein, TDP-43 is structurally distinguished into N-terminal, 
C-terminal and two-RNA binding domains (RRM1 and RRM2)19-27. Being a protein of 
nuclear origin, TDP-43 protein plays a significant role in health and diseases. Under normal 
conditions TDP-43 performs a wide variety of functions basically in the regulation of 
mRNA pathways which I will discuss in following paragraphs. 
 
Figure 1: Schematic representation of TDP-43 showing different regions.  
Biological Functions of TDP-43 
TDP-43 is known for its role in protein-protein interaction which occurs through the 
glycine rich C-terminal region. TDP-43 is associated with the members of hnRNP family 
like hnRNP A2/B1, hnRNP A1, hnRNP C1/C2 and hnRNP A3, interaction of which are 
dependent on C-terminal region. TDP-43 plays a wide variety of biological functions 
mainly in the regulation of RNA pathways as summarized in the figure 317, 19. 
a. TDP-43 as a transcriptional regulator 
The conversion of DNA to RNA is regulated by the transcriptional regulator. TDP-43 is 
well conserved among invertebrates and mammals and is expressed in almost all tissues.  
First identified in 1995, as a transcriptional inactivator of Human immunodeficiency virus 
type 1 (HIV-1), TDP-43 role is known in transcription repression. Binding of TDP-43 with 
the double stranded HIV TAR DNA repeats takes place through its RRMs domain. 
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Presence of polypyrimidine rich region in TAR DNA facilitates its binding with TDP-43 
as a result of which recruitment of TATA binding protein to TATA element is inhibited. 
TDP-43 also binds with mouse SP-10 gene promoter and is involved in transcript ion 
repression in spermatids18,19, 28-30.  
TDP-43 in splicing regulation 
Splicing is the process by which the introns are removed and the exons are joined together 
to produce the mature messenger RNA. TDP-43 is known to be involved in splicing 
regulation of several gene transcripts such as Cystic fibrosis transmembrane conductance 
regulator (CFTR), TARDBP, FUS, SNCA (α-synuclein), HTT (Huntingtin), and APP 
(Amyloid precursor protein). The splicing pattern of the targets is known to be altered by 
the level of TDP-43, i.e. overexpression or its depletion. The glycine rich C-terminal 
domain of TDP-43 is involved in the interaction with different proteins involved in splicing 
11, 6, 7. Being a member of hnRNP family, TDP-43 is found to interact with various members 
of hnRNPs like hnRNP A2/B1, hnRNP A1, hnRNP C1/C2 and hnRNP A3. The C-terminal 
region of TDP-43 is involved in binding with hnRNPs and the hnRNPs regulate the 
splicing. TDP-43 also regulates survival of motor neuron, apolipoprotein A2 and 
serine/arginine–rich splicing factor 211, 16, 18. 
 
b. TDP-43 in micro-RNA processing 
The presence of TDP-43 in Drosha complex (a nuclear RNase type-III protein) together 
with FUS/TLS as well as its association with the perichromatin fibers first raised the 
possibility of TDP-43 role in miRNA biogenesis. Further studies suggested the 
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dysregulation of several miRNAs upon depletion of TDP-43. An example of this includes 
let-7b, miR-9, miR-132, miR-520, miR-663 etc. 11,19, 20. TDP-43 is involved in 
dysregulation either by binding with the miRNAs or its precursors molecules. However, 
TDP-43 is involved in controlling the stability of Drosha protein during the neuronal 
differentiation.  
c. Role of cytosolic TDP-43 in regulation of RNA subcellular localization 
TDP-43 is a nuclear protein and can shuttle between nucleus and cytoplasm. It performs a 
diverse role in nucleus and cytoplasm. In the cytosol, TDP-43 regulates the subcellular 
localization of RNA as well as its transport, translation and stress-granule formation. TDP-
43 role in translation repression is also known by interacting with proteins involved in 
translation.  
During the condition of stress, the formation of cytoplasmic foci represents TDP-43 as a 
component of stress granules. Under the condition of stress TDP-43 translocate into 
cytoplasm and colocalizes with stress granules and may play role in mRNA stability as 
well as its trafficking. However, how the TDP-43 positive stress granules play role is yet 
to be identified16, 29, 30,33. 
d. Role of TDP-43 in mRNA stability  
Though identified to be highly localized in the nucleus and perform its functional activity, 
role of TDP-43 is also identified in the cytoplasm. TDP-43 is involved in the transport, 
stability and translation of mRNA in the cytoplasm. The role of TDP-43 in mRNA stability 
was first identified in two targets namely human low molecular weight neurofilament and 
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the histone deacetylase HDAC6 transcripts.  More mRNAs are now known whose stability 
is altered by TDP-43. An example of this includes: Add2, VEGFA and GRN, and IL-6 34.  
The maintenance of neuronal activity and synaptic plasticity in the neurons requires the 
transport of mRNA into axons and dendrites. In a study reported by Fallini et.al. 2012, 
TDP-43 was known to be actively transported along axons in primary motor neurons. Also, 
TDP-43 colocalizes with other RNA binding proteins like SMN and FMRP, in RNA 
granules 34. 
e. Role of TDP-43 in Genome stability 
TDP-43 is important for early mouse embryogenesis, the homozygous disruption of tar 
DNA binding gene are embryonically lethal. The expression of TDP-43 is tightly regulated. 
It has been observed that the knockdown of TDP-43 leads to death of differentiated neurons 
as well as tumor cells. Similarly, the lethality of the second-larvae stage in Drosophila 
occurs due to TDP-43 disruption while semi-lethality was reported by some other groups 
35. 
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Fig 2: Biological functions of TDP-43. TDP-43 plays a wide variety of biological functions 
mainly in the regulation of RNA pathways28. (a) TDP-43 being a component of 
heterogenous ribonucleoprotein (hnRNPs) participates in the pre-mRNA splicing 
regulation.  (b)TDP-43 binds to the 3' untranslated region and affects the mRNA stability 
as well as turnover (c) TDP-43 localize with the RNA granules and is involved in mRNA 
trafficking as it can shuttle between nucleus and cytoplasm. (d) TDP-43 is part of the 
Drosha complex and is involved in processing of miRNAs (e) TDP-43 can act as a 
transcriptional repressor by binding to the promoter sequences of single stranded DNA. (f) 
TDP-43 stabilizes the mRNA under the condition of stress by colocalizing with the stress 
granules. (Figure reprinted from Lee , et.al. Used with permission from the publisher)  
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TDP-43 distinguished into different domains, possess specific roles. Compared to other 
domains, N-terminal domain function was explored late and was found to be crucial for 
regulating its self-interaction. Also, N-terminal region is reported  to regulate TDP-43 
aggregation. RRM1 and RRM2 domain is involved in binding to RNA/DNA sequence and 
protein-protein interaction takes place through Glycine rich C-terminal domain 11,18, 19, 32. 
TDP-43 plays an important role in health and disease. Being involved in the pathways of 
RNA regulation, TDP-43 under pathological conditions is involved in several 
neurodegenerative diseases.  
TDP-43 in neurodegeneration 
TDP-43 first identified to be involved in neurodegenerative disease as a ubiquitinated 
neuronal cytoplasmic inclusions in FTD and ALS patients is also known to be involved in 
several neurodegenerative diseases like Alzheimer’s, Huntington, Parkinson’s Lewy 
bodies 37-42. In 97% cases of ALS, TDP-43 inclusions are known to be positive. The 
common pathological features include ubiquitinated and hyperphosphorylated aggregates 
in the cytoplasm, devoid of TDP-43 in the nucleus. All of the neurodegenerative diseases 
that are associated with deposition of TDP-43 are commonly termed as ‘TDP-43 
proteinopathies’ which possesses common pathological features. Intracellular and 
extracellular accumulation of protein aggregates comprises the major characteristics of 
wide variety of neurodegenerative diseases. Although neurodegenerative diseases like 
Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), 
Amyotrophic lateral sclerosis (ALS) have distinct proteins associated with them such as 
SOD1 with ALS, Amyloid β with Alzheimer’s etc. There’s a renewed focus on TDP-43 as 
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its role and importance in all these diseases have been reported. There lies a common 
pathogenic mechanism involved in many neurodegenerative diseases, which involve the 
central nervous system amyloidosis because of aggregation and deposition of misfo lded 
protein. During this process, the soluble proteins are transformed into the insoluble and 
filamentous polymers, which are rich in cross-β-pleated sheet structures. These structures 
accumulate in the nuclei or cytosol as a fibrillar amyloid deposits in the affected brain cells 
or in extracellular space. For the majority of neurodegenerative diseases, the effective 
method of treatment is lacking due to difficulty in identifying the disease-causing toxic 
fold of the protein. As TDP-43 is involved in multiple neurodegenerative diseases it has 
been target of study by basic and clinical researchers, as well as industry to understand its 
role in the disease process.  
 The cytoplasmic localization of TDP-43 is the common feature observed in 
neurodegenerative diseases. Apart from this, the modifications like hyperphosphorylat ion, 
ubiquitination and C-terminal truncation is observed in several neurodegenerative diseases. 
Most of the mutations in TDP-43 is present in C-terminal domain. The hyper-
phosphorylated and ubiquitinated C-terminal fragment of TDP-43 comprises the major 
component in the neuronal inclusion bodies in case of ALS and FTLD patients. 
Experiments carried out in cultured cells showed that the prion -like activity is present in 
TDP-43 and is capable of converting the normal cells into the abnormal form 32. Due to the 
importance of C-terminal domain, there is increasing demand to examine the sequence of 
this domain.  Analysis by PONDR PROGRAM, which predicts the naturally disordered 
region, identified that about 80% of the C-terminal region is structurally disordered 41. The 
intrinsically disordered proteins can undergo the transition between order/disorder when 
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they bind with their partners even though they lack the secondary and tertiary structures in 
their native states. The structure of full- length TDP-43 protein has not been determined by 
traditional methods such as NMR or X-ray crystallography. The reported NMR and 
crystallography structures are for parts of protein that represent the RRM domains and the 
N-terminal region. Recently, a computational composite predicted structure of TDP-43 
full- length protein was presented based on NMR structure of RRM (2cqg, aa 81-191), 
RRM2 (1wf0, aa 186-273) 2N4P (aa1-77), and 2N2C (aa 307-349) as shown in figure 2. 
In 2010, Chen et.al attempted to explore the physical characteristics and conformationa l 
properties of the C-terminal domain by synthesizing four peptide fragments D1 (287-322), 
D2 (321-353), D3 (351-383) and D4 (381-414). Their study showed that the D1 formed 
the fibers and D2-D4 formed the amorphous aggregates further suggesting that the D1 
plays an important role in aggregate formation41. In a recent study conducted by Shimonaka 
et.al. (2016), amino acid sequence of TDP-43 that is necessary for aggregation was 
identified. The result showed that the glycine rich region, residues 274-313 is necessary 
for the aggregate formation. In addition, it was reported that the region 274-353 is 
necessary for the conversion of TDP-43 into the amyloid- like fibrils and the peptide fibrils 
had a seeding ability. Several research groups have carried out studies to identify the amino 
acid sequences of TDP-43 responsible for the aggregate formation (Figure 4). Although C-
terminal domain plays an important role in protein aggregation, N-terminal domain 
(residues1-77) has been found to play a role in the recruitment of TDP-43 monomers into 
the aggregation process. In a study carried out by Kametani et.al. (2016), novel cleavage 
sites in TDP-43 were reported suggesting the N-terminal half have the major cleavage sites 
42. Recently, more studies have been reported on the role of N-terminal domain of TDP-43 
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protein. In a study by Zhang et.al. (2013), the role of residues 1-10 in N-terminus was 
explored and was found to play an important role in folding of TDP-43 monomer as well 
as formation of TDP-43 inclusion43.  
 
Figure 3: Schematic representation of TDP-43 structure based on the NMR structure 
provided. Homology modeling and loop building technique was used to generate this 
schematic of composite TDP-43 structure 44. (Figure reprinted from Wobst J.H. et.al. 
(2017). Used with permission from the corresponding author) 
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Figure 4: TDP-43 protein schematic summarizes aggregation studies carried out on the 
protein using truncated constructs of varying lengths41-43, 45-48. A– Extreme N-terminus 
region is responsible for formation of TDP-43 inclusions. Zhang Y.J. et.al. (2013) Human 
Molecular Genetics. B – Truncated RRM2 forms amyloid negative fibrils. Wang Y. T. 
et.al. (2013) J. Biol. Chem. C – Residue 274-313 in glycine- rich region is essential for 
aggregation. Shimonako S. et.al. (2016) J. Biol. Chem. D – Residue 318-343 as the 
amyloidogenic core is essential for TDP-43 aggregation. Jiang L. L. et.al. (2013) J. Biol. 
Chem.  E – Region in RRM2 (246-255) and C-terminal (311-320) has a propensity to form 
aggregates and residue 311-320 plays the crucial role among both. Saini A. and Chauhan, 
V. S. (2011) Chembiochem. F – Residue 287-322 formed fibers whereas other residues 
taken under study were not amyloid in nature. Chen A. K. et.al. (2010) J.  Am.Chem. Soc.  
G – Transduction of aggregates prepared from in vitro functional TDP-43 triggered the 
intracellular aggregation of TDP-43. Furukawa Y. et.al. (2011) J. Biol. Chem. 
Advancement in the field of TDP-43 has led to identification of this particular protein in 
several neurodegenerative diseases. However, the exact mechanism of neurotoxicity is not 
clear and there are two main hypotheses: 1) supports the toxicity by toxic gain of function, 
and 2) the other supports the loss of critical function because of dominant negative 
mechanism. Both mechanisms of toxicity have been supported by several independent 
studies by scientists. In case of a gain-of-toxic function, two possible pathways are 
followed, first the overexpression of mutant in gene leads to disease phenotype, in which 
expression of normal phenotype (wild type) does not cause the disease.  In the second 
pathway, one of the normal functions is increased in a mutant gene to greater amount 
leading to the toxicity. In this situation, not only the mutant but also overexpression of wild 
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type gene will eventually lead to disease phenotype. A loss of function involves gene 
knockout or knockdown. A dominant-negative mechanism is the condition where the wild-
type allele function is affected by mutant allele, as the mutant allele will not be functiona l 
and inhibits the function of wild type. Studies suggests that the overexpression of this 
protein leads to toxicity. On the other hand, deletion of TDP-43 has been reported to be 
embryonically lethal. Furthermore, the absence of cytoplasmic TDP-43 aggregates was 
reported to develop disease in case of TDP-43 mutant transgenic mice suggesting that the 
loss of  TDP-43 function contributes to its pathogenesis. Also, in the study by Feiguin et.al., 
2009 the in vivo neurodegeneration was observed when the TDP-43 was depleted from 
neuron. Considering the aggregates of TDP-43, the answer remains unclear whether these 
aggregates have toxic or beneficial role. Studies suggest the direct toxicity of these 
aggregates while study carried out in Drosophila model suggests protective role of these 
aggregates in early stage of disease. TDP-43 has property of self aggregation and can 
sequester other proteins into its aggregates. However, how this process occurs and what 
factors play role is yet to be determined. As a consequence of TDP-43 aggregates abnormal 
function of protein such as disruption of mRNA transport, altered mRNA splicing, problem 
in cellular clearance pathways etc.12, 34, 45, 50. The figure below shows the pathologica l 
mechanism involved in neurodegeneration.  
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Figure 5: Pathological mechanism involved in TDP-43 neurodegeneration34. TDP-43 is 
involved in several neurodegenerative diseases like ALS, AD, HD etc. Under such 
conditions, the normal functions of TDP-43 is altered and cellular clearance mechanism is 
also affected. (Figure reprinted from Ratti, A et.al. Used with permission from the 
publisher).  
The above model underscores the diverse role TDP-43 plays in health as well as disease 
process. To better understand how these diverse functions maybe mediated by this protein 
we need to better understand its biochemical and biophysical properties. For carrying out 
characterization of physicochemical properties of TDP-43 protein we need pure protein 
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and preferably from a eukaryotic source. Biochemical and biophysical work reported on 
TDP-43 protein so far have been from protein expressed and purified using prokaryotic 
source such as bacteria. Furthermore, most studies are on truncated version of protein as 
indicated in figure 4. Except for computationally generated full-length structure of TDP-
43 protein (Figure 3), not much structural information is available on the full- length 
protein. Though, a substantial amount of work has been reported on TDP-43 protein, 
almost all of them involve the use of prokaryotic expression system. Therefore, to better 
understand the biochemical and biophysical properties of full- length TDP-43 protein and 
its implication for health and disease we need pure protein from eukaryotic source.  Protein 
from eukaryotic source will have all-natural posttranslational modifications, that is 
expected in an eukaryotic protein and will be better suited to understand the disease 
process. TDP-43 protein has six cysteine residues and studies so far have not clarified if 
there are any inter-chain or intra-chain disulfide bonds (or not) in the protein. Knowing the 
disulfide status of a protein will help to better understand proteins biophysical properties 
including role disulfide bonds (or sulfhydryl residues) play in protein aggregation and/or 
toxicity.  Hence, in this study we first standardized the protocol for purification of TDP-43 
full- length protein and C-terminal construct using the eukaryotic expression system. This 
will help us characterize biochemical and biophysical properties of full- length protein that 
may be different than the properties observed for truncated versions of the protein. 
Purification of TDP-43 has been challenging because it aggregates when overexpressed 
due to presence of intrinsically disordered region. We also carried out some preliminary 
studies on the effect of reducing agents on TDP-43 full- length protein aggregation and how 
it modulates the nature of aggregates.  
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3.2 Materials and Methods: 
1. Purification of TDP-43 protein: 
a) Preparation of expression constructs, production of recombinant baculovirus  
The Baculovirus particles were generated as reported previously (Hayward et al., 2002) 
with slight modification. Briefly, the recombinant Baculovirus were generated by 
transfecting the recombinant bacmid DNA into sf21 cells using the transfection reagent 
Cellfectin II (Invitrogen). The transfection was carried out in a 6-well plate seeded at 8 X 
105 cells/well. 1 µg of recombinant DNA and 8 µl of Cellfectin II reagent were mixed with 
Grace’s medium, unsupplemented (without antibiotics and serum) separately in equal 
volume. Both are combined and incubated for 30 min. at room temperature. The mix was 
added dropwise onto the sf21 cells and incubated at 27 °C for 5 hours. The transfectio n 
medium was removed and replace with 2 ml of complete growth medium (Grace’s Insect 
medium, supplemented + 10% FBS). The cells were incubated at 27 °C for 72 hours or 
more until the signs of viral infection was noticed. The cells and media were collected and 
centrifuged at 1000g/5 min. The supernatant containing the virus particles was stored at 4 
°C and cell pellet at -20 °C.  
b) Cellular localization of recombinant TDP-43 in insect cells 
The cellular localization of expressed TDP-43 protein was confirmed using 
immunohistochemistry. First, the High-five cells were cultured in a 6 well plates containing 
glass cover slips and incubated overnight at 27oC. Once the cells were nearly 50% 
confluent, infection with baculovirus generated for recombinant TDP-43 was performed 
and cells were incubated for 24, 48 and 72 hr at 27oC. Fixation was carried out for 15 
minutes at the end of each time point. For this, 3% paraformaldehyde in 0.1M Pipes buffer, 
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pH 6.9 was used. Cells were permeabilized by using 0.1% triton-X-100 in pipes buffer for 
15 min and rinsed with pipes buffer for 3 times of 5 min each. To prevent non-specific 
binding of antibodies, cells were incubated with 1% of BSA in 0.1 M pipes buffer and 
washed with pipes buffer three times of 5 min each. Cells were incubated with either anti-
TDP-43 (C-term) or anti-TDP-43 (N-term) antibodies or without any primary antibodies 
(negative control) in 1% BSA in 0.1M pipes buffer for 1 hr at room temperature. Excess 
antibodies were removed by rinsing with pipes buffer for 5 min and repeated for 3 times. 
The cells were further incubated with anti-rabbit secondary antibodies conjugated with 
Alexa Fluor 488 (Invitrogen, Cat# A11034) for 30 min at room temperature. Excess 
antibodies were rinsed with pipes buffer for 5 min and repeated for 4 times. Mounting 
media with DAPI was used to mount the coverslips on the glass slide. Finally, the images 
were acquired using the EVOS fluorescence microscope using DAPI and GFP light cubes.  
c) Expression and purification of TDP-43 full length protein in High five cells: 
High five cells were grown in Express Five Serum free media (externally supplemented 
with 20mM L-Glutamine and 1X antibiotic antimycotic) at 270C with a constant speed of 
impellor at 95rpm. The cells in suspension culture were infected with viral stock at a log 
phase density of 1.0-1.5 X 106 cells/ml. After 48-72h of infection, the cells were harvested 
at the centrifugation speed of 1000g for 10 minutes. A small portion of pellet was tested 
for protein expression and remaining was stored at -80oC.  
The purification of full length TDP-43 was carried out using the protocol published by 
V.Lee et.al 2015 with slight modification51. The cell pellet was extracted in RIPA buffer 
(50mM Tris pH 8.0, 150mM NaCl, 1% Triton X-100, 5mM EDTA, 0.5% sodium 
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deoxycholate, 0.1% SDS, 1mM phenylmethylsulfonyl fluoride, and phosphate inhibitors 
(2mM imidazole, 1mM NaF,1mM sodium orthovanadate)) and centrifuged at the 
centrifugation speed of 19000 rpm (42000g) at 40C for 30 minutes. Then, the insolub le 
pellet was re-extracted in RIPA buffer at same speed and the resulting insoluble fraction 
was extracted in the urea buffer (30mM Tris pH 8.5, 7M urea, 2M Thiourea and 4% 
CHAPS) at the centrifugation speed of 42000g at 250C.  The soluble fraction was then 
subjected to the purification by Ni-NTA affinity chromatography. The column was 
equilibrated with equilibration buffer (30mM Tris pH 8.5, 7M urea, 2M Thiourea, 4% 
CHAPS containing 10mM imidazole). The unbound proteins were washed by increasing 
the imidazole concentration to 50mM and decreasing the buffer component by 25%. 
Finally, the protein was eluted in 30mM Tris pH 8.5, 300mM NaCl, 500mM Imidazo le. 
The eluted fractions containing the TDP-43 protein were identified by SDS-PAGE and 
western blot. The fractions were pooled, concentrated, and stored at -800C. 
2. SDS PAGE and Western blot: 
Protein estimation was done by using BCA (Bicinchoninic acid) assay.  Samples for SDS 
PAGE were prepared by incubating the desired concentration of protein with 3X SDS 
sample loading buffer for 5mins in a boiling water bath. The proteins were then separated 
in 12% SDS polyacrylamide gel by running the gel at 80V for 3 hours in a running buffer 
(25 mM Tris (pH 8.3), 192 mM glycine, and 0.1% SDS). The gels after the run were stained 
in R-250 stain (0.1% Coomassie Blue R250, 50% methanol, 10% glacial acetic acid) 
overnight and destained in fast and slow destaining solution. Finally, the image was 
captured using an Epson Scan. 
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After the completion of 3 hours of run, the gel was electro blotted into PVDF membrane 
for western transfer.  The transfer was carried out at 100V for 1 hour. The membrane was 
blocked in 5% blocking solution for 1 hour at 40C shaker and incubated with primary 
antibody (1:4000) for overnight. Next day, the membrane was incubated with secondary 
antibody for 2 hours in Goat anti-rabbit IgG-HRP (1:10000).  Finally, the membrane was 
imaged using the Gel Doc System.  
3. Reducing and Non-reducing SDS PAGE: 
Reduced sample was prepared by adding 5% beta-mercaptoethanol while non-reduced 
sample was incubated with 1mM Iodoacetamide for 2 hours at room temperature. The 
reaction for non-reducing sample was terminated by adding SDS sample buffer without 
reducing agent. All sample was subjected to boil for 5 minutes and loaded (1.5µg/lane) on 
gel. The gel was run for 3 hours at 80V in a running buffer (25 mM Tris (pH 8.3), 192 mM 
glycine, and 0.1% SDS). The gels after the run were stained in R-250 stain (0.1% 
Coomassie Blue R250, 50% methanol, 10% glacial acetic acid) overnight and destained in 
fast and slow destaining solution. Finally, the image was captured using an Epson Scan. 
3.   Field Emission Scanning Electron Microscopy  
The morphology of the aggregates was studied using Hitachi S-4700 field-emiss ion 
scanning electron microscope (FESEM). For FSEM imaging protein (1µM) was incubated 
in buffer (30mM HEPES buffer pH 7.2 + 150mM NaCl) for 0h, 1h, 6h and 48h at 370C 
under reducing environment i.e. at different concentration of TCEP (0,1mM and 10mM). 
After the incubation, samples were washed using Millipore Amicon Ultra centrifugal filters 
(3000 Da – 5000 Da cut off) to remove the impurities. The samples were allowed to dry at 
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room temperature after aliquoting on Scanning electron microscope (SEM) stubs. The 
samples were coated with platinum on the SEM stubs at a thickness of 10nm using a sputter 
coater. Finally, the samples were imaged at the acceleration voltage of 5kV52.  
3.3 Results: 
We expressed and purified TDP-43 protein using the eukaryotic baculovirus expression 
system. Among the different insect cell lines like Sf21, High-five and Sf9, we choose High-
five cells because of its well-known expression of the secreted protein. As compared to 
Sf9, it expresses 5-10-fold higher secreted proteins. As shown in figure 6, we purchased 
different constructs of TDP-43 from Addgene. These constructs were 28206 consisting of 
full- length gene (1-414 amino acid residues and 1245 bp), 28207 which does not contain 
the N-terminal region of TDP-43 and consist of 86-414 amino acid residues and code for 
996bp of TDP-43. 29209 is the region without the C-terminal domain and consist of 1-314 
amino acid residues and codes for 948bp and lastly 28198 is the region containing glycine 
rich domain and C-terminal domain i.e. from 257-414 amino acid residues coding 471bp.  
The constructs thus obtained were confirmed by Polymerase Chain reaction (PCR) using 
the specific primers that were designed to subclone into insect expression vector. As shown 
in Figure 5, we did observe the gene inserts at the designated bp. In this study we choose 
to use insect expression vector, pFastBac/HBM-TOPO (Figure 6). This is due to the fact 
that it has eukaryotic expression system, Honey bee mellitus secretory signal, polyhedrin 
promoter (PPH) and 6XHis-tag at the C-terminal. This vector matched our focus of study, 
we aimed to express our protein in eukaryotic system with secreted overexpression and 
purify our protein through affinity chromatography. The positive recombinant 
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pFastBac/HBM-TOPO constructs were transformed into DH10Bac E.coli cells for 
transposition into the bacmid DNA. The transformation procedure was followed as per the 
Invitrogen user manual (Invitrogen, part# A11341) on Bac-to-Bac HBM-TOPO secreted 
expression system. Further, the positive bacmids were isolated using PureLink HiPure 
Plasmid DNA Miniprep Kit (Invitrogen) for high quality bacmid DNA. The bacmid DNA 
concentration was estimated by UV absorbance at 260 nm using Epoch Take3 micro-
volume plate (Bio-Tek Instruments, Inc.) and stored in aliquots at -20 °C to avoid freeze-
thaw cycles. The recombinant Baculovirus was generated by transfecting the recombinant 
bacmid DNA into sf21 cells using the transfection reagent Cellfectin II (Invitrogen). The 
supernatant containing the virus particles was stored at 4 °C and cell pellet at -20 °C. The 
outline for generation of recombinant bacmid followed by production of recombinant 
Baculovirus is represented in Figure 6. 
 
Figure 6: Different constructs of TDP-43 and vector used for sub-cloning.  The different 
constructs of TDP-43 namely 28206 (1-414 amino acid residues), 28207(86-414 amino 
acid residues), 29209 (1-314 amino acid residues) 28198 (257-414 amino acid residues) 
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were purchased from Addgene and pFastBac/HBM-TOPO insect expression vector was 
used for sub-cloning of these constructs.  
 
Figure 7: Verification of TDP-43 constructs obtained from addgene by PCR. Lane M: 
Marker, lane 1: TDP43-28206 (insert size 1245 bp), lane 2: TDP43-28207 (996 bp), lane 
3: TDP43-28209 (948 bp) and lane 4: TDP43-28198 (471 bp). (The cloning work was 
carried out by Dr. Ashutosh Tiwari and Dr. Jagadeesh Janjanam and the figure is placed 
with their permission). 
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Figure 8: Schematic representation for the production of recombinant Baculovirus (with 
TDP-43 genes) using sf-21 insect cells (source Invitrogen user manual, part # A11341).  
Cellular localization of recombinant TDP-43 protein in insect cell was confirmed by 
immunocytostaining. For this purpose, we used High-five cells and proceeded as described 
in material and method section for immunocytostaining. As previously stated, high-five 
cells are well known for more secretory protein production when compared to Sf9 and even 
Sf21 cells 56. As shown in figure 9 and 10, we did not observe any signal for Control cells 
i.e. High-five cells without any viral stock under GFP channel using both antibodies 
specific to N- and C-terminal. However, our immunocytostaining data for High-five cells 
using anti-TDP-43 antibodies specific to N-terminal (Figure 10) or C-terminal (Figure 9) 
sequences shows that the protein is stuck in the membrane than being a secreted in a media 
which can be seen under GFP channel. 
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Figure 9: Immuncytostaining of high-five cells after infecting with TDP-43 viral stock. 
The recombinant expression of TDP-43 was detected using anti-TDP-43 antibodies 
specific to C-terminal 
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Figure 10: Immuncytostaining of high-five cells after infecting with TDP-43 viral stock. 
The recombinant expression of TDP-43 was detected using anti-TDP-43 antibodies 
specific to N-term antibodies. 
Purification of protein was most challenging and we employed different combination of 
techniques to purify our protein. Among these methods, we applied different percentage of 
ammonium sulfate, detergent, and denaturing agents. Specific details on use of different 
purification techniques and data are provided in supporting information for chapter 3. First, 
I will discuss the results for purification of full- length TDP-43 protein. Before proceeding 
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to the purification step, it is important to check the expression level of protein to verify if 
our protein of interest is expressed or not. For that we checked each batch of our harvested 
cell pellets before carrying out the purification. This was accomplished by cell lysis 
followed by protein estimation by BCA assay and running different concentration of 
lysates in gel and carrying out western blot using anti-TDP-43 antibodies. As represented 
in figure S1, control/uninfected cell (Φ) and infected cell (I) lysates were loaded at different 
concentration (5, 10, 20 and 30 µg/lane) in SDS PAGE and Western blot. As shown in 
figure S1, the western blot data showed the presence of protein band (~50 kDa) only in 
infected cell lysate but not for control lane at all concentrations loaded. The SDS PAGE 
showed the multiple bands at all concentration but represents the identical loading for 
control and infected cell lysates. Further, SDS-PAGE confirms the need of further 
purification.  
Next, we proceeded to enrichment of protein by using ammonium sulfate. As represented 
in the flow chart figure S2, different percentage of ammonium sulfate was added to protein. 
We used 30% , 50% and 70% saturated ammonium sulfate solutions. As presented in 
figures S3-S4, we observed band for TDP-43 protein in Western blot for lysates 
supernatant (S) or pellet (P) fractions represented as S0 (total lysate after lysis) ,S30 (lysate 
after 30% ammonium sulfate precipitation) and P0 (pellet after cell lysis), and P30 (pellet 
after 30% ammonium sulfate precipitation). Only a faint band was observed for P50 and 
no band was observed for S50, S70 and P70. Ni-NTA purifications of P30 fraction showed 
band for TDP-43 eluted in different fractions but was not a clean single band as observed 
by SDS-PAGE (Figure S5-S6). In addition, significant amount of protein was also 
observed in bound flow through and wash flow through obtained from column. Analyzing 
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the results from ammonium sulfate precipitation, the protein did not completely precipitate 
in different percentage of ammonium sulfate solutions as shown by presence of protein in 
S0, S30, and P30.  
Our next step was solubilizing the protein using detergent. For that purpose, we used SDS. 
The SDS PAGE and Western blot data for detergent soluble fraction (Figure S14) 
represented the band for TDP-43 full length protein in western blot but not in SDS-PAGE. 
The higher amount of protein was observed with increasing concentration but some 
additional faint bands were also observed with increasing protein concentration. We saved 
the detergent insoluble fraction and ran them on gel loading different volumes (1, 4, 6, 10, 
14, 16 and 20ul) represented as DI2, DI4, DI6, DI10, DI14, DI 16, DI20 and ran detergent 
soluble 10µg/lane for comparison of band with detergent insoluble fraction (Figure S10). 
We observed the thick band for our protein of interest ~50kDa for all volumes loaded in 
SDS-PAGE but there were several other bands observed. Also, the thickness of band 
observed for DI2 was corresponding with detergent soluble loaded 10µg/lane. We observed 
that our protein band is present but contains impurities and most of the protein is in 
detergent insoluble fraction.  
After several rounds of trials and errors, we came up with the procedure that uses 
combination of salt, detergent and denaturant for solubilizing protein and purifying it to 
homogeneity. Using urea buffer combination helped us to purify protein with >95% purity 
(figure 11). The purity of protein in each step during this procedure is shown in Figure S11. 
As shown in figure, the control lysate , infected cell lysate , RIPA re-extracted fraction did 
not show any band in western blot. However, a clear band is observed for urea soluble and 
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NI-NTA purified fraction. Also, the SDS-PAGE corresponds the purified protein in Gel 
and Western blot. A clear depiction of urea soluble and purified protein is shown in figure 
11. Since, the same concentration of protein was loaded in gel and western blot i.e. infected 
lysate (10µg/lane), urea soluble fraction (5 µg/lane), Purified protein (2 µg/lane), the level 
and purity of protein is clearly detected. A significant amount of protein is seen in urea 
soluble fraction, but some impurities was observed but after NI-NTA chromatography, the 
eluted protein was found to be highly pure.  
 
Figure 11: Reducing SDS PAGE and Western blot showing the purification of TDP-43 
full length protein. Lane 1(infected lysate, 10µg/lane), Lane 2 (urea soluble fraction, 5 
µg/lane), Lane 3 (Purified protein, 2 µg/lane) was loaded on 12% SDS PAGE. The gels 
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were run for 3 hours. For Western blot, the blot was incubated with Anti-TDP-43 (N-
terminal region) produced antibody (1:4000) and Goat anti-rabbit IgG-HRP (1:10000). 
Aggregation of TDP-43 full- length protein was observed using FESEM. We did not 
observe any aggregates for TDP-43 full length protein fresh samples suggesting the protein 
is soluble. However, the aggregates were observed after 1 h  of incubation for all samples 
incubated in presence and absence of  TCEP and same phenomenon was observed for 6h 
and 48h of incubation (Figure 12). The shape of aggregates were different in presence and 
absence of TCEP but all were amorphous in nature. Increasing the concentration of TCEP 
from 1mM to 10mM also resulted into amorphous aggregates (Figure S11-S14).  
 
Figure 12: FESEM images of TDP-43 full-length aggregates in presence and absence of 
TCEP. TDP-43 protein (1µM) was incubated in presence or absence of TCEP (0,1mM) for 
0,1, 6 and 48h at 370C. Protein aggregates were observed under FESEM. Zoomed in image 
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for the area in the box is represented on its side.  Scale bar =10µM and 1µM from left to 
right. 
In order to investigate the status of disulfide bond in TDP-43 full- length protein, we first 
ran the protein samples under reduced and non-reduced conditions. Our data showed 
almost similar pattern in 12% SDS Gel for TDP-43 full- length protein (Figure 14). Since, 
we did not observe any difference in mobility and shape of protein,  we need to investigate 
further to understand the disulfide status of the protein.   
 
Figure 13: Amino acid sequence of TDP-43 full- length (1-414) protein representing acidic, 
basic, aromatic, polar uncharged, non-polar aliphatic groups and cysteine residues. Six 
cysteine residues are located in TDP-43 at the positions 39, 50, 173, 175, 198 and 244. 
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Figure 14: SDS PAGE showing TDP-43 reduced and non-reduced samples. Reduced 
sample (R) was treated with 5% beta-mercaptoethanol and non-reduced sample (NR) was 
treated with Iodoacetamide. Protein was loaded 1.5 µg/each lane and run on a 12% SDS-
PAGE for 3 hours.   
Purification of C-terminal construct (28198) was carried out in a way similar to as 
described for full- length protein. Like, full- length protein, majority of protein was present 
in the insoluble fraction after lysis so we solubilized protein in urea buffer before purifying 
on a Ni-NTA chromatography column (Figure S15-S16). 
3.4 Discussion : 
Expression and purification of protein is routinely employed in lab procedure to study its 
biophysical, molecular and physicochemical properties. However, identifying the proper 
method of purification yielding pure protein of interest is very challenging. In our study, 
we employed different combination of methods to purify TDP-43 protein. Among these 
methods, we employed different percentage of ammonium sulfate, detergent, and 
chaotropic agents. Several studies on truncated forms of TDP-43 protein have been 
reported. However, information on biochemical and biophysical properties of full- length 
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protein is limited due to its difficulty in expression and purification. Furthermore, studies 
reported are from proteins from prokaryotic source. To investigate the full- length protein 
and characterize its physicochemical properties along with other constructs of TDP-43, we 
used pFastBac/HBM-TOPO vector for subcloning (Figure 4), a eukaryotic vector.  
pFastBac/HBM-TOPO vector has many features including a secreted protein expression 
signal (HBM)  and a 6X His-tag. This can facilitate protein purification using Ni-NTA 
affinity chromatography. However, in our case the purification needed several intermed iate 
steps before purification on an affinity column. Confirmation of the constructs were 
performed through PCR and subcloning and viral amplification were carried out using the 
established protocol from Invitrogen. For production of viral stock, we used Sf21 cells 
because they are well suited for transfection, plaque purification, generating high-titer 
stocks, plaque formation, and expression of recombinant proteins. After generating the 
viral stock, it’s important to test the cellular localization of protein. As shown in figure 3, 
we used high-five cells for testing the cellular localization and production of our 
recombinant protein. Incubation of cells with either N or C-terminal antibodies resulted in 
signal in GFP channel and no signal in control cells. Immunocytostaining confirmed the 
cellular expression of our protein upto 72h of post-infection of viral stock. However, we 
did not observe the secreted expression of protein. Instead of protein being released in the 
media, protein was stuck in the membrane. We employed different methods to purify the 
TDP-43 full length protein to get greater than 95% purity. Before applying any purifica t ion 
technique, it’s very important to confirm the expression of the protein. For that purpose, 
we also tested each batch of our harvested cell pellet for its expression of TDP-43 protein 
and confirmed by Western blot. Presence of protein band only in infected cell lysate and 
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absence in control lysate confirms our protein expression (Figure S1). After confirming the 
expression of protein, the bulk lysis as well as purification procedure was carried out.  
We first chose to enrich our protein using ammonium sulfate for precipitation by salting-
out. Precipitation of protein does not mean its denaturation, it’s the condition of reduced 
solubility which is also related to the enhancement of protein native form stability. 
Ammonium sulfate is most commonly used salt in the enrichment of protein because of its 
high solubility in water and ability to salt-out some proteins preferentially. Therefore, 
initially we also employed the enrichment of TDP-43 protein using saturated solution of 
ammonium sulfate. As shown in figures S2-S7, different percentage of saturated 
ammonium sulfate solution was used, and protein mostly remained in pellet fraction at 30% 
ammonium sulfate concentration or higher. Affinity chromatography of pellet fraction 
yielded the bands on western blot but could not resolve the clear bands on the SDS-PAGE.  
Detergents are the molecules carrying the amphipathic properties and can disrupt or form 
the hydrophobic–hydrophilic interactions among molecules. Detergents are used in 
research especially in biological samples for various purposes like cell lysis for the release 
of soluble proteins, lipids and membrane proteins solubilization, prevents nonspecific 
binding in affinity purification as well as in immunoassay, additives in electrophoresis. We 
also used SDS, anionic detergent to solubilize our full- length protein as our protein was 
stuck in the membrane. SDS-PAGE and Western blot data showed the protein fraction 
present in higher amount in insoluble fraction compared to the soluble fraction. (Figure S8-
S9). After several trials, we developed a purification strategy for full- length TDP-43 
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protein using a combination of salt, denaturant, detergent, and affinity chromatography to 
get >95% pure protein.  
Urea is the chaotropic agent which is most commonly used in solubilization as well as 
denaturation of proteins.  Apart from this urea is used for protein renaturation that has been 
denatured using 6M guanidine hydrochloride53-55. Since, most of our protein was present 
in pellet fraction after lysis in RIPA buffer, we used combination of buffer containing urea, 
thiourea and CHAPS to solubilize our protein present in pellet. Using this method, we were 
able to achieve >95% purity which we confirmed by gel and Western blot. (Figure 11) 
Protein aggregation is well studied topic. Next, question in the field of TDP-43 is 
understanding the nature of aggregated form of TDP-43 protein. Different studies carried 
out by different groups reported on the aggregates of TDP-43 protein (Figure 4). Some 
studies support the nature of aggregates to be amorphous while other supports the 
aggregates to be amyloid in nature56-59. Since, we do not have clear picture regarding the 
disulfide status of the protein, we wanted to understand if full- length TDP-43 protein forms 
aggregates under disulfide reducing environment or not. The interesting of all is the studies 
reported are on the different truncated constructs of the protein and is carried out using 
prokaryotic source. Aggregation of TDP-43 full- length protein carried out in bacteria 
shows the amorphous nature. Therefore, we studied the aggregation of TDP-43 by 
subjecting it to different concentration of reducing agent and incubation time and observing 
the aggregates under microscope. Our finding suggests the TDP-43 forms aggregates under 
disulfide reducing environment and the nature of TDP-43 full- length aggregates are 
amorphous. Also, our fresh protein did not form any aggregates in absence and presence 
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of 1mM TCEP up to 1 h, suggesting our protein is soluble and stable and does not form 
aggregate under its normal condition. 
TDP-43 has six cysteine residues located at position 38, 49, 172, 174, 197 and 243 (Figure 
10). The possibility of formation of disulfide linked TDP-43 dimers and oligomers in vivo 
was reported in the study conducted by Zhang et.al. (2011). However, it was suggested that 
formation of aggregates does not require such modification. However, the exact disulfide 
status of TDP-43 has not been reported yet. It is not clear that how many disulfide bonds 
are there in TDP-43 protein. Disulfide bond is present in most of the proteins and it ensures 
the correct folding of protein under native conditions. Disulfide bonds occupy 15% of the 
human proteome and are present mainly in secreted protein where it makes up to 65%. 
Next to peptide bond, the common covalent link between the amino acids in the protein is 
the disulfide bond. Disulfide bonds are known to decrease the entropy of the unfolded state 
thereby stabilizes the protein thermodynamically. The presence of disulfide bonds are 
found in 55% of the pathologic amyloid forming proteins providing the information about 
the importance of disulfide bonds in the aggregation kinetics as well as its role in the 
toxicity and structure of aggregates. For the proper folding of protein into its native 
structures, many proteins require the correct formation of disulfide bonds. Protein 
misfolding results when there is abnormal reduction/formation of disulfide bonds. 
Disulfide bonds are involved in proteins involved in neurodegeneration. Until date, the role 
of disulfide bonds have been studied and found to be important in three proteins involved 
in neurodegeneration: prion, SOD1 and Tau. The folding/misfolding pathway can thus be 
traced by determining the thiol-disulfide status in the protein. For example, the 
folding/misfolding is regulated by thiol-disulfide status in case of SOD1 (Cu, Zn-
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superoxide dismutase). The stabilization of matured SOD1 is achieved by the formation of 
intramolecular disulfide bonds whereas the reduction of these disulfide bonds leads to the 
misfolding and aggregation of SOD1 due to a decrease in conformational stability of a 
protein. Therefore, the disulfide bonds play important role in familial form of amyotrophic 
lateral sclerosis (fALS)60-63. In order to understand the disulfide status of TDP-43, we ran 
the samples under reduced and non-reduced conditions (Figure 14). The mobility of 
proteins under two conditions showed no major variation suggesting us need of further 
confirmation.  
To compare the characteristics of TDP-43 we next purified C-terminal domain of TDP-43 
using the same protocol used for full- length protein (Figure S15-S16). Purifying more of 
protein will help to compare the properties of full- length protein with most aggregation 
prone domain of TDP-43. C-terminal region is the most studied domain of TDP-43 and 
much of mutations known are found in this domain. Having this region for comparison will 
help us to compare the findings reported in prokaryotic system with our eukaryotic source 
and report any variations if present.  
3.5 Conclusion: 
In summary, this study describes the standardized protocol for expression and purifica t ion 
of TDP-43 full- length protein using eukaryotic source. The result shows the purity of 
protein >95% as confirmed by gel and Western blot. Further, the nature of aggregates of 
full- length proteins were confirmed under reducing environment and were found to be 
amorphous in nature. Apart from full-length protein our purification protocol is applicable 
to intrinsically disordered portion of this protein, i.e. C-terminal region.  
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4.1 Introduction
Protein misfolding and aggregation leads to several neurodegenerative diseases among 
which Alzheimer’s disease (AD) is the sixth leading cause of death in U.S. with estimate 
of 5.8 million Americans living with the disease in 2019. Alzheimer’s is a progressive 
neurodegenerative disease leading to behavioral and cognitive disorder in the elderly1, and 
is characterized by the presence of senile plaques and neurofibrillary tangles. Senile plaque 
constitutes mainly of beta amyloid peptide and neurofibrillary tangles is composed of 
microtubule associated protein known as Tau 2. The peptide of Amyloid β vary in length 
from 39-43 amino acids. In normal individual, Aβ40 is the major form of Aβ produced and 
only 5-15% of total Aβ is comprised of Aβ42. Though Aβ40 is present in higher 
concentration in cerebrospinal fluid (CSF) compared to Aβ42, the amyloid plaques from 
Aβ42 constitutes the major component in AD brains.  
The extracellular amyloid plaques recognized as one of the major hallmark of the disease, 
have been reported for variability of toxicity for different structures of Aβ aggregates 3-8. 
However, the relationship between different aggregated structures of Aβ peptides and its 
associated toxicity is not well understood. This is further underscored by the failure of AD 
treatment based on Aβ aggregates as these treatments targeted mature amyloid fibril forms 
but failed to target highly transient and dynamic Aβ species that are naturally formed in 
the brain 5, 9, 10.  
Post-translational modification is well known for its role in protein folding and 
aggregation. Likewise, while considering the in vivo “pool” of Aβ, post-translation 
modified forms of Aβ are present besides Aβ peptides of different lengths7. Different post-
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translational modifications (PTMs) such as phosphorylation 11-13, truncation 14-16 
isomerization17,18, and pyroglutamate formation 16,19, were found to play role in Aβ peptide 
structure and aggregation propensity. In a recent study, protein PTM level were found to 
increase roughly two-fold in AD samples compared to normal controls, especially in Aβ 
and tau enriched area21. Among the various post-translational modifications in proteins, 
acetylation is one of the major PTM that plays a vital role in health and diseases. Some 
major role in health includes DNA repair, protein structure, signaling, and protein self-
assembly and is also involved in diseases like cancer and neurodegenerative diseases 21-28. 
Interestingly, among all the identified PTM types in AD brains, acetylation only affects ~ 
10% of the total modified peptides but showed the highest increase level in Aβ- and Tau-
containing aggregates 20.  Acetylation of Tau has already been identified and is proposed 
for new therapeutic targets for AD.29-31  However, acetylation on Aβ peptide has not been 
investigated in detail. The Aβ peptide has two potential acetylation sites, lysine 16 (K16) 
and lysine 28 (K28) (Figure 1A); the effect of K28 acetylation has been investigated, 
though K16 residue as an acetylation site was often ignored. Lysine 28 was recognized as 
a key player during Aβ fibril formation as it forms a salt bridge with A42 in Aβ42 fibrils 
32, or with D23 in Aβ40 fibrils 33, to stabilize the β-sheet structure.  
We notice that a systematic study investigating the impact of acetylation of potential 
acetylation sites of Aβ on protein aggregation  and the effect of aggregates on biologica l 
health has not yet been reported. This is important because many common drugs and 
metabolites were recently found to be able to facilitate protein acetylation21,34. In this study, 
synthesized Aβ42 peptides were modified with single acetylation on K16 (K16Ac), K28 
(K28Ac), or were double acetylated on both Lysine residues (KKAc) (Figure 1 B–E). The 
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fibril formation was simulated via assembly of 9 strands of Aβ42 peptides. The effect of 
WT acetylated and 1:1 mixture peptides on cellular heath was measured using cell viability, 
cytotoxicity and free radical formation assays. Surprisingly, we found that side-chain 
acetylation of K16 can profoundly impair the fibrillization property of Aβ42 peptide and 
significantly affects the toxicity, which could account for the modulation of Aβ42 
pathogenicity. 
 
Figure 1. (A) Sequence of Aβ42 peptide (PDB entry: 1Z0Q 33). Atomic structures of (B) 
WT, (C) K16Ac, (D) K28Ac, and (E) KKAc monomer. The two acetylated positions, K16 
and K28, are highlighted in ball and stick.  
4.2 Methods 
Preparation of amyloid β peptide samples – Peptides: Synthetic wild-type (WT), K16Ac, 
K28Ac and KKAc were purchased from Biomatik (Canada). All the peptides were 
confirmed for their identity and purity (>95%) by mass spectrometry and RP-HPLC. The 
peptides were dissolved as per the methods reported by Roychaudhuri et. al.36 In brief, the 
lyophilized peptide was first dissolved in 10% (v/v) of 60 mM NaOH, followed by 45% 
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(v/v) MilliQ water. The pH was adjusted by adding 45% (v/v) of 10 mM sodium phosphate 
buffer (pH 7.4). Then the centrifugation was carried out at 16,000 × g at 4 °C for 10 
minutes. The supernatant fluid thus obtained was filtered through 0.22 μm membrane. 
Concentration of peptide stock was determined using ε214 = 75,887 M-1cm-1 and BCA 
Assay.  For experiments, 50 µM peptide was mixed with 50 mM phosphate buffer, 300 
mM NaCl, pH 7.4 and were incubated at 37 °C with agitation for indicated time. All buffers, 
salts and MilliQ water were filtered through 0.22 μm membrane. The peptide stocks were 
stored at -800C. 
Fluorescence measurements – All fluorescence measurements were carried out at the final 
concentration of 10µM in 10mM phosphate buffer, pH 7.4. Stocks of fluorescent probes 8-
anilino-1-naphthalene sulfonic acid (ANS), and 4,4'-dianilino-1,1'-binaphthyl-5,5'-
disulfonic acid (bis-ANS) were prepared in ethanol and then added to samples to final 
concentrations of 10 μM (ANS), and 1 μM (bis-ANS). Emission spectra were collected 
using a Horiba Jobin Yvon spectrofluorometer (Fluoromax-4) at room temperature. For 
samples with ANS and bis-ANS, spectra were acquired from 400 – 700 nm, with excitation 
at 380 nm and 360 nm, respectively. 
Field emission scanning electron microscopy (FESEM) – Fibrils and aggregates of peptides 
were analyzed using a cold field emission high-resolution scanning electron microscope, 
Hitachi S-4700 FESEM. After incubation, fibrils or aggregates were pelleted by 
centrifuging at 9,000 × g for 45 min at 25 °C. To wash off salts, the pellets were suspended 
in MilliQ water (0.22 μm membrane filtered) and centrifuged at 9,000 × g for 45 min at 25 
°C. Washed fibrils or aggregates were applied on SEM stubs and air dried at room 
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temperature. The SEM samples were then coated with 10 nm platinum. For FESEM 
imaging, 10 kV of acceleration voltage and 5 μA of emission current were used. 
Cell viability (MTS) assay – SH-SY5Y human neuroblastoma cells (both from ATCC) were 
cultured in Medium 199 and DMEM/F-12 medium, respectively, with 10% FBS and 100 
U/ml penicillin-streptomycin at 37 oC in 5% CO2 humidified environment and used within 
the first 10 passages. Cells were plated at 2 × 104 cells/well (SH-SY5Y) on 96-well plates 
and allowed to grow overnight. The next day, cells were washed with 1X PBS buffer (pH 
7.4) twice. Then 100 μl fresh media containing peptide samples were added. Six replicates 
were prepared per sample. Media without any peptide were used as controls. After 48 h 
incubation, 20 μl of CellTiter 96® AQueous One Solution Cell Proliferation (MTS) Assay 
kit (Promega) were added and incubated for 4 h. Absorption at 490 nm were collected using 
an ELISA plate reader (BioTek Instruments, Inc.). Blanks containing media and peptide 
samples but no cells were similarly prepared and used for background subtraction.   
Cytotoxicity (LDH) assay – SH-SY5Y human neuroblastoma cells (from ATCC) were 
cultured as described above and plated at 2 × 104 cells/well on 96-well plates and allowed 
to grow overnight. The next day, cells were washed with 1X PBS buffer (pH 7.4) twice. 
Then 100 μl of fresh media containing peptide samples were added. Six replicates were 
prepared per sample. After 48 h incubation, 10 μl of lysis solution (CytoTox 96® Non-
Radioactive Cytotoxicity Assay (LDH) Assay kit, Promega) was added to maximum LDH 
release control wells and incubated for 45 minutes at 37 °C in 5% CO2. 50µl of supernatant 
from all the wells were transferred into a new plate and to each of those wells 50µl of LDH 
reagent was added.  The plate was further incubated in dark for 30 minutes. After 
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incubation, 50µl of stop solution was added to each well. Absorption at 490 nm were 
collected using a plate reader (BioTek Instruments, Inc.). Appropriate blanks containing 
media and peptide samples (without cells) were similarly prepared and used for 
background subtraction. Max LDH Control was represented as 100% cytotoxic and all 
samples were normalized to Max LDH Control 37. Primary hippocampal neuronal cells 
were prepared as described in the immunostaining protocol (below). The LDH assay was 
carried out for neuronal cells as described for SH-SY5Y cells above with the following 
variations. Neuronal cells were plated at 1× 104 cells/well in 96-well plate. And the cells 
were incubated with 2 µM of peptides in 100 µL of media for 24 h.  
2',7'-dichlorofluorescin diacetate (DCFH-DA) fluorescence assay – SH-SY5Y human 
neuroblastoma cells (from ATCC) were cultured and were plated at 2 × 104 cells/well on 
96-well plates and allowed to grow overnight. The next day, cells were washed with 1X 
PBS buffer (pH 7.4) twice. Then, cells were incubated with 20 µM DCFH-DA for 45 
minutes at 37 °C in dark. After incubation, the cells were washed twice with 1X PBS (pH 
7.4) and then 100µl of fresh media containing peptide samples were added to DCFH-DA 
(Sigma) treated cells in five replicates and incubated for 24 h at 37 °C in 5% CO2 
humidified environment. Cells without any treatment and blanks were also incubated under 
identical condition. For positive control, cells after DCFH-DA treatment were incubated 
with 50 µM of t-butyl-hydroperoxide (tBHP) for 4 h at 37 °C. Finally, the fluorescence 
intensity was measured using fluorescence plater reader (Fluoroskan Ascent, Thermo 
Scientific) at excitation wavelength of 485 nm and emission wavelength of 538 nm. All 
data were normalized to tBHP wherein tBHP treated cells were represented as 100% free 
radical generating 38. DCFH-DA assay for primary hippocampal neuronal cells was same 
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as that detailed for SH-SY5Y cells above with the following variations. Neuronal cells 
were plated at 1× 104 cells/well in 96-well plate. And the cells were incubated with 2 µM 
of peptides in 100 µL of media for 24 h. 
Immunostaining of primary hippocampal neuronal cells – Sprague Dawley rats were 
purchased from Charles River Laboratories (Wilmington, MA, USA) and used in our 
breeding colony to generate1-day-old pups which were euthanized via overdose of 
pentobarbital. Hippocampus and cortex from 1-day old rats were dissected, combined 
and neuron cells dissociated as detailed previously 39. Cells were plated in poly-L-Lysine 
coated 24 well plates at the seeding density of 5X104 cells/well and incubated at 
neurobasal medium containing B27 supplement (Thermo Fisher Scientific) in 370C 
incubator. Culture medium was changed every 3 days and the cells were allowed to grow 
for 10~14 days prior to their use in experiment. During the experiment, 500 µl of fresh 
media containing 2 µM of 7 d Aβ42 peptide aggregates (WT and acetylated) were added 
to neuronal cells and incubated for 24h at 370C incubator. Control cells did not have any 
peptides added to them but were incubated similarly. After 24h, the cells were washed 
twice with PBS. Then cells were fixed with 4% paraformaldehyde for 10 minutes at room 
temperature. Cells were then washed with PBS three times for 5 minutes each. Blocking 
solution (5% horse serum and 0.3% Triton X-100 in PBS) was added to each well and 
incubated for 1 hour. After one hour, cells were incubated overnight at 40C in a cocktail 
consisting of 1:200 dilution of mouse anti-tau antibody (Invitrogen, catalog# AHB0042) 
and 1:100 dilution of rabbit anti-β-tubulin antibody (Cell Signaling Technology, 
Catalog# 15115S). Afterwards, cells were washed in PBS thrice for 5 minutes and 
incubated overnight at  40C in a mixture of secondary antibodies (Alexa Fluor  594 
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donkey anti-mouse IgG and Alexa Fluor 488 donkey anti-rabbit IgG, both in 1:300 
dilution). The sections were mounted in Vectashield (Vector Labs, Burlingame, CA) and 
images were taken with a Leica fluorescence microscope (LEICA DM IL LED) at 20X 
and were analyzed using Image J software 40,41 
Statistical analysis – Statistical analysis was performed using one-way ANOVA and post-
hoc t-test. The p values < 0.05 were considered as significant and are represented *, 
p<0.005 represented as ** and p<0.0005  represented as ***. 
Computational methods – To construct the acetylated (K16Ac, K28Ac and KKAc) 
peptides, we started with the WT Aβ42 monomer as shown in Figure 1B (PDB entry: 
1Z0Q). The NH3+-group of Lysine 16 and Lysine 28 residues of Aβ42 monomer was 
modified by substituting with an acetyl-group in the side-chain. Likewise, init ia l 
configurations of 9-strand aggregates of Aβ42 fibrils (WT and acetylated) were constructed 
by aligning the individual Aβ42 monomers parallel to one other, avoiding any close 
contacts or atomic clashes during the assembly. The Aβ42 monomers and fibril structures 
were initially placed in an periodic orthorhombic box and solvated with water molecules 
defined using the TIP3P model 38. The H-atoms of water molecules were constrained using 
the SETTLE algorithm 39 and counter ions were added to maintain overall charge neutrality 
of the system. The details of system size are provided in Supplementary Information, Table 
2. 
Atomistic MD simulations of WT and acetylated Aβ42 peptides were performed in the 
isothermal-isobaric (NPT) ensemble using NAMD program and CHARMM27 force field. 
The simulation temperature (310 K) and pressure (101.3 kPa) was maintained using the 
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Langevin dynamics and Langevin piston Nose-Hoover method 40. The long-range 
electrostatic interactions were calculated using the particle mesh Ewald method with a 
cutoff of 12.0 Å 41.  For each system, we performed energy minimization for 2000 steps at 
a time step of 1.0 fs using the conjugate gradient method, followed by 100 ns of production 
run at a time-step of 1 fs. We performed a total of 800 ns runs for all systems and each 
simulation run was repeated for reproducibility of the results. Simulation snapshots 
corresponding to structural changes, and convergence of MD simulation trajectory was 
analyzed using the backbone root-mean-square deviation (RMSD) for the peptides using 
VMD 1.9.2. program 42. The surface hydrophobic patches for 9 strands of WT and 
acetylated (K16Ac, K28Ac, and KKAc) Aβ42 peptides in aqueous solution were analyzed 
using the SPDB software. 
4.3 Results 
Physicochemical characterization of Aβ peptides aggregation    
The fibrillization/aggregation properties of WT Aβ, acetylated peptides and 1:1 mixture 
ratios was already monitored by ThT fluorescence and reported in Dissertation work of 
Yang. M (2016). Based on the findings WT, K28Ac and WT:K28Ac followed the sigmo ida l 
fluorescence trend whereas K16Ac and K28Ac showed non-sigmoidal Tht fluorescence 
trend. Further to verify the aggregates, FESEM was carried out for 7d incubated samples . 
In line with the previously reported data for Tht and FESEM, the new batch of peptides 
displayed similar morphology for 7d incubated samples (Figure 2). The WT, K28Ac and 
WT:KKAc was able to form fibril like structures upon incubation for 7 days while K16Ac, 
KKAc and 1:1 mixture of both with WT remained amorphous even after incubation for 7 
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days (Figure 2). All peptides of Aβ remained amorphous in nature upto 72h incubation  
(Supplementary information 1). 
Next, we determined the structure flexibility of WT, acetylated and 1:1 mixture of Aβ 
peptides by using the structure sensitive probe bis-ANS. We found that K16Ac and KKAc 
have flexible structure compared to other peptides. Among all peptides K16Ac showed the 
most structure flexibility while KKAc aggregates are more denser compared to K16Ac 
(Figure 3). Furthermore, the mixtures of single and double acetylated peptides with WT 
Aβ42 peptide (1:1 ratio) formed more rigid amorphous aggregates with fluorescence signal 
comparable to WT Aβ42 aggregates than those formed by pure K16Ac peptides (Figure 3). 
 
       
Figure 2. The morphology of the 7d incubated WT, acetylated and 1:1 mixtures confirmed 
by SEM. WT, K28Ac and WT:K28Ac forms fibrils while K16Ac, KKAc, WT:K16Ac and 
WT:KKAc remains amorphous in nature under 7d incubation. Scale bar = 5 µm, 1 µm and 
500 nm from left to right, respectively. 
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Figure 3: Structure flexibility of the fresh Aβ42 peptides and their aggregates were 
measured by Bis-ANS fluorescence by incubating 10 μM of peptide samples with 1μM of 
Bis-ANS and measuring peak intensities at 484 nm. Mixture represents the 1:1 ratio of the 
acetylated peptides with WT Aβ42 peptides. Error bars = ± S.D, (n=3) (* represents 
significant differences (p < 0.05). 
Molecular aggregation dynamics and surface properties of Aβ peptides 
To gain atomistic insights into the conformation changes, aggregation dynamics, and map 
the folding pathways of Aβ42 peptides 43-49, we performed molecular dynamics (MD) 
simulations of WT and acetylated Aβ42 monomers along with 9 strand aggregates of all 
four peptides (WT, K16Ac, K28Ac, and KKAc) in aqueous solution using NAMD program 
50 and CHARMM27 force field 51. Note that aggregation of 9 strands of WT and acetylated 
peptides were considered as replica models for simulating the formation of fibril- like 
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structures. Supplementary Figure 2 A–D displays the structural changes in WT and 
acetylated Aβ42 monomer in aqueous solution at time=0 and100 ns. WT Aβ42 is mostly 
α-helical at residues 11–23 and 29–37, which agrees well with previously reported results 
based on the discrete MD simulation method 52. In our case of atomistic MD study, the 
flexible regions are the first 10 amino acids of N-terminus, residues 38–42 of C-terminus 
that adopt a random coil structure, and the β-turn region between residues 24–28 
(Supplementary Figure 3A). Snapshots of WT and acetylated peptide aggregates at time = 
0 and 100 ns elucidate that the nature of fibrillization is distinctive of the modifications : 
K16Ac and KKAc assemble into an amorphous structure while K28Ac retains a fibril- like 
structure similar to WT peptides (Figure 2). MD simulation snapshots (Supplementary 
Figure 6) of K16Ac at 100 ns affirm the formation of amorphous aggregate as seen in SEM 
micrographs (Figure 2). A comparison of the orientation of K16 and K28 residues in 
acetylated aggregates suggests that in the former structure, K16Ac residues are somewhat 
embedded within the aggregate, stabilized by inter-chain hydrophobic interactions while 
in the latter, K28Ac residues project outwards with reduced inter-chain interactio ns 
(Supplementary Figure 4). Both MD simulation and experimental results thus find that 
K16Ac presents a flexible structure with loss of α-helicity and acetylation significant ly 
impacts aggregation dynamics and impedes fibril formation. Root mean square deviation 
(RMSD) analysis was performed for the simulations of each system (Supplementary Figure 
9). RMSD of WT and acetylated peptides increases in the first 20 ns and then reaches a 
plateau, suggesting an overall stability of the system. A slightly higher RMSD of K16Ac 
correlate to the molecular flexibility and observed conformational transition to an 
amorphous structure. 
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Figure 4. Simulation snapshots depicting the structural changes in aggregation of 9 strands 
of WT and acetylated (K16Ac, K28Ac and KKAc) Aβ42 peptides in aqueous solution. For 
each structure, the predicted hydrophobic patches (yellow) were mapped on the molecular 
surface (violet) using SPDB software. (A) WT, (B) K16Ac, (C) K28 Ac and (D) KKAc 
aggregates. The waters molecules are not shown for clarity. (The computational work was 
conducted by Professor Ravindra Pandey and Dr. Nabanita Saikia . The figure 3 is added 
with their permission).
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Hydrophobic patches on a protein surface identify accessible regions of neighboring apolar 
atoms that may play a crucial role in protein folding, structural dynamics, and protein-
ligand interactions 53. Surface hydrophobicity of WT and acetylated peptide aggregates 
were analyzed for 100 ns structures (Figure 4).  Note that acetylation of the positive ly 
charged K16 and K28 lysine residues into hydrophobic moiety destabilizes fibril formation 
with an overall increase in the surface area (Supplementary Table 1). Interestingly, the 
surface area of KKAc is intermediate to K16Ac and K28Ac with relatively scattered 
hydrophobic patches on the molecular surface. K16Ac has the highest surface area and 
consequently exhibits a greater flexibility to adopt an amorphous structure. WT Aβ42 
peptides have one patch above 300 Å2 and 9 patches between 100–300 Å2 (Supplementary 
Table 1). Acetylation leads to loss of the dominant patch above 300 Å2 followed by 
decreases in size of the hydrophobic patches but increases the number of patches on the 
molecular surface. For acetylated peptides, the hydrophobic patches range between 100–
300 Å2. These findings are consistent with bis-ANS fluorescence data (Figure 3) that shows 
increased fluorescence for 7 d aggregates of K16Ac peptides compared to WT Aβ42 
peptides. 
Surface hydrophobicity of Aβ peptides  
Surface hydrophobicity of the peptides and aggregates were also measured by ANS 
fluorescence (Figure 5). All three fresh acetylated peptides showed ANS fluorescence 
similar to WT Aβ42 peptides. Interestingly, after 3 days of incubation, ANS fluorescence 
of WT Aβ42 peptides increased significantly compared to acetylated peptides and then 
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decreased upon longer incubation of 7 d to levels comparable to fresh WT Aβ42 peptides 
(Figure 5).  Differences in hydrophobicity among the four peptides were amplified after 7 
days of incubation, and was extremely significant for K16Ac peptides that almost doubled 
(Figure 5). Seven day incubated K28Ac Aβ42 peptides showed fluorescence signal that 
were significant and KKAc aggregates showed signal that were highly significant 
compared to WT peptides (Figure 5). In addition, for 7 day’s samples incubated as mixture, 
the aggregates showed slightly less hydrophobicity compared to pure K16Ac and KKAc 
peptides but signals were significant compared to pure WT Aβ42 aggregates (Figure 5).  
 
Figure 5. Hydrophobicity of fresh Aβ42 peptides and their aggregates measured by ANS 
fluorescence by incubating 10 μM of peptide samples with 10 μM of ANS and measuring 
peak intensities at 485 nm. Mixture represents the 1:1 ratio of the acetylated peptides with 
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WT Aβ42 peptides. Error bars = ± S.D. (n = 3).  *, **, and *** represents significant 
differences (* = p < 0.05), (** = p < 0.005), and (*** = p < 0.0005). 
Cellular toxicity of Aβ peptides. 
In addition to measuring the morphology, surface hydrophobicity and structure flexibi lity 
of Aβ42 WT, acetylated and 1:1 mixture, we investigated the effect of these aggregates on 
biological health of the cells. For this purpose, we tested the effect of two different 
concentration of peptide samples (2 and 5µM) on SHSY-5Y neuroblastoma cells health 
(Supplementary Figure 12 and Figure 6) and 2 µM Aβ42 peptides on primary neuronal 
cells from rat (Figure 7). Based on the previous work reported by Yang, M et.al. (2016) on 
Tht fluorescence response of these peptides at different time points, we choose to carry out 
all cellular experiments at three different time points (Fresh, 72h and 7d). We monitored 
the effect of Aβ42 fibrils and aggregates on cell viability of SH-SY5Y neuroblastoma cells 
by MTS assay (Figure 6A and Supplementary Figure 11). The data shows that WT and 
single acetylated peptides slightly decrease SH-SY5Y cell viability but 7 d aggregates of 
KKAc peptides or 1:1 mixture of WT: K16Ac, and WT: K28Ac inhibit cell growth 
significantly (Figure 6A). And the 1:1 mixture of WT: KKAc peptides inhibit cell growth 
significantly more than KKAc peptides alone (Figure 6A). 
Oxidative stress has been implicated in several neurodegenerative diseases includ ing 
Alzheimer’s disease 54-60. Therefore, we wanted to measure effect of 5 μM of Aβ42 peptides 
(fresh as well as aggregates) on generation of reactive oxygen species (ROS) in cells. We 
used 2’,7’-dichlorofluorescein diacetate (DCFH-DA) as a fluorescent probe to measure 
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levels of ROS in cells (Figure 6B) 36. Compared to untreated cells the cells treated with 
WT Aβ42 peptides showed significant increase in ROS production in cells. The 7 d 
aggregated acetylated peptides K16Ac, K28Ac, and KKAc peptides showed much higher 
production of ROS in cells (Figure 6B). Interestingly, the 1:1 mixture of WT and all 
acetylated Aβ42 peptides also showed much higher production of ROS compared to the 
pure peptides aggregates with WT:KKAc peptide aggregates showing the highest ROS 
production (Figure 6B).  To better understand the implication of Aβ42 peptides aggregates 
on ROS production and hence cell health, we also measured toxicity of these peptides by 
lactate dehydrogenase (LDH) cytotoxicity assay (Figure 6C) 35. The aggregates from pure 
WT Aβ42, K16Ac, and K28Ac peptides and equimolar mixture with WT (1:1) all show 
highly significant increase in toxicity for SH-SY5Y cells for 7 d aggregates consistent with 
increased ROS production (Figure 6B, C). Interestingly, among the group double 
acetylated peptides (KKAc) aggregates showed the highest toxicity (Figure 6C).  
Equimolar mixtures (1:1) of WT and KKAc 7 d Aβ42 peptides aggregates showed much 
higher increase in ROS production compared to pure KKAc (Figure 6B).  However, the 
mixtures observed cytotoxicity was comparable to pure KKAc aggregates (Figure 6C). 
This maybe because both aggregates (pure KKAc and 1:1 mixture of WT:KKAc) are 
extremely toxic and values are close to Max LDH value which is the positive control 
(Figure 6C).  
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Figure 6. The effect of 5µM fresh Aβ42 peptides and their aggregates on SH-SY5Y 
neuroblastoma cells health were measured by (A) MTS assay, (B) DCFH-DA assay, and 
(C) LDH assay. The fresh peptides, 72 h, or 7 d aggregates were added to the cells to a final 
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concentration of 5 μM. Cells were incubated for 48 h in presence of peptides for MTS and 
LDH assay and for 24 h for DCFH-DA assay. For t-butyl-hydroperoxide (tBHP) control 
for DCFH-DA assay, cells were incubated with 50 µM of tBHP for 4 h at 37 oC. The 
mixtures represent samples containing equimolar (1:1) WT and acetylated peptides. Error 
bars = ± S.D. (for A n = 6; for B n = 5; and for C n = 5). *, **, and *** represents significant 
differences (* = p < 0.05), (** = p < 0.005), and (*** = p < 0.0005). 
To further validate results on SH-SY5Y neuroblastoma cells, we carried out toxicity and 
ROS studies on primary neuronal cells from rat (Figure 7). Since 5 µM of peptides was 
extremely toxic to SH-SY5Y neuroblastoma cells we used a lower concentration of 
peptides (2 µM) to evaluate cytotoxicity and ROS production for primary neuronal cells. 
We incubated neuronal cells with 2 µM of WT and acetylated Aβ42 peptides for 24 h before 
the assay. Compared to the untreated neuronal cells, cells treated with 7 d aggregates of 
WT Aβ42 peptides and K28Ac peptides show a highly significant increase in ROS 
formation (Figure 7A). Cells treated with 7 d aggregates from K16Ac, KKAc, and 
equimolar mixtures (1:1) of WT and acetylated Aβ42 peptides showed much higher 
increase in ROS production (Figure 7A). Consistent with increased ROS production, all 
neuronal cells treated with 2 µM WT and acetylated Aβ42 peptides and their (1:1) mixtures 
showed an extremely significant increase in cytotoxicity as measured by LDH assay 
(Figure 7B). The double acetylated Aβ42 peptides (KKAc) showed the highest increase in 
cytotoxicity as well as ROS production (Figure 7).  
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Figure 7. The effect of 2µM fresh Aβ42 peptides and their aggregates on primary neuronal 
cells health were measured by (A) DCFH-DA assay, and (B) LDH assay. The fresh 
peptides, 72 h, or 7 d aggregates were added to the cells to a final concentration of 2 μM. 
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Cells were incubated for 24 h in presence of peptides for both assays. For t-butyl-
hydroperoxide (tBHP) control for DCFH-DA assay, cells were incubated with 50 µM of 
tBHP for 4 h at 37 oC. The mixtures represent samples containing equimolar (1:1) WT and 
acetylated peptides. Error bars = ± S.D. (for A n = 5; and for B n = 4). *, **, and *** 
represents significant differences (* = p < 0.05), (** = p < 0.005), and (*** = p < 0.0005). 
Immunostaining of primary neuronal cells treated with WT and acetylated Aβ42 peptides.  
In order to visualize the effect of WT and acetylated Aβ42 peptides on primary neuronal 
cells, we carried out immunostaining of cells after treating them with 2 µM of 7 d Aβ42 
peptides aggregates for 24 h (Figure 8). We chose 2 µM peptides concentration based on 
our ROS and LDH cytotoxicity assay for neuronal cells (Figure 7). We compared the 
morphology of neuronal cells treated with Aβ42 peptides for 24 h to control cells (untreated 
cells) that were similarly incubated by immunofluorescence microscopy (Figure 8).  We 
used anti-tubulin antibody (green) to image tubulin protein and anti-Tau antibody (red) to 
image Tau protein in cells. The control cells (untreated primary neuronal cells) show a 
normal morphology with Tau signal that is diffused and evenly distributed in neurons (both 
soma and neurites) (Figure 8). The neuronal cells treated with 2 µM of WT, K16Ac, and 
KKAc Aβ42 peptides for 24 h showed a significantly higher immunofluorescence signal 
for Tau in soma of neurons compared to neurites (Figure 8, Supplementary Figure 15). Cell 
bodies of primary neurons showed the highest Tau signal for cells treated with KKAc 
peptides, high Tau signal for cells treated with WT and K16Ac peptides, and a much lower 
Tau signal for cells treated with K28Ac peptides (Figure 8).  These findings are consistent 
with the ROS production and cytotoxicity data reported for these cells (Figure 8). 
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Figure 8. Immunostaining of primary neuronal cells. Primary neuronal cells were 
incubated with 2 µM of 7 d incubated Aβ42 WT and acetylated peptides for 24 h at 37 0C. 
Control indicates cells that are untreated and incubated under identical conditions with 
which Aβ42 treated cells were compared. The cells were fixed and then stained for 
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immunofluorescence with antibodies for tubulin (green) and Tau (red). The images were 
acquired using Leica DMIL LED at 20X magnification. Scale bar =50 µm. 
4.4 Discussion 
Scientific literature suggests that formation of highly ordered amyloid fibril or less ordered 
oligomer structures could be an outcome of the competition between hydrogen bonding 
and hydrophobic interactions, as the higher ordered structures are usually stabilized by high 
density of direct inter-chain hydrogen bonds and steric zipper interactions 61,62. 
Furthermore, amyloid fibril dynamics could be affected by the chemical nature of the Aβ 
peptide through side-chain interactions and/or post-translation modifications 63. In theory, 
introducing an acetyl moiety to a lysine residue removes a charge and hence can increase 
surface hydrophobicity of the peptide. Interestingly, in this study we showed that 
acetylation of lysine 16 and 28 on Aβ42 does not affect protein aggregation the same way; 
K16 acetylation affects the aggregation morphology as well as kinetics very severely.  
We found that the K16Ac peptide is much more hydrophobic with a higher structure 
flexibility than WT and other two acetylated peptides (Figures 3, 5). The structural changes 
on Aβ42 monomer in aqueous solution (Supplementary Figure 2) agree well with a 
previously reported results based on the discrete MD simulation method 52. Acetylation of 
Aβ42 monomer at K16 leads to one extra β-turn between residues 14-17 (Supplementary 
Figure 3B) but acetylation at K28 retains a structure very similar to WT (Supplementary 
Figure 3C and A). In addition, acetylation of Aβ42 at K16 and K28 residues on KKAC 
introduces a pleated region between residues 31-37 with loss in α-helix (Supplementary 
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Figure 3D). In agreement with our MD results, a rapid aggregation kinetics with no lag 
time was reported in a simulation study of Aβ16-22 fragment, where the Aβ16-22 
oligomers were disordered molten globular structures due to strong hydrophobic 
interactions 61, since K16 located in the central hydrophobic core, L17-F20, and the 16-20 
residues (KLVFF) acts as a docking motif of Aβ fibrillation 33. This fact is also supported 
by our MD simulations of 9 strands K16Ac aggregates, where the K16Ac residues are 
embedded inside the aggregate structure, stabilized by the inter-chain hydrophobic 
intercalations (Supplementary Figure 4). Aβ fibril grows in two distinct steps: a rapid and 
reversible “dock” phase, followed by a slow but irreversible “lock” phase 64. In case of 
K16Ac peptide aggregation as observed in the current study, it is possible that the inter-
chain hydrophobic interactions of the 16-20 region are enhanced after removal of the 
positive charge on K16 (Figure 9). This may result in initial rapid docking process that 
becomes irreversible and as a consequence kinetically inhibits the conformationa l 
reorganization in the locking phase. Even if the formation of amyloid fibrils is 
thermodynamically favored, the transition from monomers to amyloid conformations is 
kinetically limited 65.  
The other lysine residue, K28, is known to form important salt bridges in Aβ fibrils 30,31. 
Removing the positive charge on K28 by acetylation results in K28Ac peptide having 
longer lag time than WT Aβ42 during fibril formation. This is consistent with the 
stabilizing role of K28 salt bridge on the amyloid fibrils 66. However, the K28Ac peptides 
were capable of forming amyloid structures upon longer incubation, either as pure K28Ac 
peptide sample, or in a heterogeneous equimolar mixture with WT Aβ42 (Figure 2), 
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suggesting K28 salt bridge may not play a role in the conformational transition from Aβ42 
monomers to mature amyloids. This finding is also supported by a previously study of N-
ε-amino acetylation on K28 of Aβ25-35 fragment, where the gross structure of Aβ25-
35_K28Ac fibril were very similar to WT Aβ25-35 fibrils 67.  
In this study we identified two major forms of aggregated structures: amorphous and 
fibrillar, from WT, acetylated Aβ42 peptides and their mixtures.  The aggregates from these 
7 different Aβ42 peptides (WT, K16Ac, K28Ac, KKAc, and 1:1 mixtures of WT:K16Ac, 
WT:K28Ac, and WT:KKAc) can be further categorized based on their unique 
physicochemical properties as measured by fluorescent dyes, cell viability, ROS 
production, and their associated cytotoxicity (Table 1). WT Aβ42 peptides 7 d aggregates 
show well organized fibrillar structure that has low flexibility, moderate ROS production, 
and high toxicity at 5µM concentrations (Figures 2, 3, 6B, C). K28Ac peptides aggregates 
form fibrils that are similar to the WT peptides but show high ROS production with high 
toxicity (Figures 2, 3; 6B, C). K16Ac peptides form aggregates that are amorphous, highly 
hydrophobic, and flexible (Figure 2, 3, 5). In addition, these aggregates also show 
cytotoxicity that is slightly higher than WT or K28Ac peptide with high ROS production 
(Figure 6B, C). In case of neuronal cells, 7 d aggregates of 2 µM WT Aβ42 peptides and 
K28Ac show moderate ROS production but high cytotoxicity (Figure 7). In comparison, 
K16Ac peptides show much higher ROS production as well as cytotoxicity (Figure 7). 
Interestingly, 7 d aggregates from KKAc peptides that are amorphous in nature show 
significantly higher ROS production as well as cytotoxicity for SH-SY5Y as well as 
primary neuronal cells (Figures 6B, C, 7). Furthermore, the 1:1 mixtures of WT peptides 
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with K16Ac, K28Ac, and KKAc, although have variable structural morphology, all show 
very high ROS production and cytotoxicity (Figures 2; 6B, C, 7), with WT: KKAc mixture 
showing the highest ROS production as well as cytotoxicity (Figure 6B, C). In addition, 
the KKAc peptides (pure or 1:1 mixture with WT Aβ42 peptides) inhibit cell growth 
significantly (Figure 6A). The increased oxidative stress has been considered very 
important for pathogenesis in Alzheimer’s disease as it can lead to oxidation of proteins, 
lipid peroxidation, free radical generation, mitochondrial dysfunction, and synaptic 
dysfunction 68. And neurons are particular sensitive to ROS, which serves as source of 
oxidative stresses and results in damages in the brain 60,69,70.   
Table 1. Comparison of unique physicochemical properties of WT and acetylated Aβ42 
peptides and their mixtures for 7 d aggregates. 
Aβ42 
peptides 
Structure 
type 
(SEM) 
Hydroph
obicity 
(ANS) 
Flexibilit
y 
(Bis-
ANS) 
Cell viability 
(MTS) 
Cytotoxi
city 
(LDH) 
ROS 
production 
(DCF-HDA) 
WT Fibril + + 
No 
significant 
inhibition 
+++ ++ 
K16Ac Amorphous ++++ +++ 
No 
significant 
inhibition 
+++ +++ 
K28Ac Fibril ++ + 
No 
significant 
inhibition 
+++ +++ 
KKAc Amorphous +++ ++ 
Significant 
Inhibition 
++ 
++++ ++++ 
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WT + 
K16Ac 
(1:1) 
Amorphou
s ++ + 
Significant 
Inhibition + +++ +++ 
WT + K28 
Ac (1:1) Fibril ++ + 
Significant 
Inhibition + +++ +++ 
WT + 
KKAc 
(1:1) 
Amorphou
s ++ + 
Significant 
Inhibition 
+++ 
++++ ++++ 
 
Number of + indicates proportional levels: (+) = low; (++) = moderate; (+++) = high; 
(++++) = highest among the group.  
To visualize the effect of aggregated peptides we treated neuronal cells from rat with 2 µM 
of 7 d Aβ42 peptides aggregates for 24 h (Figure 8). The neuronal cells treated with Aβ42 
peptides for 24 h, all show a significantly higher immunofluorescence signal for Tau in 
soma of neurons compared to neurites (Figure 8, Supplementary Figure 15). This is 
consistent with other literature reports where a direct relationship between amyloid β 
oligomers leading to altered Tau protein biochemistry that may result in Tau that maybe 
fragmented, soluble, with/without requiring hyperphosphorylation and maybe toxic71-75 
1278.full;. Therefore, to better understand the oligomeric nature of 7 d Aβ42 peptides 
aggregates we analyzed by SDS-PAGE (Supplementary Figure 16).  The 7 d peptides 
samples were run on a 15% SDS-gel and electrophoretically separated under fully 
denaturing conditions. These peptides largely separated in two groups, monomers and large 
higher molecular weight species with some oligomeric species seen for different Aβ42 
peptides as smear (Supplementary Figure 16). Although these 7 d Aβ42 peptides aggregates 
   
137 
 
have distinct structural morphology as seen by SEM (Figure 2), on SDS-PAGE these 
largely show presence of monomeric and high molecular weight SDS-resistant species with 
some low molecular weight oligomeric species (Supplementary Figure 16). It is possible 
that cytotoxic effect of these peptides maybe mediated due to aberrant hydrophobic 
interaction directly or through Tau76,77 71,73,78-80.  
Consistent with ROS production and cytotoxicity data of primary neuronal cells (Figure 
7), immunostaining data showed significantly higher immunofluorescence signal for Tau 
in soma of neurons compared to neurites with the highest Tau signal for cells treated with 
KKAc peptides (Figure 8, Supplementary Figure 15). This is also consistent with other 
animal/cell model studies where increased cross talk between Aβ and Tau has been reported 
with Aβ exerting its toxicity via Tau that maybe fragmented, become oligomeric, 
with/without hyperphosphorylation and impact synaptotoxicity 74,75,81-84.  Our data shows 
that the Aβ42 peptides aggregates lead to increased Tau signal in soma of neuronal cells 
compared to control cells (Figure 8).  
 Although both K16Ac and KKAc aggregates are amorphous, the K16Ac aggregates are 
bead-like structures that are slightly more hydrophobic and flexible compared to KKAc 
(Figures 2, 3; 5). Both of these peptides 7 d aggregates show high toxicity but the difference 
in ROS production of these two peptides may be related to their subtle structure variations 
(Table 1)78. This is consistent with recently reported literature findings where the toxicity 
of misfolded proteins was determined by both size and surface hydrophobicity of the 
molecule23. As large assemblies have lower surface hydrophobicity/volume ratios, they 
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have lower diffusional mobility and lower potential to interact with cell membrane and 
receptors23.  
An alternative hypothesis suggests that the cytotoxicity may be related to the aggregation 
process that is dynamic, rather than a single structural species 9,88. Minor shifts in the Aβ40: 
Aβ42 ratio was demonstrated to be enough to modulate neurotoxicity 89. The non-toxic 
K16N mutation of Aβ42 exhibits severe toxicity when mixed with WT peptides91. Here in 
this study, the aggregates formed from heterogeneous mixtures of WT and acetylated 
peptides all showed increased ROS production and toxicity compared to homogeneous 
samples  of WT and K28Ac (Figures 6B, C, 7). Therefore, in addition to the structural 
characteristics, the dynamic interactions of different species contribute significantly to 
aggregation related toxicity.  
 
Figure 8. Suggested schematic model for WT and acetylation modified Aβ42 peptides 
aggregation and cytotoxicity.  WT Aβ42 and K28Ac peptides show a lag and log phase of 
aggregation kinetics and form ordered aggregates with large surface hydrophobic patches 
(yellow) that can assemble as amyloid fibrils and have moderate toxicity. Peptides 
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acetylated at K16 (K16Ac or double acetylated KKAc) show rapid aggregation kinetics 
and form disordered, amorphous, and flexible aggregates that have higher surface 
hydrophobicity and high toxicity. 
4.5 Conclusion 
In this study, we focused on understanding how acetylation of Aβ42 peptides (K16Ac, 
K28Ac, and KKAc) impacts its physicochemical properties and modulates its toxicity. For 
comparison WT Aβ42 and 1:1 mixture of acetylated peptides with WT were also studied.  
As, acetylation plays an important role in protein folding and aggregation, understanding 
the effect of acetylation on Aβ42 peptides biophysical properties and biological health is 
critical to understanding its role in the disease process. Our study shows that although the 
structural morphology of peptides (WT, K16Ac, and KKAc) are different, all show 
increased cytotoxicity and ROS production. Compared to WT and K28Ac, all other 
peptides (K16Ac, KKAc, and 1:1 mixture of acetylated Aβ with WT peptides) showed 
much higher increase in ROS production as well as cytotoxicity. Furthermore, the increased 
Tau signal in soma of neurons compared to control cells when treated with Aβ42 peptides 
aggregates suggests a dynamic interaction between Tau and Aβ42 peptides . Overall, the 
data suggests that in addition to the structural characteristics, the dynamic interactions of 
different Aβ species may contribute significantly to toxicity directly or through cross-talk 
with other proteins such as Tau. 
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Chapter 5:  Summary and Future Perspective 
Protein folding, misfolding, and aggregation are at the core of proteinopathies and have 
been studied extensively. How protein aggregates morphology and its unique 
physicochemical properties are linked to cellular toxicity is still a subject of intense debate. 
There are substantial number of published studies that have focused on fibrillar structure 
of proteins, with very few studies exploring the role of amorphous protein aggregate 
structures in the disease process. In this dissertation, we focused on two proteins that are 
very important from a neurodegenerative perspective: 1) Role of acetylation of amyloid β 
42 on cytotoxicity and 2) Expression, purification, and characterization of Tar-DNA 
binding protein 43 (TDP-43) from a eukaryotic source.  Both of these studies are very 
important as role of amyloid β in Alzheimer’s toxicity has long been known but still the 
toxic form/fold of Aβ is not well understood. Moreover, role posttranslational modifica t ion 
such as acetylation may play in the disease process is still not very well understood and is 
a topic of intense debate. For the TDP43 project, the importance of this protein has been 
shown for several neurodegenerative diseases such as ALS, Alzheimer’s, and Parkinson’s 
disease and the literature is filled with biochemical and biophysical characterization from 
prokaryotic sources with very little work done using proteins from eukaryotic source. 
Therefore, in this dissertation I tried to shed light on the role, acetylation of Aβ42 (K16Ac, 
K28Ac, and KKAc) have on amyloid β toxicity, and also expressed and purified TDP43 
protein from insect cells (eukaryotic source) and studied their basic biochemical and 
biophysical properties.  
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We chose to investigate the effect acetylation of Aβ peptide have on modulating cellular 
toxicity, as these have major implication for pathogenesis in Alzheimer’s disease. Analys is 
of physicochemical properties of acetylated peptides showed that amorphous structures 
play a critical role in proteins physicochemical properties and its associated toxicity. This 
work underscores the importance of posttranslational modification such as acetylation of 
Aβ peptides on toxicity as well as aggregate morphology (e.g. K16Ac has amorphous 
structure) which will lead to better drug designs in future. 
Next, we standardized the procedure for purification of TDP-43 protein, now known to be 
involved in several neurodegenerative diseases like ALS, FTLD, Alzheimer’s, Lewy body, 
and Huntington. Even though, several elegant research studies have been conducted on this 
protein using prokaryotic proteins, a method for purifying full- length protein using a 
eukaryotic expression system is lacking. Furthermore, purification of full- length protein is 
challenging as its overexpression leads to aggregation. And for the same reasons, detailed 
biochemical and biophysical studies on full- length protein from eukaryotic source and its 
associated toxicity are lacking. We have standardized the procedure for purifying full-
length TDP-43 protein using a eukaryotic expression system that is rigorous but 
reproducible. Furthermore, we investigated the morphology of TDP-43 protein aggregates 
under disulfide reducing and non-reducing conditions and found these form amorphous 
structures. This opens-up possibility of future studies on exploring the role sulfhydryl status 
of the protein plays in the toxicity of these proteins and hence the disease process.  
TDP-43 has six sulfhydryl residues (Cys) which opens up the possibility of disulfide bond 
formation that maybe inter-chain or intra-chain. Our initial experiment on TDP-43 full-
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length protein using mal-PEG (5KDa) shows some shift in the band of proteins suggesting 
susceptibility of TDP-43 to disulfide reducing agent. How these Cys residues may play a 
role in aggregation and cellular toxicity needs to be explored further keeping in view the 
redox status of cells and how this equilibrium can shift under cellular stress.  
There has been a renewed interest in determining the toxic fold of a protein to better 
understand its role in protein misfolding, aggregation, and its toxicity. This is where having 
aggregates that are well characterized from a eukaryotic source for TDP-43 protein will be 
of great interest to researchers trying to understand role of TDP-43 protein in the disease 
process. This is because a protein from eukaryotic source will have all natural 
posttranslational modification that are expected in the mature protein. While, studies on 
TDP-43 proteins from bacterial source have contributed significantly to scientific 
literature, it may still miss out some key findings that may be linked to its natural 
posttranslational modifications. In addition, a methodical study exploring morphology and 
physicochemical properties of TDP-43 full- length aggregates under reducing and non-
reducing cellular environment are lacking. Hence, we made an attempt to study the nature 
of aggregates of TDP-43 at physiological temperature in presence and absence of reducing 
agent like TCEP. Our results show that TDP-43 full length protein forms amorphous 
aggregates. These aggregates need to be further explored to investigate their associated 
toxicity using neuronal cell lines for biological relevance. These can be some of the same 
assays as outlined in amyloid β toxicity chapter such as MTS, DCF-HDA, and LDH assay.  
The future studies can explore two areas of research that are intricately related to my PhD 
work: 1) Role of posttranslational modification such as acetylation, phosphorylation, in the 
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disease process (stems from Aβ acetylation study), 2) Do TDP-43 protein from a eukaryotic 
source may have some unique characteristics that the prokaryotic protein does not have. 
Future studies on these can help better understand the toxic fold/nature of proteins and can 
help shed light on the pathogenesis in the disease process. Eventually, these studies may 
lead to development of better and more effective drugs.  
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Appendix A Supporting Information for Chapter 3 
 
 
Figure S1: Reducing SDS PAGE and Western blot showing the expression of TDP-43 full 
length protein. M-Marker, Φ (Uninfected lysate), I (Infected lysate). Uninfected or infected 
lysate was loaded 5 , 10 , 20 and 30 µg/lane represented as Φ5, Φ10, Φ20, Φ30 on 12% 
SDS PAGE. The gels were run for 3 hours. For Western blot, the blot was incubated with 
Anti-TDP-43 (N-terminal region) produced antibody (1:4000) and Goat anti-rabbit IgG-
HRP (1:10000).  
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Ammonium sulfate precipitation: 
Ammonium sulfate precipitation is one of the common method employed in purifica t ion 
of a protein. It is based on the principle of salting out. Different percentage of saturated 
ammonium sulfate solution was used for protein extraction. The schematic representation 
for ammonium sulfate precipitation is shown below in figure S2. In brief, the cell pellets 
were first lysed in lysis buffer and centrifuged at 20,000g for 1 hour at 40C. The resultant 
supernatant was then subjected to slow addition of ammonium sulfate to make it 30% 
saturated. The saturated solution was subjected to centrifugation at 20,000g for 1 hour at 
40C. The supernatant obtained in this step was again subjected to ammonium sulfate to get 
30% saturated solution. The resultant solution was then centrifuged at same speed, time 
and temperature. The supernatant thus obtained from this step was again subjected to 
ammonium sulfate to get 50% saturated solution. Then, after 70% saturated solution was 
subjected to centrifugation at 20,000g for 1 hour at 40C. The supernatant and pellet 
obtained in each step was saved and tested in western blot. The procedure for SDS PAGE 
and Western blot was followed similarly as explained in material and methods in Chapter 
3. As shown in figure S3, the protein bands were observed in Supernatant obtained after 
cell lysis and 30% ammonium sulfate precipitation represented by S0 and S30 respectively. 
However, no clear bands were observed in supernatant obtained after 50 and 70% (S50 and 
S70) ammonium sulfate precipitation. Similarly, the total pellet (P0) and pellet obtained 
after 30% ammonium sulfate precipitation (P30) showed the significant amount of protein 
and to some extent in pellet obtained after 50% ammonium sulfate precipitation (P50). But 
no band was observed in pellet obtained after 70% ammonium sulfate precipitation (P70). 
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Based on finding from western blot we decided to run the fractions S0, S30 and P30 in 
SDS PAGE and Western blot . We used BCA assay to estimate the protein concentration 
and ran 10µg/lane of each fraction for gel and western blot (Figure S4). As shown in figure 
S4, we observed the protein bands at our desired molecular weight (~50kDa) in all three 
samples but while comparing SDS PAGE we did not observe the concentrated band for 
protein at 50KDa instead a smear/multiple bands were observed in all three samples 
suggesting of protein mixtures.  
Ammonium sulfate precipitation of lysates: 
Pellets stored at -800C 
 
                                               Resuspend in Lysis buffer (work on ice) 
 
Homogenize using bead beater for 12 cycles 
 
          Centrifuge the lysates at 20,000g/maximum possible speed for 1 hour at 40C 
 
 
 
 
 
 
 
 
Save 200µl of 
supernatant at 
-200C  
Add (NH4)2SO4 to the 
supernatant slowly to 
make 30% saturated 
Dissolve pellet 
in 20mM 
phosphate 
buffer and save 
at -200C 
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Centrifuge at 20,000g for 30 minutes at 40C   
 
 
 
 
   Centrifuge at 20,000g for 30 minutes at 40C   
      
 
 
 
 
         
 
Centrifuge at 20,000g for 30 minutes at 40C 
 
 
 
 
 
 
 
 
 
Dissolve pellet 
in 20mM 
phosphate 
buffer and save 
at -200C 
 
Save 500µl of 
supernatant at -200C  
Dissolve pellet in 20mM 
phosphate buffer and save 
at -200C 
 
Add (NH4)2SO4 to 
the supernatant 
slowly to make 70% 
saturated 
Add (NH4)2SO4 to the 
supernatant slowly to 
make 50% saturated 
saturatedsaturated 
Save 500µl of 
supernatant at -200C  
Save 500µl of 
supernatant at -200C  
Dissolve pellet in 20mM 
phosphate buffer and 
save at -200C 
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Note: 
To each 500µl of supernatant saved after 30%, 50% and 70% saturation with (NH4)2SO4 
carry out following protocol: 
 500 µl of supernatant 
 
                                     Dilute by 50% in autoclaved double distilled water 
 
Concentrate using 5k cutoff Centricon 
 
Add buffer 
 
Concentrate using 5k centricon and make the volume around 200µl to 250µl. (Save at -
200C) 
 
                                           Perform Protein estimation of each fractions 
 
                                                           Run the SDS- PAGE 
 
                                                                  Western blot 
Figure S2: Schematic representation of Scheme for Ammonium Sulfate Precipitation  
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Figure S3: Western blot of supernatant and pellet fractions obtained after different 
percentage of ammonium sulfate precipitation. The notation in the figure represents as 
follows: M-Marker, S0- Supernatant obtained after cell lysis, S30, S50 and S70- 
Supernatant obtained after 30, 50 and 70% ammonium sulfate precipitation and P0-pellet 
obtained after cell lysis, P30, P50 and P70-Pellet obtained after 30, 50 and 70% ammonium 
sulfate precipitation. The blot was incubated with primary antibody N-terminal TDP-43 
(1:4000) and secondary antibody, Goat anti-rabbit IgG-HRP (1:10000) 
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Figure S4: SDS Page and Western blot of S0, S30 and P30 fractions.  
Next, we decided to proceed the NI-NTA purification using the pellet obtained after 30% 
ammonium sulfate precipitation (P30). The pellet obtained was dissolved in phosphate 
buffer and stored at -20oC. Then, on the day of purification, the pellet was diluted in 
equilibration buffer (20mM sodium phosphate, 300mM NaCl (PBS) containing 10mM 
imidazole, pH 7.4) and loaded on the packed Ni-NTA column. The bound flow through 
was collected after loading the dissolved pellet on the column. The column was washed 
with wash buffer (PBS with 25mM imidazole, pH 7.4) for 3-5 column volume and wash 
flow through was collected to remove the unbound proteins. Finally, the elution fractions 
were collected in microcentrifuge tubes using elution buffer (PBS containing 0.5M 
imidazole, pH 7.4). After the column purification Western blot of elution fractions were 
performed to determine the elution fractions containing the protein (Figure S5-S6). Figure 
S5 represents the Ni-NTA carried out with only small portion of pellet. As shown in figure 
S6, the elution fractions from tube number 1 to13 shows the presence of TDP-43 protein 
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in good amount. However, a good amount of protein was obtained in bound flow through 
and wash flow through.   
 
 
Fig S5: Western blot result of P30 after Ni-NTA column (Carried out with larger 
portion of pellet) 
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Fig S6: SDS PAGE and Western blot results of Pellet and supernatant fractions of 
total lysates after 20 and 50 % ammonium sulfate precipitation.  
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Fig S7: Western blot results of P20 after Ni-NTA column. (TDP-43 full length)  
 
SDS PAGE and Western blot results of detergent soluble fractions from total pellet 
(P0). 
After ammonium sulfate precipitation, we next tried to dissolve our protein using detergent 
(0.5% SDS). For this purpose, to the pellet obtained after cell lysis phosphate buffer was 
added and then 0.5% SDS was added. The pellet was allowed to incubate at 40C for 
overnight in a shaker. Next day, the soluble fraction was obtained by centrifugation and 
protein estimation of detergent soluble fraction was carried out by BCA assay. The 
insoluble fraction was dissolved in 20mM phosphate buffer and stored at -200C. SDS 
PAGE and western blot for detergent soluble and insoluble fractions were carried out using 
same primary and secondary antibody used for N-terminal TDP-43. SDS-PAGE and 
Western blot of soluble fraction was carried out at different concentrations (1, 2 , 5 and 
10µg/lane). Applying this procedure, we could see the bands for TDP-43 with increasing 
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concentration as loaded but some additional bands were observed at higher exposure of 
blot in western blot imaging which is suggestive of some degraded products. Further, while 
running SDS PAGE multiple bands were observed in 2, 5 and 10µg/lane loaded lanes 
suggestive of protein mixtures. Also, no darker bands were observed towards our expected 
molecular weight .  
The schematic representation of procedure is shown below: 
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Figure S8: Reducing SDS PAGE and Western blot showing the TDP-43 protein level in 
detergent soluble fraction. Detergent soluble fraction (DS) was loaded at different volumes 
1µg/lane, 2µg/lane, 5µg/lane and 10µg/lane represented as DS1, DS2, DS5 and DS10. 
 
Figure S9: Reducing SDS PAGE showing the TDP-43 protein level in detergent insolub le 
fraction. Detergent insoluble fraction (DI) was loaded at different volumes 1, 4, 6, 10, 14, 
16 and 20ul, represented as DI2, DI4, DI6, DI10, DI14, DI 16, DI20 and detergent soluble 
fraction loaded 10µg/lane represented as DS10. 
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Figure S10: SDS-PAGE and Western blot showing the purification steps of TDP-43 full 
length protein. Lane 1(Control lysate, 10µg/lane), Lane 2 (Infected lysate, 10µg/lane), 
Lane 3 (lysate re-extracted in RIPA buffer, 10µg/lane), Lane 4 (urea soluble fraction, 
5µg/lane) and Lane 5 (Purified protein, 3µg/lane) was loaded on 12% SDS PAGE and run 
for 3 hours. For Western blot, all samples were loaded 1/10th of the gel and incubated with 
Anti-TDP-43 (N-terminal region) produced antibody (1:4000) and Goat anti-rabbit IgG-
HRP (1:10000). 
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Figure S11: FESEM images of TDP-43 full- length aggregates in presence and absence of 
TCEP. TDP-43 protein (1µM) was incubated in presence or absence of TCEP (0, 1 and 
10mM) for 0h. Protein aggregates were observed under FESEM. Scale bar =10µm, 5µm, 
and 1µm from left to right respectively.  
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Figure S12: FESEM images of TDP-43 full- length aggregates in presence and absence of 
TCEP. TDP-43 protein (1µM) was incubated in presence or absence of TCEP (0, 1 and 
10mM) for 1h at 370C. Protein aggregates were observed under FESEM. Scale bar =10µm, 
5µm, and 1µm from left to right respectively. 
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Figure S13: FESEM images of TDP-43 full- length aggregates in presence and absence of 
TCEP. TDP-43 protein (1µM) was incubated in presence or absence of TCEP (0, 1 and 
10mM) for 6h at 370C. Protein aggregates were observed under FESEM. Scale bar =10µm, 
5µm, and 1µm from left to right respectively. 
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Figure S14: FESEM images of TDP-43 full- length aggregates in presence and absence of 
TCEP. TDP-43 protein (1µM) was incubated in presence or absence of TCEP (0, 1 and 
10mM) for 48h at 370C. Protein aggregates were observed under FESEM. Scale bar 
=10µm, 5µm, and 1µm from left to right respectively. 
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Figure S15: Ni-NTA purification of TDP-43 C-terminal construct. Different elution 
fraction after Ni-NTA purification was run on the 15% gel and western blot was developed 
for it using primary and secondary antibody.  
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Figure S16: Purification TDP-43 C-terminal construct. TDP-43 construct 28198 
containing glycine rich and c-terminal region was subjected to purification as shown in 
schematic diagram on  left and the urea soluble fraction (1) and concentrated Ni-NTA 
purified sample (2) was loaded on the gel to maximum volume possible. 15% reducing gel 
was run for SDS-PAGE and Western blot. For western blot, Anti-TDP-43 (C-terminal 
region) produced antibody (1:1000) was used as primary antibody and Goat anti-rabbit IgG 
–HRP (1:10000) was used as secondary antibody.  
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Appendix B Supporting Information for chapter 4 
 
 
 
Supplementary Figure 1. SEM images of the WT and acetylated Aβ42 aggregates after 
72 h of incubation. Scale bars are 5 μm, 1 μm, and 500 nm from right to left respectively. 
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Supplementary Figure 2. Simulation snapshots representing the structural changes in WT 
and acetylated Aβ42 monomer at 100 ns in aqueous solution. (A) WT, (B) K16Ac, (C) 
K28Ac and (D) KKAc. The waters molecules are not shown for clarity. The inset figure 
highlights the α-helix, β-turn, and random coil regions in WT Aβ42 monomer.  
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Supplementary Figure 3. The α-helix, β-turn, and random coil regions in Aβ42 monomer. 
(A) WT, (B) K16Ac, (C) K28Ac and (D) KKAc. 
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Supplementary Figure 4. Orientation of (A) K16Ac residues in 9 strands of K16Ac 
peptides, and (B) K28 residues in 9 strands of K28Ac aggregates at 100 ns.   
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Supplementary Figure 5. Simulation snapshots depicting the structural changes in 
aggregation of 9 strands of WT Aβ42 peptides for 100 ns of dynamics. The waters 
molecules are not shown for clarity. 
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Supplementary Figure 6. Simulation snapshots depicting the structural changes in 
aggregation of 9 strands of K16Ac peptides for 100 ns of dynamics. The waters molecules 
are not shown for clarity. 
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Supplementary Figure 7. Simulation snapshots depicting the structural changes in 
aggregation of 9 strands of KKAc peptides for 100 ns of dynamics. The waters molecules 
are not shown for clarity. 
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Supplementary Figure 8. Simulation snapshots depicting the structural changes in 
aggregation of 9 strands of K28Ac peptides for 100 ns of dynamics. The waters molecules 
are not shown for clarity. 
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Supplementary Figure 9. (A) Root mean-square deviation (RMSD) in 9 strands of WT, 
K16Ac, K28Ac, and KKAc Aβ42 peptides in aqueous solution.  
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Supplementary Figure 10. Hydrophobicity of fresh Aβ42 peptides and their aggregates 
measured by ANS fluorescence by incubating 10 μM of peptide samples with 10 μM of 
ANS and measuring peak intensities at 485 nm. Mixture represents the 1:1 ratio of the 
acetylated peptides with WT Aβ42 peptides. Error bars = ± S.D. (n = 3).  *, **, and *** 
represents significant differences (* = p < 0.05), (** = p < 0.005), and (*** = p < 0.0005). 
(+,#,* represents statistics for Fresh, 72h and 7d data respectively and significant 
differences are set identical for all time points). 
Note: Statistical analysis (one-way ANOVA) for 7d sample is included at the end of the 
document. For Fresh and 72h sample statistical analysis as separate file is included.  
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Supplementary Figure 11. Structure flexibility of the fibrils or aggregates was measured 
by bis-ANS fluorescence by incubating 10 μM of peptide samples with 1 μM of bis-ANS 
and measuring peak intensities at 484 nm. Error bars = ± S.D. (n = 3). +,#,* represents 
statistics for Fresh, 72h and 7d data respectively and significant difference are set identica l 
for all time points. +,* represents significant differences (p < 0.05). 
Note: Statistical analysis (one-way ANOVA) for 7d sample is included at the end of the 
document. For Fresh and 72h sample statistical analysis as separate file is included.  
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The effects of 2 µM of WT and acetylated fresh Aβ42 peptides and their aggregates on 
SH-SY5Y neuroblastoma cells health measured by MTS and DCF-HDA assay. Refer 
next page for more details. 
A 
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Supplementary Figure 12. The effect of 2µM of WT and acetylated fresh Aβ42 peptides 
and their aggregates on SH-SY5Y neuroblastoma cells health were measured by (A) MTS 
assay, (B) DCFH-DA assay, and (C) LDH assay. The fresh peptides, 72 h, or 7 d aggregates 
were added to the cells to a final concentration of 2 μM. Cells were incubated for 48 h in 
presence of peptides for MTS and LDH assay and for 24 h for DCFH-DA assay. For t-
butyl-hydroperoxide (tBHP) control for DCFH-DA assay, cells were incubated with 50 µM 
of tBHP for 4 h at 37 oC. The mixtures represent samples containing equimolar (1:1) WT 
and acetylated peptides. Error bars = ± S.D. (for A n = 6; for B n = 5; and for C n = 6). *, 
**, and *** represents significant differences (* = p < 0.05), (** = p < 0.005), and (*** = 
p < 0.0005). (+,#,* represents statistics for Fresh, 72h and 7d data respectively and 
significant differences are set identical for all time points). 
Note: Statistical analysis (one-way ANOVA) for 7d sample is included at the end of the 
document. For Fresh and 72h sample statistical analysis as separate file is included.  
 
  
C 
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The effects of 5 µM of WT and acetylated fresh Aβ42 peptides and their aggregates on 
SH-SY5Y neuroblastoma cells health measured by MTS and DCF-HDA assay. Refer 
next page for more details. 
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Supplementary Figure 13. The effect of 5 μM of WT and acetylated fresh Aβ42 peptides 
and their aggregates on SH-SY5Y neuroblastoma cells health were measured by (A) MTS 
assay, (B) DCFH-DA assay, and (C) LDH assay. The fresh peptides, 72 h, or 7 d aggregates 
were added to the cells to a final concentration of 5 μM. Cells were incubated for 48 h in 
presence of peptides for MTS and LDH assay and for 24 h for DCFH-DA assay. For t-
butyl-hydroperoxide (tBHP) control for DCFH-DA assay, cells were incubated with 50 µM 
of tBHP for 4 h at 37 oC. The mixtures represent samples containing equimolar (1:1) WT 
and acetylated peptides. Error bars = ± S.D. (for A n = 6; for B n = 5; and for C n = 5). *, 
**, and *** represents significant differences (* = p < 0.05), (** = p < 0.005), and (*** = 
p < 0.0005). (+,#,* represents statistics for Fresh, 72h and 7d data respectively and 
significant difference are set identical for all time points). 
Note: Statistical analysis (one-way ANOVA) for 7d sample is included at the end of the 
document. For Fresh and 72h sample statistical analysis as separate file is included.  
  
C 
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Supplementary Figure 14. The effect of 2 μM of WT and acetylated fresh Aβ42 peptides 
and their aggregates on primary neuronal cells health were measured by (A) DCFH-DA 
assay, and (B) LDH assay. The fresh peptides, 72 h, or 7 d aggregates were added to the 
cells to a final concentration of 2 μM. Cells were incubated for 24 h in presence of peptides 
for both assays. For t-butyl-hydroperoxide (tBHP) control for DCFH-DA assay, cells were 
incubated with 50 µM of tBHP for 4 h at 37 oC. The mixtures represent samples containing 
equimolar (1:1) WT and acetylated peptides. Error bars = ± S.D. (for A n = 5; for B n = 4). 
*, **, and *** represents significant differences (* = p < 0.05), (** = p < 0.005), and (*** 
= p < 0.0005). (+, #, * represents statistics for Fresh, 72h and 7d data respectively and 
significant difference are set identical for all time points). 
Note: Statistical analysis (one-way ANOVA) for 7d sample is included at the end of the 
document.  
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Supplementary Figure 15. Immunostaining of primary neuronal cells from rat brain. 
Primary neuronal cells were incubated with 2 µM of 7 d incubated Aβ42 WT and acetylated 
peptides for 24 h at 37 0C. Control indicates cells that are untreated and incubated under 
identical conditions with which Aβ42 treated cells were compared. The cells were fixed 
and then stained for immunofluorescence with antibodies for tubulin (green) and Tau (red). 
The images were acquired using Leica DMIL LED at 20X magnification. Scale bar =50 
µm (A). Zoomed in images of (A) are represented in (B) and are shown in boxes in panel 
A. Scale bar for panel B=20 µm.  
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Silver staining of Aβ WT and acetylated peptides 
For silver staining 15% homemade SDS-PAGE was used and followed the manufacture r’s 
instructions (ThermoScientific). In brief, the Aβ 7d incubated samples were mixed with 3X 
sample loading buffer and boiled for 3-5 minutes. All samples were loaded at the final 
concentration of 2µg/lane and ran for 3 hours at 80V. After the run, the gel was rinsed with 
MilliQ water for 5 minutes with two repeats. All steps were carried out in shaker with 
gentle agitation. The gel was fixed with fixing solution (30% Ethanol: 10% acetic acid) for 
15 minutes and repeated for another 15 minutes followed by two washes in 10% Ethanol 
at the interval of 5 minutes. Next, the gel was washed twice in MilliQ water for 5 minutes 
and sensitized for 1 minutes with Silver stain sensitizer working solution. The gel was then 
washed twice with MilliQ water for 1 minutes and incubated in Silver stain working 
solution for 30 minutes. After the incubation, the gel was washed twice for 20 seconds and 
the gel was developed by adding the Developer working solution. Once the desired band 
intensity were observed the stop solution (5% Acetic acid) was added. The gel was further 
incubated for 10 minutes in stop solution and the image was captured using Epson scanner. 
The gel was quantified using the Image J software and the plot was plotted for the ratio of 
High molecular weight vs monomer.  
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 Supplementary Figure 16. Silver staining of 7d incubated WT, acetylated, and mixture 
of Aβ42 peptides. Samples were mixed with 3X sample loading buffer and boiled for 3-5 
minutes. All samples were loaded 2µg/lane in 15% gel and ran for 3 hours at 80V. The gel 
was then subjected to silver staining as per manufacturer’s instructions. * and ** represents 
monomer and high molecular weight respectively. (←) represents the oligomeric species 
of varying molecular weight (A).  The gel was quantified using the Image J software and 
the data was plotted as ratio of high molecular weight vs monomer (B). 
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Supplementary Figure 17. Full-size gel image of silver staining of 7d incubated WT, 
acetylated, and mixture of Aβ42 peptides. B- blank, M-Marker, * represents monomer and 
** represents high molecular weight. (←) represents the oligomeric species of varying 
molecular weight.   
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Supplementary Table 1. Calculated 
surface area and hydrophobic patch values 
of WT and acetylated (K16Ac, K28 Ac 
and KKAc) aggregates obtained using 
SPDB software.  Hydrophobic patch 
values below 100 Å2 are not reported. 
Parameters WT K16Ac K28Ac KKAc 
     
Surface area 
(Å2) 
 
Hydrophobic 
patch area 
(Å2) 
19199 20209 19703 19582 
579 219 248 223 
278 208 200 196 
243 193 199 143 
220 173 179 133 
189 151 153 130 
 181 
 
143 140 121 
 164 136 138 121 
 118 122 125 120 
 109 120 110 115 
 105 117 105 111 
 - 104 101 - 
 - - 101 - 
Simulation systems. 
Initial structural configuration of WT 
Aβ42 monomer with sequence   
DAEFRHDSGYEVHHQKLVFFAEDV
GSNKGAIIGLMVGGVVIA  
was taken from the PDB entry 1Z0Q. For 
MD simulations of WT and acetylated 
(K16Ac, K28Ac, and KKAc) Aβ42 
monomer, the peptide was first placed in a 
periodic box having dimension of 61.90 × 
60.00 × 60.00 Å3.  The simulation box was 
uniformly solvated with water molecules 
with explicit waters defined using the 
TIP3P water model. Counter ions were 
added to the system to maintain charge 
neutralization. The solvated peptide 
system (WT and acetylated) was subjected 
to 200 steps of the energy minimization at 
a time step of 1 fs followed by 100 ns of 
production run.  
To simulate the assembly and 
fibrillization process of 9 strands of WT 
and acetylated Aβ42 peptide aggregates in 
aqueous solution, initial structure was 
taken to be the 9 monomer strands aligned. 
The peptides were then placed in the 
periodic box having dimension of 85.00 × 
80.00 × 85.00 Å3 and solvated with water 
molecules with the TIP3P water model.  
The total number of atoms and number of 
water molecules for all systems are 
provided in Table S2.  Counterions were 
added to maintain charge neutralization in 
the system. The solvated peptides (WT 
and acetylated) was subjected to 200 steps 
of the energy minimization at a time step 
of 1 fs followed by 100 ns of production 
run.  
All simulations were performed at 310 K 
temperature and 101.3 kPa pressure in the 
NPT ensemble using NAMD program and 
CHARMM27 force field.  The 
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experiments were performed at 310 K. 
Data were saved every 20 ps intervals for 
analysis of the structural changes for 100 
ns of MD trajectory. Convergence of the 
simulations was further confirmed using 
the root mean-square deviation (RMSD) 
analysis, implemented in VMD 1.9.2. 
suite of program. In addition, electrostatic 
potential isosurface for WT and acetylated 
peptides were computed using VMD 
program. Surface hydrophobic patches of 
WT and acetylated peptides 
corresponding to the structures at 100 ns, 
were mapped on the molecular surface for 
the 4 systems using the SPDB program.   
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Supplementary Table 2. Number of water molecules and total number of atoms in WT 
and acetylated (K16Ac, K28Ac, and KKAc) Aβ42 monomer and peptide aggregates for 
MD simulations in aqueous solution. 
 
 
 
Aβ42 
monomer 
 WT K16Ac K28Ac KKAc 
# total atoms 20868 21728 20873 20779 
# water 
molecules 
20238 21093 20238 20139 
# Aβ42 
monomer 
627 631 631 635 
#  
counterions 
3 4 4 5 
 
 
 
9 strands of 
Aβ42 
peptides 
 WT K16Ac K28Ac KKAc 
# total atoms 58893 49486 58770 58824 
# water 
molecules 
53222 43776 53055 53064 
# Aβ42 
monomer 
5643 5679 5679 5715 
#  
counterions 
27 31 36 45 
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Statistical Analysis of 7d samples  
One-way ANOVA was used for the statistics calculation of Fluorescence experiments 
(ANS, Bis-ANS) and toxicity assays (MTS, LDH, and DCF-HDA) carried out in SH-SY5Y 
and primary neuronal cells. Statistics for all 7 days data are provided below.  
A. Statistical Analysis of ANS data. All acetylated and 1:1 mixture of Aβ42 7d data were 
compared with WT of 7d. p<0.05 was considered as significant and represented as *, 
p<0.005 represented as ** and p<0.0005 represented as *** (Refer to figure 5 in 
chapter 4) 
WT vs K16Ac- 7d  
Anova: Single Factor     
SUMMARY      
Groups Count Sum Average Variance   
WT 3 
54710
0 
18236.666
7 
858433.333
3   
K16Ac 3 96450 32150 
701633.333
3   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 2.9E+08 1 29037126 
372.254946
4 
4.25336E-
05 7.70864 
Within Groups 3120133 4 780033.33    
       
Total 
2.93E+0
8 5         
 
     
   
201 
 
WT vs K28Ac-7d  
Anova: Single Factor 
SUMMARY      
Groups Count Sum Average Variance   
WT 3 54710 18236.67 858433.3   
K28Ac 3 67330 22443.33 5549200   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 26544067 1 26544067 8.285139 0.045086 7.708647 
Within Groups 12815267 4 3203817    
       
Total 39359333 5         
 
WT vs KKAc-7d  
Anova: Single Factor     
SUMMARY      
Groups Count Sum Average Variance   
WT 3 54710 18236.67 858433.3   
KKAc 3 86130 28710 6242533   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
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Between 
Groups 1.65E+08 1 1.65E+08 46.34188 0.002433 7.708647 
Within Groups 14201933 4 3550483    
       
Total 1.79E+08 5         
 
WT vs WT:K16Ac-7d      
Anova: Single Factor     
SUMMARY      
Groups Count Sum Average Variance   
WT 3 54710 18236.67 858433.3   
WT:K16Ac 3 70640 23546.67 3206233   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 42294150 1 42294150 20.81064 0.010324 7.708647 
Within Groups 8129333 4 2032333    
       
Total 50423483 5         
 
WT vs WT: K28Ac-7d       
Anova: Single Factor      
SUMMARY       
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Groups Count Sum Average Variance    
WT 3 54710 18236.6667 858433.3333    
WT:K28Ac 3 72040 24013.3333 6580800    
     
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 5005481 1 50054816 13.4569825 0.02142173 7.70864 
Within 
Groups 1487846 4 3719616.6    
       
Total 6493328 5         
 
WT vs WT: KKAc- 7d  
Anova: Single Factor     
SUMMARY      
Groups Count Sum Average Variance   
WT 3 54710 18236.67 858433.3   
WT:KKAc 3 67060 22353.33 3204100   
 
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 25420417 1 25420417 12.51456 0.024065 7.708647 
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Within Groups 8125067 4 2031267 
          
Total 33545483 5         
       
 
B. Statistical Analysis of Bis-ANS data. All acetylated and 1:1 mixtures of Aβ42 7d data 
were compared with WT of 7d. p<0.05 was considered as significant and represented 
as *, p<0.005 represented as ** and p<0.0005 represented as *** (Refer to figure 3 in 
chapter 4) 
WT vs K16Ac-7d  
Anova: Single Factor      
SUMMARY       
Groups Count Sum Average Variance   
WT 3 363680 121226.666 1.2E+08   
K16Ac 3 445230 148410 
1.59E+0
8   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 1108400417 1 1108400417 
7.95500
8 
0.04780
6 
7.70864
7 
Within 
Groups 
557334666.
7 4 
139333666.
7    
       
Total 1665735083 5         
 
WT vs K28Ac- 7d      
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Anova: Single Factor 
SUMMARY      
Groups Count Sum Average Variance   
WT 3 363680 121226.7 1.2E+08   
K28Ac 3 336100 112033.3 56194433   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 1.27E+08 1 1.27E+08 1.439423 0.296435 7.708647 
Within Groups 3.52E+08 4 88074233    
       
Total 4.79E+08 5         
 
WT vs KKAc- 7d  
Anova: Single Factor      
SUMMARY      
Groups Count Sum Average Variance   
WT 3 363680 121226.6667 1.2E+08   
KKAc 3 408830 136276.6667 1539064   
Anova: Single Factor     
ANOVA       
Source 
of SS df MS F P-value F crit 
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Variatio
n 
Betwee
n 
Groups 
33975375
0 1 
33975375
0 
5.59297
2 
0.07724
5 
7.70864
7 
Within 
Groups 
24298619
5.3 4 
60746548.
83    
       
Total 
58273994
5.3 5         
 
WT vs WT:K16Ac- 7d  
SUMMARY      
Groups Count Sum Average Variance   
WT 3 363680 121226.7 1.2E+08   
WT:K16
Ac 3 365120 121706.7 
1.33E+0
8   
ANOVA       
Source 
of 
Variatio
n SS df MS F P-value F crit 
Betwee
n 
Groups 345600 1 345600 
0.00273
6 0.960792 
7.70864
7 
Within 
Groups 5.05E+08 4 1.26E+08    
       
Total 5.06E+08 5         
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WT vs WT:K28Ac 
Anova: Single Factor     
SUMMARY      
Groups Count Sum Average Variance   
WT 3 363680 121226.7 1.2E+08   
WT:K28Ac 3 386920 128973.3 2.07E+08   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 90016267 1 90016267 0.55121 0.499055 7.708647 
Within Groups 6.53E+08 4 1.63E+08    
       
Total 7.43E+08 5         
 
WT vs WT:KKAc-7d  
Anova: Single Factor     
SUMMARY      
Groups Count Sum Average Variance   
WT 3 363680 121226.7 1.2E+08   
WT:KKAc 3 382380 127460 1.1E+08   
ANOVA       
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Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 58281667 1 58281667 0.507399 0.515612 7.708647 
Within Groups 4.59E+08 4 1.15E+08    
       
Total 5.18E+08 5         
 
C. Statistical Analysis of MTS (5µM) data carried out in SH-SY5Y cells. WT, 
acetylated and 1:1 mixtures of Aβ42 7d data were compared with untreated cells 
which was used as control. p<0.05 was considered as significant and represented as 
*, p<0.005 represented as ** and p<0.0005 represented as *** (Refer to figure 6 in 
chapter 4) 
Untreated vs WT-7d 
Anova: Single Factor     
SUMMARY      
Groups Count Sum Average Variance   
Untreated 6 0.279 0.0465 0.000212   
WT 6 0.187 0.031167 0.000163   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 0.000705 1 0.000705 3.756435 0.081329 4.964603 
Within Groups 0.001878 10 0.000188    
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Total 0.002583 11         
 
Untreated vs K16Ac-7d   
Anova: Single Factor     
SUMMARY      
Groups Count Sum Average Variance   
Untreated 6 0.279 0.0465 0.000212   
K16Ac 6 0.203 0.033833 2.02E-05   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 0.000481 1 0.000481 4.143472 0.06916 4.964603 
Within Groups 0.001162 10 0.000116    
       
Total 0.001643 11         
 
Untreated vs K28Ac-7d   
Anova: Single Factor     
SUMMARY      
Groups Count Sum Average Variance   
Untreated 6 0.279 0.0465 0.000212   
K28Ac 6 0.199 0.033167 2.58E-05   
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ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 0.000533 1 0.000533 4.483048 0.060295 4.964603 
Within Groups 0.00119 10 0.000119    
       
Total 0.001723 11         
 
Untreated vs KKAc-7d   
 
 
Anova: Single Factor     
SUMMARY      
Groups Count Sum Average Variance   
Untreated 6 0.279 0.0465 0.000212   
KKAc 6 0.122 0.020333 0.000494   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 0.002054 1 0.002054 5.81756 0.036561 4.964603 
Within Groups 0.003531 10 0.000353    
       
Total 0.005585 11         
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Untreated vs WT:K16Ac-7d      
Anova: Single Factor     
SUMMARY      
Groups Count Sum Average Variance   
Untreated 6 0.279 0.0465 
0.00021
2   
WT:K16Ac 6 
0.17333
3 
0.02888
9 
0.00011
3   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 0.00093 1 0.00093 5.71889 0.03786 4.96460 
Within Groups 0.00162 10 0.00016    
Total 0.00255 11         
 
Untreated vs WT:K28Ac-7d   
Anova: Single Factor     
SUMMARY      
Groups Count Sum Average Variance   
Untreated 6 0.279 0.0465 0.000212   
WT:K28Ac 6 0.164 0.027333 2.24E-05   
ANOVA       
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Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 0.001102 1 0.001102 9.39676 0.011934 4.964603 
Within Groups 0.001173 10 0.000117    
       
Total 0.002275 11         
 
Untreated vs KKAc-7d   
Anova: Single Factor     
       
SUMMARY      
Groups Count Sum Average Variance   
Untreated 6 0.279 0.0465 0.000212   
WT:KKAc 6 0.1 0.016667 4.28E-05   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 0.00267 1 0.00267 20.94457 0.001016 4.964603 
Within Groups 0.001275 10 0.000127    
       
Total 0.003945 11         
 
D. Statistical Analysis of LDH (5µM) data carried out in SH-SY5Y cells. WT, 
acetylated and 1:1 mixtures of Aβ42 7d data were compared with untreated cells 
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which was used as control. p<0.05 was considered as significant and represented as 
*, p<0.005 represented as ** and p<0.0005 represented as *** (Refer to figure 6 in 
chapter 4) 
Untreated vs WT-7d  
Anova: Single Factor 
SUMMARY      
Groups Count Sum Average Variance   
Untreated 6 0.183 0.0305 0.00171   
WT 6 0.819 0.1365 9.35E-05   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between Groups 0.033708 1 0.033708 37.37719 0.000113623 4.964603 
Within Groups 0.009018 10 0.000902    
       
Total 0.042726 11         
 
Untreated vs K16Ac-7d   
Anova: Single Factor      
SUMMARY      
Groups Count Sum Average Variance   
Untreated 6 0.183 0.0305 0.00171   
K16Ac 6 1.104 0.184 
0.00195
6   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
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Between 
Groups 
0.07068
7 1 
0.07068
7 
38.5630
7 0.0001 
4.96460
3 
Within Groups 0.01833 10 
0.00183
3    
       
Total 
0.08901
7 11         
Untreated vs K28Ac-7d        
Anova: Single Factor      
SUMMARY      
Groups Count Sum Average Variance   
Untreated 6 0.183 0.0305 0.00171016   
K28Ac 6 0.971 0.16183 0.00204896   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 0.05174 1 0.05174 27.5304591 
0.00037
5 4.96460274 
Within Groups 0.01879 10 0.00188    
       
Total 0.07054 11         
       
Untreated vs KKAc-7d  
Anova: Single Factor      
SUMMARY      
Groups Count Sum Average Variance   
Untreated 6 0.183 0.0305 0.00171   
KKAc 6 1.617 0.2695 0.000489   
ANOVA       
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Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 0.171363 1 0.171363 155.8365 
2.0133E-
07 
4.96460
3 
Within Groups 0.010996 10 0.0011    
       
Total 0.182359 11         
 
Untreated vs WT:K16Ac-
7d  
Anova: Single Factor      
SUMMARY      
Groups Count Sum Average Variance   
Untreated 6 0.183 0.0305 0.00171   
WT:K16Ac 6 1.141 0.190167 0.002583   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between Groups 0.07648 1 0.07648 35.62914 0.000137691 4.964603 
Within Groups 0.021466 10 0.002147    
       
Total 0.097946 11         
 
Untreated vs WT:K28Ac-
7d  
Anova: Single Factor      
SUMMARY      
Groups Count Sum Average Variance   
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Untreated 6 0.183 0.0305 0.00171   
WT:K28Ac 6 1.117 0.186167 0.002071   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between Groups 0.072696 1 0.072696 38.44807 0.000101 4.964603 
Within Groups 0.018908 10 0.001891    
       
Total 0.091604 11         
 
Untreated vs WT:KKAc-
7d  
Anova: Single Factor      
SUMMARY      
Groups Count Sum Average Variance   
Untreated 6 0.183 0.0305 0.00171   
WT:KKAc 6 1.637 0.272833 0.0025   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between Groups 0.176176 1 0.176176 83.69289 3.5714E-06 4.964603 
Within Groups 0.02105 10 0.002105    
       
Total 0.197227 11         
 
E. Statistical Analysis of DCFH-DA (5µM) data carried out in SHSY-5Y cells. WT, 
acetylated and 1:1 mixtures of Aβ42 7d data were compared with untreated cells 
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which was used as control. p<0.05 was considered as significant and represented as 
*, p<0.005 represented as ** and p<0.0005 represented as *** (Refer to figure 6 in 
chapter 4) 
Untreated vs WT-7d  
Anova: Single Factor     
SUMMARY      
Groups Count Sum Average Variance   
Untreated 5 0.4361 0.08722 
0.00058
4   
WT 5 
1.08523
3 
0.21704
7 
0.00336
2   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 0.04213 1 0.04213 21.3556 
0.00170748
7 5.31765507 
Within 
Groups 0.01578 8 0.00197    
Total 0.05792 9         
 
Untreated vs K16Ac-7d  
Anova: Single Factor     
SUMMARY      
Groups Count Sum Average Variance   
Untreated 5 0.4361 0.08722 0.000584477   
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K16Ac 5 2.2993 0.45986 0.000222993   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 0.347151 1 0.347151424 859.8497133 
1.98174E-
09 5.317655 
Within 
Groups 0.00323 8 0.000403735    
       
Total 0.350381 9         
 
Untreated vs K28Ac-7d  
Anova: Single Factor      
SUMMARY      
Groups Count Sum Average Variance   
Untreated 5 0.4361 0.08722 0.000584   
K28AC 5 2.550633 0.510127 0.005405   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 0.447125 1 0.447125 149.3156 
1.86708E-
06 5.317655 
Within Groups 0.023956 8 0.002994    
       
Total 0.471081 9         
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Untreated vs KKAc-7d  
Anova: Single Factor     
SUMMARY      
Groups Count Sum Average Variance   
Untreated 5 0.4361 0.08722 
0.00058447
7   
KKAc 5 
3.28833
3 
0.65766
7 0.0013063   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 
0.81352
3 1 0.81352 860.517658 
1.97565E
-09 
5.31765507
2 
Within 
Groups 0.00756 8 0.00094    
       
Total 0.82108 9         
Untreated vs WT:K16Ac-7d  
Anova: Single Factor     
SUMMARY      
Groups Count Sum Average Variance   
Untreated 5 0.4361 0.08722 0.00058447   
WT:K16Ac 5 
2.78883
3 
0.55776
7 0.0011343   
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ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 0.55353 1 0.55353 
644.103817
7 
6.22434E-
09 5.31765 
Within Groups 0.00687 8 0.00085    
       
Total 0.56041 9         
 
Untreated vs WT:K28Ac-7d  
Anova: Single Factor     
SUMMARY      
Groups Count Sum Average Variance   
Untreated 5 0.4361 0.08722 0.00058447   
WT:K28Ac 5 2.53896 0.50779 0.00385373   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 0.44220 1 0.44220 199.271698 
6.16418E-
07 5.31765 
Within Groups 0.01775 8 0.00221    
       
Total 0.45995 9         
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Untreated vs WT:KKAc-7d  
Anova: Single Factor     
SUMMARY      
Groups Count Sum Average Variance   
Untreated 5 0.4361 0.08722 0.000584   
WT:KKAc 5 5.187167 1.037433 0.004266   
       
       
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 2.257263 1 2.257263 930.6428 
1.44778E-
09 5.317655 
Within Groups 0.019404 8 0.002425    
       
Total 2.276667 9         
 
F. Statistical Analysis of LDH (2µM) data carried out in primary neuronal cells. WT, 
acetylated and 1:1 mixtures of Aβ42 7d data were compared with untreated cells which 
was used as control. p<0.05 was considered as significant and represented as *, 
p<0.005 represented as ** and p<0.0005 represented as *** (Refer to figure 7 in 
chapter 4) 
Untreated vs WT -7d  
 
Anova: Single Factor      
SUMMARY      
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Groups Count Sum Average Variance   
Untreated 4 1.200667 0.300167 0.001145   
WT 4 3.538667 0.884667 0.002106   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between Groups 0.683281 1 0.683281 420.351 
8.75603E-
07 5.987378 
Within Groups 0.009753 6 0.001626    
       
Total 0.693034 7         
       
 
Untreated vs K16Ac-7d  
Anova: Single Factor      
SUMMARY      
Groups Count Sum Average Variance   
Untreated 4 1.200667 0.300167 0.001145   
K16Ac 4 6.187667 1.546917 0.004958   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between Groups 3.108771 1 3.108771 1018.726 
6.28689E-
08 5.987378 
Within Groups 0.01831 6 0.003052    
       
Total 3.127081 7         
 
   
223 
 
Untreated vs K28Ac-
7d  
 
Anova: Single Factor      
SUMMARY      
Groups Count Sum Average Variance   
Untreated 4 1.200667 0.300166667 0.001145   
K28Ac 4 4.781 1.19525 0.000308   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 1.602348 1 1.602348347 2206.205 
6.24123E-
09 5.987377607 
Within 
Groups 0.004358 6 0.000726292    
       
Total 1.606706 7         
 
Untreated vs KKAc-7d  
Anova: Single Factor      
SUMMARY      
Groups Count Sum Average Variance   
Untreated 4 1.200667 0.300167 0.001145   
KKAc 4 8.228667 2.057167 0.004659   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
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Between 
Groups 6.174098      1 6.174098 2127.532047 
6.95769E-
09 5.987377607 
Within 
Groups 0.017412 6 0.002902    
       
Total 6.19151 7         
Untreated vs WT: K16Ac-7d  
Anova: Single Factor      
SUMMARY      
Groups Count Sum Average Variance   
Untreated 4 1.200667 0.300167 0.001145   
WT:K16Ac 4 6.220667 1.555167 0.004269667   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 3.15005 1 3.15005 1163.524994 
4.22778E-
08 5.987377607 
Within Groups 0.016244 6 0.002707    
       
Total 3.166294 7         
 
Untreated vs  
WT:K28Ac-7d  
Anova: Single Factor      
SUMMARY      
Groups Count Sum Average Variance   
Untreated 4 1.200667 0.300167 0.001145   
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WT:K28Ac 4 6.021667 1.505417 0.003206   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 2.905255 1 2.905255 1335.366 
2.80151E-
08 5.987378 
Within 
Groups 0.013054 6 0.002176    
       
Total 2.918309 7         
Untreated vs 
WT:KKAc-7d  
Anova: Single Factor      
SUMMARY      
Groups Count Sum Average Variance   
Untreated 4 1.200666667 0.300167 0.001145   
WT:KKAc 4 6.841666667 1.710417 0.00518825   
ANOVA       
Source of 
Variation SS  df MS F P-value F crit 
Between 
Groups 3.97761 1 3.97761 1256.103936 
3.36352E-
08 5.987378 
Within 
Groups 0.019 6 0.003167    
       
Total 3.99661 7         
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G. Statistics Analysis of DCFH-DA (2µM) data carried out in primary neuronal cells. 
WT, acetylated and 1:1 mixtures of Aβ42 7d data were compared with untreated cells 
which was used as control. p<0.05 was considered as significant and represented as 
*, p<0.005 represented as ** and p<0.0005 represented as *** (Refer to figure 7 in 
chapter 4) 
Untreated vs WT- 7d  
Anova: Single Factor     
SUMMARY      
Groups Count Sum Average Variance   
Untreated 5 0.3787 0.07574 0.000917   
WT 5 0.964567 0.192913 0.002527   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 0.034324 1 0.034324 19.93725 0.002097 5.317655 
Within Groups 0.013773 8 0.001722    
       
Total 0.048097 9         
 
Untreated vs K16Ac-7d   
Anova: Single Factor     
SUMMARY      
Groups Count Sum Average Variance   
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Untreated 5 0.3787 0.07574 0.00091   
K16Ac 5 1.44263 0.28852 0.00499   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 0.11319 1 0.11319 38.2676 0.000263396 5.317655 
Within Groups 0.02366 8 0.00295    
       
Total 0.13685 9         
 
Untreated vs K28Ac-7d   
Anova: Single Factor      
SUMMARY       
Groups Count Sum Average Variance    
Untreated 5 0.3787 0.07574 0.000917    
K28AC 5 1.068567 0.213713 0.003781    
ANOVA        
Source of 
Variation SS df MS F P-value F crit  
Between 
Groups 0.047592 1 0.047592 20.26017 0.001999 5.317655  
Within Groups 0.018792 8 0.002349     
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Total 0.066384 9          
 
Untreated vs KKAc -7d 
Anova: Single Factor     
SUMMARY      
Groups Count Sum Average Variance   
Untreated 5 0.3787 0.07574 0.000917   
KKAc 5 2.192133 0.438427 0.004799   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 0.328854 1 0.328854 115.0654 
5.01524E-
06 5.317655 
Within Groups 0.022864 8 0.002858    
       
Total 0.351718 9         
Untreated vs WT: K16Ac -7d   
Anova: Single Factor     
SUMMARY      
Groups Count Sum Average Variance   
Untreated 5 0.3787 0.07574 0.000917   
WT:K16Ac 5 1.604033 0.320807 0.000374   
ANOVA       
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Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 0.150144 1 0.150144 232.7355 
3.37998E-
07 5.317655 
Within Groups 0.005161 8 0.000645    
       
Total 0.155305 9         
 
Untreated vs K28Ac -7d  
Anova: Single Factor     
SUMMARY      
Groups Count Sum Average Variance   
Untreated 5 0.3787 0.07574 0.000917   
WT:K28Ac 5 1.52106 0.304213 0.000622   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 0.1305 1 0.1305 169.638 
1.14564E-
06 5.317655 
Within Groups 0.00615 8 0.00076    
       
Total 0.13665 9         
Untreated vs WT: KKAc -7d   
Anova: Single Factor     
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SUMMARY      
Groups Count Sum Average Variance   
Untreated 5 0.3787 0.07574 0.000916608   
WT: KKAc 5 2.2765 0.4553 0.004404   
ANOVA       
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 0.36016 1 0.36016 135.3847094 
2.71104E-
06 5.317655 
Within Groups 0.02128 8 0.00266    
       
Total 0.38144 9         
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